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 “Searching for therapeutic strategies in a mouse model of Machado-Joseph disease: 
targeting proteostasis” 
 
Abstract 
Machado-Joseph Disease (MJD) belongs to the group of nine Polyglutamine (PolyQ) diseases, which 
are characterized by the appearance of misfolded protein species, protein aggregates, neuronal dysfunction 
and ultimately cell death, of which is triggered by the presence of an expanded CAG repeat in the respective 
disease-causing genes. Along with the pathogenic motif, all these disease-associated proteins are widely 
expressed but the diseases only affect specific subsets of neurons. So far there is no effective treatment 
available for these disorders. Because the pathogenic mechanism(s) underlying MJD are poorly understood, 
which might be hampering the progression of effective therapeutical targets, this work focused on the 
search for new therapies based on hypotheses that additionally allow the study of molecular mechanism of 
disease. For this, we used the CMVMJD135 mouse model, which recapitulates the human disease both at 
the phenotypic and neuropathologic levels. We tested the efficacy of several compounds acting on different 
aspects of cellular function: (i) molecular chaperone load, (Hsp90 inhibitor - 17-dimethyl 
aminoethylamino-17-demethoxygeldanamycin hydrochloride - 17-DMAG); (ii) autophagy (lithium chloride 
and a combination of lithium chloride – LiCl - and temsirolimus - CCI-779); (iii) Endoplasmic reticulum 
(ER) stress response, (taroursodeoxycholic acid - TUDCA), also known to have multiple actions in the 
cells, and (iv) the energy status in the cell (creatine).  
Chronic treatment of CMVMJD mice with 17-DMAG resulted in a delay in progression of the motor 
coordination deficits and a reduction in neuropathology. While we observed limited induction of heat-shock 
proteins with treatment, we found evidence that 17-DMAG could be acting through autophagy, as levels of 
LC3-II and beclin-1 were induced in the brain of treated animals. This resulted in decreased levels of the 
mutant ataxin-3 (ATXN3) and reduced intranuclear aggregation of this protein. To further test autophagy 
induction as potential therapeutic approach for MJD, we tested LiCl alone and a combination of LiCl with 
CCI-779 (m-TOR independent and dependent inducers, respectively). In spite of activating autophagy, as 
suggested by the increased levels of Beclin-1, Atg7, and LC3- II, and a reduction in the p62 protein levels, 
lithium had no overall beneficial effects in MJD model concerning motor performance. Furthermore, the 
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combined therapy using LiCl and CCI-779 proved to be deleterious to both WT and transgenic animals, 
failing to rescue their neurological symptoms in the first and exerting in neurotoxic effects in the latter.  
 TUDCA is an orally bioavailable and BBB permeable bile acid with known neuroprotective action, 
through its anti-amyloidogenic and chemical chaperone activities and its ability to modulate apoptotic 
pathways. In addition, TUDCA is FDA-approved for chronic use in humans to treat liver disorders, but has 
also been shown to be beneficial in several models of different neurodegenerative diseases. In the 
CMVMJD135 model, TUDCA delayed the onset of disease and improved the motor phenotype, including 
balance, motor coordination and gait parameters, and ameliorated neurological reflexes, exploratory 
movement deficits and muscular strength problems. Although TUDCA treatment did not reduce the ATXN3 
aggregate load in the brain, it normalized the RNA levels of TNF-α, Il1β and Il10 in the brainstem and 
reduced the astrogliosis in the substantia nigra and brainstem. These results demonstrated the therapeutic 
efficacy of TUDCA supplementation for MJD, most likely mediated by its anti-inflammatory properties, 
making this compound an attractive for the treatment of neurodegenerative diseases, including MJD. 
Lastly, we tested the efficacy of creatine, another naturally-occurring compound known to balance 
energy status in the cell. Creatine-supplemented diet led to an overall improvement in the motor phenotype 
of CMVMJD135 mice, namely improved motor coordination, limb strength and gait quality, and 
amelioration of some neurological parameters such as tremors and abnormal reflexes. Remarkably, chronic 
creatine treatment delayed the onset of several symptoms and, in some cases, completely abolished their 
appearance, supporting creatine supplementation as a useful strategy to slow the progression of MJD. 
In summary in this work we validated a new MJD mouse model for use in preclinical trials as a 
powerful tool to study simultaneously pathogenic mechanisms associated with the disease and to develop 
novel therapeutic strategies. Furthermore, we found that Hsp90 inhibitors, TUDCA and creatine are relevant 
therapeutic candidates for MJD, some of which could be advanced to clinical trials in MJD patients. 
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  “Rastreio de estratégias terapêuticas num modelo de ratinho da doença de Machado-
Joseph: foco na proteostase” 
Sumário 
A doença de Machado Joseph (DMJ) pertence ao grupo de nove doenças de poliglutaminas em 
que o gene causador da doença possui uma expansão anómala do codão CAG. A presença desta expansão 
conduz ao aparecimento de espécies proteicas com conformação incorreta, agregados proteicos, disfunção 
neuronal e consequentemente, morte celular. Para além da expansão, todos os genes associados a este 
grupo de doenças possuem expressão ubíqua apesar de só afetarem subconjuntos específicos de 
neurónios. Atualmente, não existe tratamento eficaz para a DMJ. Uma das razões pelas quais há um atraso 
no desenvolvimento de alvos terapêuticos está relacionada com o conhecimento incompleto do(s) 
mecanismo(s) de patogénese associados à DMJ. Assim sendo, o objetivo deste estudo centrou-se na 
procura de novas terapias, usando uma abordagem baseada em hipóteses, que pode também permitir o 
estudo dos mecanismo(s) moleculares da doença.   
Para tal, foi usado o modelo de ratinho CMVMJD135 que recapitula a doença humana a vários 
níveis, nomeadamente fenotípico e neuropatológico. Testámos a eficácia de diversos compostos com alvos 
terapêuticos relacionados com diferentes funções celulares: (i) níveis de chaperonas moleculares 
(inibidor da Hsp90 – 17-dimetil aminoetillamino 17- demetoxigeldanamicina - 17-DMAG); (ii) autofagia 
(cloreto de lítio e combinação de cloreto de lítio –LiCl e temsirolimus  - CCI-779); (iii) resposta ao stress 
do retículo endoplasmático (ácido tauroursodesoxicólico – TUDCA), com múltiplas acções celulares, e 
(iv) estado energético celular (creatina).  
O tratamento crónico com 17-DMAG no ratinho CMVMJD135 resultou num atraso da progressão 
da descoordenação motora e redução da neuropatologia. Apesar de ter sido observada uma indução 
limitada das chaperonas moleculares, este tratamento poderá ter atuado a nível da autofagia na medida 
em que houve indução dos níveis de LC3-II e beclina-1 no cérebro de animais tratados. Esta indução 
resultou na diminuição dos níveis de ataxina-3 (ATXN3) e uma redução da agregação intranuclear desta 
proteína. Para testar mais aprofundadamente a indução da autofagia como potencial terapia para a DMJ, 
foi testado LiCl isoladamente e em combinação com CCI-779 (atuando de forma independente e 
dependente da sinalização mTOR, respectivamente). Apesar da ativação da autofagia, sugerida pelos níveis 
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aumentados de beclina-1, Atg7, LC3-II e redução dos níveis proteicos de p62, o tratamento do modelo DMJ 
com lítio foi de uma forma geral ineficaz ao nível do desempenho motor. Além disso, a terapia combinada 
de LiCl e CCI-779 revelou-se prejudicial em ambos os ratinhos WT e transgénicos, falhando na recuperação 
de sintomas neurológicos e sendo neurotóxico.  
O TUDCA é um ácido biliar com administração oral e permeável à BBB com funções 
neuroprotectoras conhecidas, através da sua capacidade anti-amiloidogénica, actividade de chaperona 
química e de modulação de vias apoptóticas. Adicionalmente, o TUDCA é um composto aprovado pela FDA 
para administração crónica no tratamento de doenças hepáticas, sendo também benéfico em diversos 
modelos de doenças neurodegenerativas. No modelo CMVMJD135, o tratamento com TUDCA atrasou o 
início da doença e melhorou o fenótipo motor incluindo equilíbrio, coordenação motora, e parâmetros da 
marcha, reduziu os reflexos neurológicos anómalos, melhorou os défices no movimento exploratório e força 
muscular. Apesar de o tratamento com este composto não ter reduzido os níveis de agregação da proteína 
ATXN3, foi eficaz na redução dos níveis de expressão de TNF-α, Il1β e Il10, tendo também reduzido a 
astrogliose no tronco cerebral e substantia nigra. Estes resultados demonstram a eficácia terapêutica da 
suplementação com TUDCA na DMJ, muito provavelmente através das suas capacidades anti-
inflamatórias, o que torna este composto atrativo no tratamento de doenças neurodegenerativas, incluindo 
a DMJ.  
Por fim foi testada a creatina, outro composto natural reconhecido pela eficácia em restabelecer o 
equilíbrio energético na célula. A dieta suplementada com creatina conduziu a uma melhoria geral no 
fenótipo motor do ratinho CMVMJD135; nomeadamente, melhorou a coordenação motora, força nos 
membros e qualidade da marcha. Também teve impacto positivo em parâmetros neurológicos como os 
tremores e reflexos anormais. Surpreendentemente, o tratamento crónico com creatina atrasou o início do 
aparecimento de diversos sintomas e até aboliu a presença de alguns, o que reinforça a suplementação 
com creatina como uma estratégica eficaz no atraso na progressão de DMJ. 
Em conclusão, este estudo validou o novo modelo DMJ de ratinho para ensaios pré-clínicos como 
uma ferramenta valiosa para estudar simultaneamente mecanismos patogénicos associado à doença e 
para desenvolver novas estratégias terapêuticas. Além disso foi demonstrado que inibidores da Hsp90, 
TUDCA e creatina são candidatos terapêuticos relevantes para a DMJ, alguns dos quais com possibilidade 
de avançarem para ensaios clínicos em doentes.   
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 Thesis planning 
The present thesis is divided into 7 chapters. Chapter 1 consists of a general introduction; Chapters 
2 to 6 describe hypothesis-driven pre-clinical trials performed in a mouse model of MJD generated in the 
lab – the CMVMJD135 transgenic line. In Chapter 7 a general discussion of the work is presented.  
In Chapter 1 a brief overview on polyglutamine diseases is provided and the potential mechanism 
(s) underlying these disorders are discussed. A more extensive part of the introduction focuses on reviewing 
the current therapeutic strategies for polyglutamine diseases. An outline of Machado-Joseph disease is 
presented, as well as the neuropathology behind this incurable disease. Furthermore, an emphasis is given 
to the existent mouse models of MJD from a phenotypic and neuropathologic perspective. The pre-clinical 
trials performed to date in these models are also described, and in the end of this chapter the clinical trials 
completed so far in MJD patients are presented.  
In chapter 2 the work “Chronic treatment with 17-DMAG improves balance and coordination in a 
new mouse model of Machado-Joseph disease”, describes the generation of a new MJD mouse model – 
CMVMJD135 – its extensive phenotypic and pathologic evaluation, and a pre-clinical trial which was 
performed in this model using 17-DMAG, a small molecule known to induce the heat-shock response in 
cells by interfering with the negative feedback imposed by Hsp90 upon Hsf-1. We show that 17-DMAG was 
effective in delaying disease onset and progression but was not able to induce the expected increase in 
heat-shock protein expression; rather, it induced autophagy in the brain of the CMVMJD135 mice. At the 
phenotypic level, this compound showed to transiently ameliorate the phenotype of these animals and 
markedly decreased ATXN3 aggregation. 
In chapter 3 the work entitled “Lithium Chloride therapy fails to improve motor function in a 
transgenic mouse model of Machado-Joseph Disease” is presented. In this work we treated the 
CMVMJD135 mice with lithium chloride, a mood stabilizer widely used in the clinics and known to induce 
autophagy independently of the mTOR pathway. This compound failed to rescue the phenotype of 
CMVMJD135 animals despite its ability to induce autophagy in the brain.  
Chapter 4,”Combined therapy with m-TOR-dependent and –independent autophagy inducers 
causes neurotoxicity in a mouse model of Machado-Joseph disease” is an extension of the work included in 
chapter 3 and focuses on a combined therapy using two autophagy inducers acting through 
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different/complementary pathways. We show that this combined therapy did not improve the CMVMJD135 
phenotype but rather worsened the phenotype of transgenic and wild-type animals, suggesting neurotoxicity 
caused by the combined therapy. This work highlights the possible dangers of manipulating autophagy in 
the central nervous system.  
In chapter 5, “TUDCA reduces neuroinflammation and improves motor symptoms in a transgenic 
mouse model of Machado-Joseph disease” a pre-clinical trial using a compound currently used for liver 
diseases is presented, but proposed by others to have neuroprotective effects. TUDCA is a safe compound 
known to be beneficial in several neurodegenerative diseases and to act thought different cellular 
mechanisms. In this work we show that chronic treatment with TUDCA was indeed able to improve the 
overall phenotype of the CMVMJD135 mice. We also show that TUDCA was able to reduce the 
neuroinflammation observed in the CMVMJD135 animals.  
Chapter 6, “Creatine-supplemented diet improves the overall phenotype and neuropathology of a 
transgenic mouse model of Machado-Joseph disease” focuses on the capacity of a natural-occurring 
compound to modulate the symptoms and neuropathology of the CMVMJD135 mice. We also show that 
creatine improves the overall phenotype of CMVMJD135 mice, and to some extent also the performance of 
wild-type mice when compared to animals under standard diet. Of notice, creatine treatment delayed the 
onset of some phenotypic parameters in CMVMJD135 mice. Creatine had no impact on the levels of 
mutant ATXN3 in the brainstem both at mRNA and protein levels, but did reduce aggregation of ATXN3. 
A general discussion of this thesis work and future perspectives are presented in chapter 7.  
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General Introduction 
General Introduction 
1.1 Summary 
 
Polyglutamine (PolyQ) diseases are a group of neurodegenerative disorders caused by the 
expansion of an unstable CAG trinucleotide repeat within the coding region of several otherwise unrelated 
genes. This expansion encodes an abnormally long polyQ tract that which, above a threshold size, leads to 
misfolding and aggregation, eventually resulting in neurodegeneration.  
These disorders all share key features including: (i) dominant transmission; (ii) adult onset; (iii) 
abnormal protein aggregation; (iv) selective neuronal susceptibility, despite the widespread expression of 
the disease-related proteins and (v) cellular toxicity that impacts at the organism level.  These 
commonalities point to shared mechanism(s) underlying their pathogenesis.  
To date, effective therapeutic strategies are still lacking for polyQ diseases, although some 
symptoms can be controlled with specific treatments. Moreover, neuroimaging studies in mutation carrying 
individuals suggest that nervous system dysfunction begins many years before the onset of any diagnosable 
symptoms. Thus, the development of therapeutic interventions becomes of great importance, not only to 
slow progression of manifest disease but also to delay, or ideally prevent, its onset. 
Potential therapeutic targets for polyQ disorders can be divided into (i) those that are aimed at the 
polyQ proteins themselves, namely gene silencing, attempts to enhance mutant protein degradation or 
inhibition/prevention of aggregation; or (ii) those that intercept the toxic downstream effects of the polyQ 
protein, such as mitochondrial dysfunction and oxidative stress, transcriptional abnormalities, UPS 
impairment, excitotoxicity, or activation of apoptotic pathways.  
The existence of relevant animal models and the recent contributions towards the identification of 
putative molecular mechanisms underlying polyQ diseases are impacting on the development of new drugs. 
Here, we provide an overview of the therapeutic strategies for polyQ disorders in cellular and animal models 
and their possible translation into the clinics. 
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1.2 Polyglutamine diseases 
 Expansions of repeating units of DNA, especially CAG triplet repeat expansions, are known to 
underlie several inherited neurodegenerative disorders (1) including Huntington disease (HD) (2), spinal and 
bulbar muscular atrophy (SBMA) or Kennedy’s disease (3), dentatorubropallidoluysian atrophy (DRPLA) (4, 
5), and the spinocerebellar ataxias (SCAs) 1, 2,3, 6, 7, and 17 and (6-12). The CAG expansion leads to an 
abnormally long polyQ tract within all the proteins involved in the mentioned diseases. The clinical 
manifestations of each disease result from brain pathology involving a specific subset of neurons that is, for 
the most part, particular to each disease. A common feature among all these disorders is a progressive 
neuronal dysfunction/death leading to neurological symptoms beginning at mid-life (13).  
The dominant transmission, progressive neurodegeneration, symptoms with onset in adulthood and 
some shared clinical manifestations in these polyQ diseases suggest a shared mechanism for their 
pathogenesis. The pathogenic mechanism of these diseases is believed to arise from a genetic gain of 
function related to the abnormal conformation(s) acquired by the elongated polyQ tracts. Besides the polyQ 
tract, the proteins involved in polyQ diseases share no homology and no functional similarity, which 
suggests that the polyQ stretch itself confers toxic properties to these proteins through a “toxic gain of 
function” (14). In agreement with this hypothesis the expression of a simple polyQ tract, in the absence of 
any additional protein context has been shown to be neurotoxic, in cell culture, mouse, Drosophila and C. 
elegans models (15-19). This toxic effect of the polyQ tract was further reinforced by a study describing the 
effect of the insertion of a CAG tract in the mouse hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
gene, encoding a metabolic enzyme, which normally does not bear such a repeat and is not known to be 
involved in any neurodegenerative disease. These mice developed a progressive late-onset neurological 
phenotype, including ataxia, seizures and premature death (20).  
 Interestingly, and despite the ubiquitous expression of polyQ mutated proteins, only some subsets 
of neurons are affected in each polyQ disorder (Table 1), indicating that there are other factors influencing 
the pathogenesis (21). 
 The CAG repeat tracts are normally highly polymorphic, but above a threshold length of around 35 
to 40 glutamine units, the symptoms of the diseases are manifested (Table 1) (1, 4). Interestingly, above 
the pathogenic threshold the CAG tracts are also unstable across generations, and they may expand or 
contract, biases towards expansion or contraction depending on the gender of the transmitter: while 
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maternal meioses are generally more stable or tend to lead to contractions, paternal transmissions display 
more instability and tend to lead to expansions. This intergenerational instability leads to a phenomenon 
called anticipation, since the disease symptoms appear earlier and are more severe in later generations 
(22-24). 
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Table 1. Molecular and pathogenic features of polyglutamine diseases. (adapted from (21, 25)) 
 
Disease name 
Mutated 
gene 
Protein 
Product 
Known or putative 
function 
Normal 
(CAG)n 
Expanded 
(CAG)n 
Regions most 
affected 
Clinical features 
HD HD Huntingtin 
Signaling, transport, 
transcription regulation 
6–34 36–121 Striatum, cerebral cortex Chorea, dystonia, dementia 
DRLPA DRPLA Atrophin 1 Transcription regulation 7–34 49–88 
Cerebellum, cerebral 
cortex, basal ganglia, 
Luys body 
Myoclonus epilepsy, ataxia, chorea, dementia 
SBMA AR 
Androgen 
receptor 
Steroid-hormone 
receptor (transcription 
regulation) 
9–36 38–62 
Anterior horn and bulbar 
neurons, dorsal root 
ganglia 
Weakness, bulbar symptom, fasciculations, 
tremors, gynecomastia 
SCA1 SCA1 Ataxin-1 Transcription regulation 6–39 40–82 
Cerebellar Purkinje cells, 
dentate nucleus, 
brainstem 
Ataxia, bulbar symptom, spasticity, 
polyneuropathy, cognitive impairment 
SCA2 SCA2 Ataxin-2 RNA metabolism 15–24 32–200 
Cerebellar Purkinje cells, 
brainstem, 
frontotemporal lobes 
Ataxia, slow saccades, ataxia, polyneuropathy, 
parkinsonism 
SCA3/MJD ATXN3 Ataxin-3 
Deubiquitinating activity 
and transcription 
regulation 
10–51 55–87 
Deep cerebellar nuclei, 
brainstem, ganglia, 
subthalamic nuclei, red 
nucleus, spinal cord 
Ataxia, ophtalmoplegia, diplopia neuropathy 
dysphagia, dystonia 
SCA6 CACNA1A CACNA1A 
P/Q-type α1A calcium 
channel subunit 
4–20 20–29 
Cerebellar Purkinje cells, 
dentate nucleus, inferior 
olive 
Ataxia, dysarthria, down-beating nystagmus 
SCA7 SCA7 Ataxin-7 Transcription regulation 4–35 37–306 
Cerebellum, brainstem, 
macula, visual cortex 
Ataxia, retinal degeneration, ophthalmoplegia 
SCA17 SCA17 TBP Transcription 25–42 47–63 
Cerebellar Purkinje cells, 
inferior olive 
Ataxia, dementia, psychosis, seizures, 
extrapyramidal signs 
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At a molecular level, the brains of patients with all polyQ diseases display proteinaceous aggregates in 
neurons, usually termed neuronal inclusions (NIs), mainly located in the nucleus (25). These inclusions are 
a common hallmark of these diseases, however it is still controversial if they are pathogenic or not. Several 
mechanisms have been implicated in polyglutamine toxicity, most of which are not mutually exclusive (21).  
Figure 1 summarizes these mechanisms and the therapeutic intervention strategies currently being 
developed for polyQ diseases. These potential therapeutic strategies can be divided into those that target 
the primary pathological events of the disease, including the therapies decreasing the levels of the toxic 
protein and inhibiting the (relevant forms of) aggregation of the mutant protein, and those intercepting the 
downstream effects of the expanded polyQ protein such as impairment in proteostasis, transcription 
abnormalities, mitochondrial dysfunction, excitotoxicity and/or apoptotic pathways (26). 
Therapeutic strategies that directly target for polyQ diseases include: i) gene silencing that leads to 
decreasing levels of the mutant protein; ii) enhancement of mutant protein degradation by modulating 
cellular degradation pathways; (iii) transcription modulation by promoting histone acetylation and (iv) 
increasing neuroprotection by decreasing excitotoxicity, improving calcium homeostasis, balancing energy 
availability and/or increasing neurotrophic factors. 
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 Figure 1 - Mechanisms suggested to underlie polyglutamine pathogenesis. The pathogenic process (red arrows) begins with 
the synthesis of a protein with an expanded polyQ tract. The expanded polyQ tract alters the native conformation of the protein 
making it more prone to aggregate. This can be modulated by the presence of molecular chaperones and co-chaperones. At least 
a fraction of the abnormally folded protein is ubiquitylated (Ub) and degraded via the proteasome and another portion is subject 
to lysosomal-dependent proteolysis. Cleavage of the abnormally folded mutant protein may produce polyQ-containing fragments 
that function as “seeds” favoring the aggregation process. The mutant proteins shift, in part, from a monomeric random coil or α-
sheet into oligomeric α-sheets and eventually into insoluble aggregates. Some of these species might contribute to pathology 
through impairment of the ubiquitin-proteasome system, mitochondrial dysfunction and/or dysregulation of calcium homeostasis 
and alterations in transcription. As a simplification, mutant proteins are depicted as originating in the cytoplasm, although some 
of them might also be located in the nucleus or cycle between the cytoplasm and nucleus. Presence in the nucleus seems to be 
key for pathogenesis. To date, no effective treatment has been developed for any polyQ expansion disease. In consideration of 
the mechanisms mentioned above, several efforts have been made in order to reestablish cellular proteostasis (green arrows) 
such as mutant gene silencing and transcriptional modulation with HDAC inhibitors, blocking cleavage and aggregation, 
restoration of the quality control machinery and improving neuronal function and survival (neuroprotection). The results of these 
strategies will be detailed in the next section. Adapted from (27). 
 
1.3  Therapeutic strategies for PolyQ diseases 
1.3.1 Gene Silencing 
The efficacy of terminating the downstream neurotoxic effects trough silencing of mutant polyQ-
encoding genes even after overt disease manifestation was demonstrated in conditional tetracycline-
regulated mouse and rat models of HD (28, 29) and SCA3 or Machado-Joseph disease (MJD) (30) and in a 
doxycycline-regulated mouse model of SCA1 (31). When the mutant proteins were inducibly expressed, 
pathological and behavioral features of the disease developed, including the neuronal inclusions and 
abnormal motor behavior. Upon shutting-down of the transgene expression some neuropathological 
features, such as aggregate formation, were reverted (28, 29, 31) and there was an amelioration of the 
neurological phenotype for all the models (28-31).  
The RNAi pathway is a natural physiological sequence-specific gene silencing mechanism in which, 
through the action of small RNAs (miRNAs), the regulation of expression of key genes involved in fate 
determination, proliferation as well as other vital biological processes may occur (32). In mammalian cells, 
primary micro-RNA (pri-miRNA) is first transcribed by RNA polymerase II as hairpins with large single 
stranded flanking-sequences in the nucleus (33). These hairpins are then cleaved by the nuclear Drosha-
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DGCR8 microprocessor complex into shorter precursor or pre-miRNAs (34, 35), which are subsequently 
exported into the cytoplasm by exportin-5 (36). In the cytoplasm, they are further processed by Dicer into 
~22 nucleotide (nt) long miRNA with characteristic 2-nt 3 ′ overhangs (37).  After being separated into two 
strands, the guide strand of the miRNA is next loaded onto the RNA-induced silencing complex RISC to 
silence target transcripts (38, 39). The mode of target repression primarily depends upon the degree of 
complementarity; near perfect base-pairing is required for target transcript cleavage by Argonaute 2, one of 
the principal protein components of RISC, while imperfect binding induces translational repression and 
mRNA decay (40). To reprogram the RNAi pathway for therapeutic intervention, inhibitory RNAs can be 
designed to mimic primary miRNA stem-loops (artificial miRNAs), processed pre-miRNAs (short hairpin or 
shRNAs), or mature miRNAs with perfect complementarity to their targets (small interfering RNAs or 
siRNAs) (41). 
The potential of RNAi therapies in polyQ diseases was first demonstrated in a cell-based model in 
which the inhibition of a truncated version of the human AR containing 112 GAG trough dsRNA significantly 
reduced polyQ-mediated cell death and caspase-3 activity as well as protein aggregation (42). Soon after 
this in vitro evidence was obtained, the viability of RNAi therapeutics was demonstrated in vivo, in a SCA1 
mouse model using a shRNA for human ataxin-1 (43). Since this mouse model expressed mutant (82 CAG) 
ataxin-1 at high levels in cerebellar Purkinje cells (44), a recombinant adeno-associated virus serotype 1 
(AAV1) expressing shRNA was developed and injected into the cerebella of 7-week-old transgenic mice (43). 
Following treatment, these mice showed improved motor coordination on the rotarod and normalization of 
several aspects of the cerebellar pathology, such as reduction of intracellular inclusions and preservation of 
the integrity of the cerebellar molecular layer (43). A similar approach was also used in a mouse model of 
HD. Intrastriatal injection of AVV1-exppressing shRNA targeting human huntingtin in 4-week-old HD-N171-
82Q mice reduced mutant htt expression and prevented the formation of the disease-associated neuronal 
inclusions (45). The treatment also had a positive effect in behavior, as treated mice displayed a better 
motor performance, both in rotarod and in stride length measurements, 3 months after vector injection. 
However it had no effect on weight loss, a systemic manifestation of disease that is very relevant in patients 
(45). In a parallel study, AAV5 vectors were used to deliver anti-mutant Htt shRNAs to the striata of R6/1 
mice, another model of HD (46). The RNAi treatment revealed to be effective in reducing the levels of 
mutant HTT mRNA and neuronal intranuclear inclusions. Furthermore, htt gene silencing resulted in a mild 
improvement of HD-associated behavior abnormalities such as clasping behavior, although it had no effect 
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on the rotarod performance and body weight (46). Even after the onset of symptoms, transgenic HD mice 
treated with AVV-shRNA demonstrated an amelioration of HD-induced neuropathology, such as decrease of 
neuronal aggregates and restoration of DARPP32 expression (47). 
Although these studies highlight the potential of  RNAi as a therapeutic tool, the translation to the 
clinics may not be so straightforward; one limitation may be the non-specific ablation of the expression of 
the normal gene copy, which may compromise cellular function and viability (26). This is important 
because, even though neurodegeneration in CAG-repeat diseases is thought to be the result of a toxic gain-
of-function, some data suggest that a partial loss-of-function also contributes to the disease pathogenesis. A 
way to overcome this problem is to adopt an allele-specific approach by using RNAi sequences directed at 
single nucleotide polymorphisms (SNPs) in linkage disequilibrium with CAG expanded alleles (40). In MJD, 
there is a SNP (G987C) at the 3´end of the CAG tract of the ataxin-3 gene (ATXN3) that is in linkage 
disequilibrium with the disease-causing expansion (48, 49). Worldwide, 70% of MJD patients carry the C 
variant at this locus (50). Taking advantage of this SNP, Miller and collaborators (2003) were successful in 
developing siRNA with different vectors that silencing the mutant allele (51).  Alves and collaborators (2008) 
assessed the efficacy and selectivity of this approach in vivo by injecting a lentiviral vector encoding human 
mutant ATXN3 together with the corresponding shRNA into rat striatum (52). Treated rats showed a 
decrease in the levels of mutant ATXN3 that was accompanied by a decrease in the formation of disease-
associated inclusions and neuronal dysfunction (52). The impact on behavior was not assessed in this 
study. In SCA7, a shRNA was designed against a SNP localized in the 3´region of ataxin-7 gene (ATXN7) 
(53) and, when expressed in a heterozygous ataxin-7 disease model, not only a significant decrease in the 
mutant ataxin-7 protein levels and protein aggregation was denoted but also the wild-type protein was 
normalized to a non-aggregated diffuse cellular distribution, suggesting that allele-specific silencing could 
counter some of the loss-of-function effect contributing to pathogenesis (54). In HD, several SNPs are 
present in ~85% of the North-American and European HD patients (55, 56), however the allele-specific 
siRNAs remains to be evaluated in vivo for efficacy and safety. Nevertheless, it was shown in vitro that the 
Δ2642 deletion in exon 58 of the HD gene, a mutation more frequently found (37%) in polyQ-expanded 
alleles (57), could be targeted by siRNA without affecting its wild-type counterpart (58). This silencing 
allowed a decrease of abnormal nuclear morphology and rescued caspase-3 activation (58).  
Another strategy involves adapting endogenous miRNA-like targeting: mismatch-containing duplex 
siRNAs complementary to the CAG repeat allowed a highly selective inhibition of mutant HTT expression in 
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two HD skin cell lines (59, 60).  In SCA6, two different approaches were taken. In the first method (gene 
knockdown and replacement), both mutant and wild-type alleles were inhibited by siRNA, and wild-type 
protein was restored with a mRNA modified to be resistant to the siRNA (61). The second method took 
advantage of the fact that in this disease, due to alternative splicing, there is an expression of two distinct 
and functional Cav2.1 isoforms that either lack or contain the C-terminal polyQ tract and a splice-isoform-
specific(SIS)-RNAi was developed (62). This RNAi selectively suppressed in vitro transiently expressed and 
endogenous polyQ-encoding Cav2.1 splice variants (62). Nevertheless, given the level of Cav2.1 silencing, it 
will be important to test this system in vivo in order to assess the extent to which SIS-RNAi targeting of 
polyQ-encoding Cav2.1 mRNAs affects overall Cav2.1 levels. 
The fact that allele-specific silencing is conceptually an ideal approach does not necessarily mean 
that the non-allele-specific approach should not be developed. As examples we have MJD and HD. In spite 
of the undeniable relevant role of htt in several cellular processes, it was recently shown that the 
simultaneous silencing of mutant human transgene and endogenous wild-type htt was tolerable and 
provided beneficial effects in rodent (63, 64) and in nonhuman primate models of HD (65). In the study 
conducted by Boudreau and collaborators (2009) the miRNA designed and injected in the striatum of HD-
N171-82Q mice was able to silencing all htt alleles by 75% (63). Treated animals presented a significant 
improvement in behavior, although the treatment did not restore body weight. This silencing also lead to 
transcriptional alterations in more than 400 genes, which is in agreement with the pivotal role of htt in cells. 
The lentiviral vectors expressing shRNA that targets all htt transcripts developed by Drouet and colleagues 
(2009) were injected in an acute rat model of HD and a reduction in HD-mediated pathology was observed, 
namely the partial restoration of striatal gene expression and reduced inclusion formation. Importantly, no 
apparent evidence of toxicity was observed for up to nine months of treatment (64). In the Rhesus 
macaque, 45% reduction of htt in the mid- and caudal putamen did not induce motor deficits, neuronal 
degeneration, astrogliosis, or an immune response (65). In MJD, the non-allele-specific silencing in an 
acute rat model of MJD lead to a ~80% reduction of mutant ataxin-3-positive inclusions and to the 
preservation of DARPP-32 expression in the striatum where the mutant protein was overexpressed, 
although was not demonstrated whether this silencing improved behavior (66). Recently, the same authors 
used an allele-specific strategy for silencing mutant ataxin-3 in a transgenic mouse model of the disease. 
This RNAi approach showed beneficial effects in motor and gait impairments and reduced the levels of 
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soluble and aggregated human ataxin-3 without affecting the endogenous levels of the murine ataxin-3 (67).  
  
The choice of therapeutic silencing effectors is also of importance. Both siRNA and shRNA cause 
gene silencing but they differ in mode of delivery and persistence. Whilst shRNAs can be expressed from 
DNA-encoded plasmids to allow incorporation into viruses for long-lasting expression, chemically 
synthesized siRNAs are delivered as dsRNA duplexes that are targets for nuclease digestion and clearance 
from the body, making their effects short-lived. 
 There are viral and non-viral approaches to achieve delivery of RNAi gene silencing molecules. Viral 
methods include Adeno-associate virus (AVV) and lentiviruses. Because of its relatively low immunogenicity 
and its ability to exist in a stable episomal form, and thus being less prone to causing insertional 
mutagenesis within the host genome, AVV has been the most widely used vector for delivery of RNAi 
contructs for polyQ diseases (68). The long-term silencing of polyQ transgenes trough this approach has 
been demonstrated in several models. Another advantage of AVV lies in the malleability of the hairpin-
expressing promoter, enabling the design of tissue- and cell-specific expression in disease-susceptible 
tissues (69). Nevertheless, cytotoxicity and neuronal damage have also been recognized. AAV.shHD2.1 
injection in mice impaired rotarod performance of wt animals at 10 weeks, although this effect was resolved 
at 18 weeks (45). Furthermore, both control shRNA (containing mismatches) and shRNA targeting HD 
caused neuronal cell death associated with increased inflammation in the striatum and resulted in short-
term deficits in motor behavior in the mouse (63, 70). This toxicity was maintained even when the dosage 
was reduced. These toxic effects are thought to be the consequence of a potential interference of shRNA 
with the endogenous small RNA processing in the case of HD. To reduce shRNA toxicity, an artificial miRNA 
driven by RNA polymerase II promoter was designed to silence the same HD target and a reduction of the 
striatal toxicity was observed, while maintaining the same level of HD silencing (70). These studies 
underscore the need to optimize the currently available RNAi methods in order to achieve a fine adjustment 
of shRNA expression and to avoid RNAi-related adverse effects. The efficacy of a conditional shRNA 
expression using lentivirus in a rat HD model, concerning its effects on endogenous htt levels, was 
demonstrated in vivo, although specificity and reversibility were not fully evaluated (64). More recently it 
was shown that mesenchymal stem cells (MSCs) can also be useful to transfer shRNA molecules to neural 
cell lines (71). Since MSCs have demonstrated a strong safety profile (immune system modulation, homing 
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to injury sites, cytokine release into damaged microenvironments), this delivery approach can offer multiple 
advantages, although several parameters need to be further optimized and tested in in vivo models (71).  
The use of synthetic siRNAs also offers an alternative approach for gene silencing that avoids the 
problem of switching off a virally delivered shRNA and circumvents the toxicity associated with specific 
shRNAs (41). Nevertheless, the fact that they can be easily degraded in vivo by endonucleases and filtered 
through the renal system, leading to a short half-life, are important disadvantages of siRNAs (72). 
Paradoxically, this transient effect also makes them attractive due to the resulting ability to regulate 
treatment; upon any indication of danger adverse effects could be halted by discontinuing treatment (69). 
Nonetheless, for long-term stability and bioavailability, chemical modifications to the sugars, backbone, or 
bases of nucleic acids appear to be a successful strategy (73-75). Intraventricular injection of siRNAs 
against huntingtin together with lipofectamine in 2-day-old R6/2 mice had long-lasting effects. Although the 
silencing of htt was almost completely diminished one week after, treated mice showed a stabilization of the 
body weight, reduced hind-limb clasping, improved open-field behavior and better rotarod retention at ages 
when symptoms would otherwise have already advanced. The lifespan of treated animals was increased by 
14%. Additionally, siRNA induced down-regulation of transgenic htt expression and decreased the density 
and number of NII in striatal neurons (76). However, delivery of siRNA with a transfection reagent is not a 
practical means to treat humans because of the neuronal toxicity of most lipid-based transfection agents. In 
another type of siRNA application, a cholesterol-conjugated siRNA against htt was injected into the striatum 
of an acute HD model generated by intrastriatal injection of AVV vector carrying expanded human HTT 
fragments. Coadministration of a cholesterol-conjugated siRNA improved neuronal survival, reduced 
monomer levels and HTT protein aggregation and ameliorated motor deficits (77). No long-term effects or 
behavioral improvements were measured.  
In conclusion, therapy using RNAi for polyQ diseases is promising and may provide beneficial to 
human patients. Still, several remaining questions or issues related to safety and efficacy of in vivo delivery 
need to be addressed to further advance this technology. 
 
Blocking Cleavage  
It has become evident that proteolysis of polyQ proteins is a biologically relevant event. The 
conformational change in the proteins with expanded polyQ leads to misfolding and may favor proteolytic 
cleavage into smaller toxic fragments. As a consequence of the cleavage, the resulting fragment could have 
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an enhanced toxic effect (15, 78) and/or could more easily enter the nucleus and/or more rapidly 
aggregate (79, 80). This “toxic fragment” hypothesis is strongly supported by evidence, showing that in 
most polyQ diseases (1) aggregates are mainly formed by small polyQ-containing fragments rather than the 
full-length polyQ proteins (81-85) and (2) truncated proteins with polyQ expansions appeared more prone 
than full-length proteins to form inclusions or to cause cell toxicity including cell death by apoptosis (15, 86-
88). These reports highlight the importance of post-translational events that occur in polyQ diseases. 
Furthermore, several polyQ proteins are known to be cleaved by specific caspases, calpains and other 
proteases (82, 89-94). 
The cleavage of mutant htt at the 568 amino acid by caspase 6 has been proposed to be essential 
for the HD-related behavioral phenotype and selective neuropathology in the YAC128 mouse model of HD. 
Moreover, caspase-6 resistant mutant htt mice showed a delay in nuclear translocation of expanded htt 
(95). More recently, a transgenic mouse expressing the N-terminal 586 aa of Htt, a putative cleavage 
fragment mediated by caspase-6, with a polyQ expansion was generated (N586-82Q). Although these mice 
showed a behavioral deficit as well as nuclear accumulation of htt aggregates, their phenotype was less 
severe than that HD mouse models expressing shorter fragments suggesting that the caspase-6 fragment is 
an intermediate of the cascade leading to disease progression (96). Atrophin 1 is also cleaved by caspases 
at aspartate 109, and cleavage site mutations reduce nuclear localization, aggregate formation and 
cytotoxicity (78, 97). Ataxin-7 is cleaved by caspase-7 at amino acid positions D266 and D344. The 
proteolytic cleavage of polyQ expanded ataxin-7 was related to the formation of inclusions in granule 
neurons of the cerebellum, transcriptional repression, disruption of nuclear export and subsequent 
accumulation of N-terminal fragments in the nucleus. Importantly, the caspase-7 cleavage products 
detected in vitro were similar in size to proteolytic cleavage fragments detected in SCA7 transgenic mice 
(98). 
Data from transgenic mouse models and human disease tissues indicate that the pathogenic 
ataxin-3 is proteolyzed in vivo. The detection of a 36-kDa polyQ fragment in a transgenic MJD mouse that 
was proposed to be closely linked with neurological symptoms and the detection of a similar fragment in 
brain samples of MJD patients supported this notion (94, 99, 100). Caspases and calcium-dependent 
calpains are possible cleavage proteases whose actions were reported to increase the aggregation of polyQ 
expanded ataxin-3 (94, 99, 100). Consistently, Jung and collaborators demonstrated the occurrence of 
ataxin-3 cleavage in a fly model of MJD and by mutating six caspase sites in the protein there was a delay 
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in progression of neurodegeneration caused by expanded ataxin-3 protein expression (100). However, a 
more recent study suggested that aggregation of ataxin-3 is calpain- rather than caspase-dependent since 
treatment with calpain inhibitors prevented the formation of SDS-insoluble aggregates in MJD patient-
specifc neural cultures; the addition of caspase inhibitors had no effect (101). Results from our lab 
demonstrate that in a C. elegans model of MJD, the expression of ataxin-3 bearing 75Qs leads to the 
formation of protein aggregates in the C.elegans nervous system within C-terminal regions, but not in the 
full-length protein (102). However, no obvious cleavage products were detected in several symptomatic 
mouse and C. elegans models of MJD expressing full-length ataxin-3, suggesting that these cleavage 
products may not be very abundant in these more “physiological” models (102, 103). 
Globally, these data support a model in which proteolysis of polyQ expanded proteins may be 
relevant in polyQ-expanded toxicity, possibly with seeding effects. With this in mind, development of 
protease inhibitors that would prevent polyQ proteins into a more toxic form and alter their cellular sub 
localization could be beneficial. Nevertheless, we must be cautious because by inhibiting these proteases 
we can deregulate several essential signaling pathways (104, 105); therefore, appropriate validation of 
these strategies in vivo is required. 
 
Blocking aggregation 
Although the toxic(s) structure (s) relevant for polyQ diseases remain unknown, many efforts have 
been made in order to identify compounds that inhibit aggregate formation. This therapeutic approach is 
based on the premise that by inhibiting protein aggregation there will be a reduction of abnormal 
interactions and direct toxic effects of the misfolded polyQ proteins. This will in turn reduce the pathogenic 
stress on cells and normalize intrinsic proteostasis (106). 
 
Small Chemical compounds 
Toward developing a pharmacological therapy for the polyQ diseases, numerous screenings for 
small chemical compounds that inhibit polyQ aggregation have been conducted in the past years. 
The first demonstration of the potential of such small compounds arose from the finding that Congo 
Red, a compound with affinity for proteins with α-sheet-enriched conformations, could interfere with 
processes of polyQ protein aggregation. The administration of this compound inhibited HD exon 1 
aggregation in transiently transfected COS cells (107), modulated aggregate formation in hippocampal 
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slices from the R6/2 mouse (108) and prevented the assembly of mutant htt into mature fibrils (109). The 
effect of Congo Red was assessed in vivo using the R6/2 model. The treatment was conducted after the 
onset of symptoms and was able to ameliorate weight loss and diabetes (110). In addition to that, several 
neurological signs were improved, with preservation of normal gait and stride length, inhibition of the 
dyskinesia of hindlimbs and better motor performance on the Rotarod test. This treatment also extended life 
span resulting in a mean survival length of 106 days as compared with 91 days in vehicle-treated mice. 
Immunostaining of the basal ganglia of treated mice revealed clearance of polyglutamine aggregates, and in 
the hippocampus there was a moderate reduction in the number of aggregates (110). In a posterior study, 
however, chronic administration of Congo Red to the same model and before the onset of clinical signs, did 
not improve either motor or cognitive deficits. There was also no effect on neuronal inclusion load, which 
might be expected since this compound has a limited ability to cross the brain-blood barrier (BBB).
 The same group that detected the potential of Congo red in vitro also developed an automated filter 
retardation assay for the identification of HD exon1 aggregation inhibitors (111). This assay is based on the 
finding that polyQ-containing aggregates are resistant to SDS and selectively retained on a cellulose acetate 
filter, whereas SDS-soluble protein under the same conditions is not. Captured aggregates are detected by 
immunobloting analysis using specific antibodies (112). Compounds that can reduce the signal intensity of 
theses aggregates are considered as hit compounds. From a library of 184 000 chemicals, 300 were 
identified as supressors of polyQ aggregation. Among these chemicals, they found that benzothiazole 
derivatives, including PGL-135 and riluzole, inhibited htt aggregation in vitro and in cell culture (111). 
However, a further study demonstrated that PGJ-135 was metabolically instable and riluzole, when 
administered in the R6/2 mouse at the maximum tolerated concentration, could not inhibit aggregation or 
have a positive impact in the disease phenotype (113). 
The automated filter retardation assay was further used to screen a library of natural compounds 
(114). From a library of ~5000 natural substances, (-)-epigallocatechin-3-gallate (EGCG), a green tea 
polyphenol, was identified as an inhibitor of htt aggregation in vitro. It reduced toxicity and aggregate load in 
a yeast model of HD and when administered in a Drosophila model of HD, it allowed a reduction in 
photoreceptor degeneration and motor impairment. This compound seemed to exert its positive effect on 
aggregation in vitro by suppressing the formation of small oligomers and stimulating the formation of larger 
aggregation species (114).  
Nukina and colleagues took a different approach. Since expanded polyglutamine sequences are 
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insoluble in water, which makes it difficult to prepare polyglutamine-containing proteins in large scale, they 
established an assay based on large-scale preparation of myoglobin bearing an expanded polyglutamine, to 
search for inhibitors of protein aggregation (115, 116). Among of ~200 non-toxic chemical compounds that 
can be administered orally, trehalose showed the strongest inhibitory effect. Trehalose is a naturally 
occurring non-reducing disaccharide found in many organisms that is synthesized as a stress-responsive 
factor when cells are exposed to environmental stresses like heat, cold, desiccation, dehydration and 
oxidation (117, 118). They further demonstrated that oral administration of this compound in the R6/2 
mouse model reduced weight loss, striatal atrophy and intranuclear aggregates in the cerebrum and liver 
(119). In addition, the trehalose treatment also improved motor dysfunction, delayed the onset and reduced 
the frequency of foot clasping and extended lifespan. This effect was specific since the oral administration 
of glucose, a potential metabolite of trehalose did not exert any beneficial effect. Furthermore, the detection 
of trehalose in the brain of homogenates of trehalose-supplemented mice as well as the results from 
western blot and Immunohistochemistry analysis suggested that the protective effect induced by this 
compound could be through binding to expanded polyQ and stabilization of the partially unfolded mutant 
protein (119). Nevertheless, the effects of trehalose may not be solely due to its action as aggregate 
inhibitor, as trehalose has also been shown to regulate the heat shock transcription factor HSF1 (120) and 
to activate macroautophagy in a mTOR-independent way to accelerate the clearance of mutant htt (121).  
Chemical compounds that target polyQ aggregation have been also identified using cell model-
based assays. Pollit and colleagues established a cellular polyglutamine protein aggregation assay based on 
fluorescence resonance energy transfer (FRET) (122). In a screen for biological active molecules that inhibit 
inclusion body formation of fluorescently-tagged polyQ proteins in cultured cells, the authors identified Y-
27632, a known ROCK inhibitor, as a hit compound. They further demonstrated the therapeutic effect of Y-
27632 in a Drosophila model of HD in which it was able to reduced htt-induced neurodegeneration (122). 
In a posterior study, the efficacy of oral administration of this compound in the R6/2 mouse model was 
evaluated (123). Y-27632 improved rotarod function in treated mice although it had no effect in the 
clasping behavior, lifespan, brain weight, gross atrophy, inclusion formation or neuron counts in the 
striatum. The authors suggested that these results were a consequence of using a sub-saturating dose of Y-
27632 (123). 
Through a yeast model-based high-throughput screening assay, Kazantsev and colleagues have 
screened 16,000 chemical compounds for their ability to suppress the cytotoxicity caused by the presence 
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N-terminal fragment of htt containing 103 glutamines. They identified nine compounds able to increase 
yeast growth and htt-103Q expression levels. After an optimization for potency, they found that one 
compound, C2-8, inhibited polyQ-mediated aggregation in vitro and brain slices from HD transgenic mice 
and rescued photoreceptor degeneration in a Drosophila model of HD (124). Posterior studies revealed that 
this compound was non toxic, available orally, had favorable brain pharmacokinetics and had no concerning 
pharmacological interactions. In addition, C2-8 reduced the decline motor performance in R6/2 mice 
although it had no impact on weight loss or survival and reduced striatal neuronal nuclear aggregate 
volume. The authors suggested that this compound can affect aggregate growth but not initiation since it 
had no effect on aggregate number (125). 
More recently, a luciferase-based assay was developed to monitor protein aggregation and 
disaggregation of polyQ proteins (126). The principle of this assay is based on the fact that the activity of 
luciferase is lost in the presence of aggregated protein. In that way, huntingtin exon1 containing 72 
glutamines was fused to the N-terminal of firefly luciferase (httQ72-Luc) and, since it only aggregates in the 
presence of expanded polyQ, this reporter system was co-transfected with Q80-cfp in HEK-293 cells. The 
screening of the Johns Hopkins Clinical Compound Library (over 1500 compounds) revealed the existence 
of four drugs able to increase luciferase activity by at least 50%. The authors demonstrated that leftunomide 
and its active metabolite, teriflunomide, inhibited protein aggregation in a dose-dependent manner through 
prevention of polyQ incorporation into an aggregate protein (126). 
 
Intrabodies 
Intracellular antibodies or intrabodies are small, recombinant antibody fragments that target 
antigens intracellularly via the Fv variable regions, that are responsible for antibody  affinity and specificity, 
but can be selected and engineered as genes, providing a  protein-based approach to neutralizing the 
pathogenic characteristics of toxic misfolding proteins (106). 
The intrabody C4, generated from a synthetic phage library, recognizes the 17 N-terminal amino 
acids of Htt exon1 and was shown to inhibit htt inclusion body formation in non-neuronal cell lines (127) 
and to prevent mutant htt (mHtt) toxicity in organotypic brain slice cultures (128). Posterior studies 
demonstrated that this intrabody neutralizes the toxic effects of mhtt by selectively binding to the soluble 
fraction of mHtt N-terminal fragments, having only weak activity against endogenous full-length mhtt and 
wild-type htt, possibly due to epitope inaccessibility (129). In vivo, in a Drosophila model of HD, the 
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expression of C4 increased eclosion rates, extended lifespan and slowed both neurodegeneration and 
aggregation although the effect became less robust as the flies aged (130). A similar effect was found with 
AAV gene therapy delivery of C4 into the striatum of B6.HDR6/1 mice. Treatment initiation at various 
stages of the disease resulted in a significant reduction in the size and number of htt aggregates, however 
the treatment was more effective when the delivery of the intrabody was conducted prior to the appearance 
of mtt aggregates. Furthermore, the neuroprotective effect also weakened with age beyond 6 months; the 
impact on phenotype was not assessed (131).  
V(L)12.3 is another intrabody that targets the N-terminal of Htt exon1 (132). After increasing its 
efficiency and affinity trough removal of its disulfide bond and mutations, respectively, this intrabody was 
able to inhibit aggregation and toxicity in a Saccharomyces cerevisae model and in a corticostriatal brain 
slice model of HD (132, 133). However, like C4, V(L)12.3 also increases the level of soluble mutant htt and 
promotes its nuclear localization which may increase toxicity in vivo (133). Indeed, although when co-
expressed in a lentiviral model of HD this intrabody improved behavior and neuropathology, it had no effect 
on the YAC128 HD model and actually increased severity of the phenotype and mortality in the R6/2 HD 
model. Perhaps the presence of V(L)12.3 prior to the introduction of mHtt may be required in order for this 
inhibitor  to have a therapeutic effect (133), which may limit its clinical application. 
 There are also intrabodies that target the proline rich region of mutant htt exon1 as well as the 
polyQ tract. MW7 recognizes the two polyP stretches of htt exon1 gene product (134). It reduced mHtt-
induced aggregation and toxicity in cell culture (135) and acute brain slice models of HD (133). Since there 
was the potential risk of this intrabody also recognizing other cellular proteins containing a polyP domain, 
intrabodies that recognize the unique P-rich epitope between the polyP domains of were developed and 
denominated as Happ1 and Happ3 (133). Like MW7, these intrabodies showed a preferential effect on the 
mutant form of htt and increased turnover without altering localization. However, the Happs were more 
effective at lower ratios to htt than MW7. In vivo, the intrastriatal AVV delivery of Happ1 in several mouse 
HD models corrected several cognitive and motor deficits as well as neuropathology (133).  
EM48 is an intrabody that has affinity for an epitope in the C-terminal of Htt exon1. It suppressed 
the cytoplasmic toxicity of mHtt in a cell culture model of HD with no impact on nuclear inclusions. When 
expressed in the striatum of R6/2 and N171-82Q HD mice model via AVV infection there was a reduction in 
neuropil aggregate formation and improvement of motor performance in N171-82Q mice (136). In vitro 
studies suggested that this intrabody promotes the degradation of cytoplasmic mHtt by increasing its 
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ubiquitination (136). Intriguingly, and in contrast with this positive effect, intrabodies that target polyQ 
domains exacerbated the toxicity and aggregation of mhtt, presumably by stabilizing a toxic conformation 
(127, 135). Currently there are two major problems that should be overcome for the development of 
intrabodies-based therapies of the polyQ. First, the ratio between the amount of intracellular antibody and 
the target mutant protein should be taken in consideration and second, the brain delivery issue. 
 
Peptides 
Peptides have potential as therapeutic molecules since they are highly specific, selective and 
relatively low in molecular size, and therefore expected to be easily delivered to the target organs (137). 
Nevertheless, this therapeutic approach faces some limitations that should be considered, such as low 
ability to cross the BBB, short half life and difficulties in administration routes.  
Based on the knowledge that the monoclonal antibody 1C2 recognizes the altered conformation of 
abnormal expanded polyQ stretch (138), Nagai and collaborators hypothesized that peptides that selectively 
bind to pathogenic–length polyglutamine domains might inhibit interaction with other proteins thereby 
slowing, or preventing disease pathology (139). By combinatorial peptide library screening, the authors 
identified PolyQ-binding protein 1 (QBP1) as an inhibitor of the toxic α-sheet conformational transition and 
aggregation of the expanded polyQ in vitro (139, 140). Trough a transgenic approach, the ability of this 
compound to inhibit polyQ aggregation and to prevent neurodegeneration was further demonstrated in a 
Drosophila model expressing a truncated form of ataxin-3. Importantly, there was a rescue of polyQ-induced 
cell death that allowed a dramatic increase of the median lifespan (141). However, since this peptide is too 
large to cross the cell membrane and to reach the target polyQ protein efficiently, efforts have been made 
in order to enable a more efficient intracellular delivery of QBP1. The fusion of protein transduction 
domains (PTDs) enabled the intracellular delivery of QBP1, inhibited polyQ aggregation in vitro and 
suppressed polyQ inclusion body formation and cytotoxicity in Cos-7 cells expressing 87 glutamines (142) . 
In the same Drosophila model, oral administration of PTD-QBP1 suppressed polyQ-induced premature 
death and inclusion body formation (142). However, only when this molecule was administered in the R6/2 
mouse model via intraperitoneal injection, did the weight loss phenotype improved, oral administration 
being ineffective (143). Although it was shown that PTD-QBP1, by virtue of the PTD, was delivered into 
brain cells, the efficiency of delivery still needs improvement (143). 
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In order to overcome the problems associated with mode of delivery, pharmacokinetics and 
efficiency of small molecules and peptides in vivo, Chen and collaborators proposed to identify a polyQ-
binding small molecule with “drug-like” properties that would have the potential to inhibit the formation of 
aggregates (144). They generated chemically a library of 60 000 of peptoids (oligomers of N-substituted 
glycines) that was screened for molecules that specifically bound to an amino-terminal fragment of mHtt 
protein (144). This screening resulted in the identification of HQP09. This peptoid prevented the 
aggregation of mHtt in vitro and in YAC128 medium spiny neurons (MSN) cultures, stabilized glutamate-
Induced Ca2+ signals and protected from glutamate-induced apoptosis. In vivo, intracerebroventricular 
delivery of HQP09 to the YAC128 HD model resulted in reduced accumulation of mHtt aggregates and 
improved motor performance. Nevertheless, this molecule needs further optimization and testing since it 
has a poor BBB permeability (144).  
Recently, another peptide, P42, was found to have beneficial effects in a Drosophila HD model 
(145). To further test the beneficial effects of P42, Arribat and collaborators tested it in the R6/2 mouse 
model o HD, using a systemic delivery route of administration. For that, they used a combinatory approach 
fusing P42 to the protein transduction domain of TAT from HIV, allowing the delivery to living cell via 
endocytosis. Also, they used a novel water-in-oil microemulsion drug delivery vector called Aonys®, providing 
a transmucosal (buccal) route of administration. P42 daily administration showed to be safe and improve 
behavior deficits observed in the R6/2 mice as well as to reduce htt aggregates and astrogliosis (146). 
 
Transglutaminase inhibitors 
The relatively increased amount of glutamine in the mutant protein suggested that there is a 
similarly increased target for transglutaminase (TGase) to form bonds with glutamine and facilitate the 
aggregation process (147). The observation that TGase is upregulated in the brains of HD patients and of 
HD mice (148-151) and is recruited into neuronal intranuclear inclusions (151, 152) support this idea. In 
that sense cystamine, a TGase inhibitor, was tested and shown to ameliorate the behavior and 
neuropathological severity, reduce mHtt agreggation and extend survival in the R6/2 mouse model (151). 
In another study, cystamine treatment also improved the mice phenotype although it had no effect in 
aggregation (149). The effects of cystamine may not be solely due to its action as a transglutaminase 
inhibitor however, as cystamine has also been shown to inhibit caspase 3 activity and to increase the levels 
of glutathione (153) and BNDF (154). 
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1.3.2 Inducing refolding/degradation of mutant protein  
Polyglutamine diseases share several common aspects regarding their pathogenic mechanism, 
namely concerning the involvement of the protein homeostasis mechanisms: misfolding, refolding, 
degradation and aggregation. The expanded polyQ tract in the causative protein results in a conformational 
alteration that increases the tendency of the protein to misfold and polymerize – misfolding (137). This 
constitutes a challenge to the cell that will recognize the non-native conformation(s) and attempt to restore 
the appropriate conformation of the protein, through the action of molecular chaperones – refolding. When 
this system fails, the proteins are sent for degradation; the inefficient removal of misfolded proteins leads to 
a steady-state of increased aggregation and possibly to disease. 
Cells possess a highly efficient protein quality control machinery to regulate protein homeostasis 
and to ensure that misfolded proteins do not accumulate (155-157). It is know that these mechanisms are 
tightly regulated to maintain cellular homeostasis, and this is well demonstrated by the fact that around 
30% of newly synthesized proteins do not pass in control checkpoints, being sent to degradation (158). In 
misfolding diseases there is an imbalance between the capability/activity of this quality control system and 
the amount of altered proteins in the cells, leading to intracellular accumulation of abnormal proteins. This 
is reinforced by experimental evidence that overexpression of molecular chaperones in animal or cellular 
models of these diseases ameliorated polyQ toxicity (159-162). Cells have three main lines of defense 
against misfolded/aggregated-prone proteins: (i) molecular chaperones, (ii) the ubiquitin-proteasome 
system (UPS) and (iii) autophagy.  
Stimulating refolding and degradation pathways that preferentially target misfolded proteins or 
direct targeting of polyQ aggregation has been a focus of therapeutic development for several years. 
 
(i) Molecular Chaperones 
Molecular chaperones are crucial for the maintenance of native protein conformation and recent 
research has shown that defective chaperone action per se may have pathogenic consequences (163-165). 
Most of the chaperones belong to the family of Heat shock proteins (Hsps) with the ability to recognize 
misfolded species such as expanded polyQ proteins and act by correcting their abnormal folding (162, 166, 
167). Several studies have shown that chaperones have a protective effect on polyQ aggregation and 
neurodegeneration. For example, it was shown that htt expressed in mammalian cells formed oligomers 
and aggregates, that were decreased in cells overexpressing HSC70, suggesting that this complex prevents 
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polyQ toxicity by reducing the amount of soluble oligomers/aggregates in living cells (168). Also, it was 
demonstrated that Hsc70 and its co-chaperone Hsp40 inhibits HttEx1Qn aggregation in a polyQ-dependent 
manner, as Hsc70 is a molecular interactor of huntingtin exon 1 fragment (169).  
In a cellular model of SCA1, overexpression of the chaperone HDJ2/HSDJ (a human HSP40 
homologue) was able to decrease ataxin-1 aggregation, whereas overexpression of Hsp70 was shown to 
suppress neuropathology and improve motor function in a SCA1 mouse model (170, 171). Interestingly, 
overexpression of Hsp70 was also able to suppress polyQ toxicity in a Drosophila MJD model, although 
without a visible effect on aggregation (160). The protective role of chaperones was also shown in other 
MJD Drosophila model, where the overexpression of two Hsp40s, DNAJ-1 and DNAJ-2, suppressed the 
aggregation of mutant ataxin-3 (172). MJD progression was accelerated by genetic reduction of the co-
chaperone and ubiquitin ligase CHIP (C-terminus of Hsp70-interacting protein), which also lead to increased 
levels of ataxin-3 microaggregates in a transgenic mouse model (161). These results suggest that 
increasing CHIP activity could be a possible therapy for MJD and other polyQ diseases. Recently, in a 
Drosophila MJD model, was demonstrated that ataxin-3 interacts with Rad23 leading to increased levels of 
the co-chaperone DnaJ-1 and depends on it to exert neuroprotection (173) In a SBMA cell model, it was 
demonstrated that overexpression of Hsp70 and Hsp40 increased expanded repeat AR solubility and 
decreased the half-life of expanded repeat AR (174). Overexpression of these two chaperones could also 
suppress aggregate formation and apoptosis in a neuronal cell model of SBMA (162). The first Drosophila 
model was very recently generated for SCA6 where it was shown that DnaJ-1 reduced the nuclear 
localization of the mutant protein as well as the mutant protein aggregates (175).  
HSF-1 is the major regulator of the heat-shock response (HSR) in mammalian cells (176). Hsp90-
containing HSF-1 complexes are present in the unstressed cell and dissociate during stress allowing 
dislocation of this transcription factor to the nucleus where it exerts its effects, initiating expression of 
several molecular chaperones. This includes Hsp90, which will contribute to terminating this stress 
response in a classic negative feedback loop. Therefore, Hsp90 by itself and/or associated with 
multichaperone complexes, is a major repressor of HSF-1 (177). In that sense, pharmacologic inactivation 
of Hsp90 leads to the overexpression of several molecular chaperones activating the Heat Shock Response 
(HSR) via HSF-1 (177, 178). Hsp90 is an ATP-dependent molecular chaperone and Hsp90 inhibitors mimic 
the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause 
potent and selective blockade of ATP binding/hydrolysis, inhibiting chaperone function (179).   
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Potent Hsp90 inhibitors, such as 17-AAG or 17-DMAG, have been shown to reduce aggregate load 
and toxicity in cell, fly, C. elegans, mouse brain and slice culture models of neurodegeneration dependently 
on HSF-1 (102, 180-185). These two compounds have also shown beneficial effects in a SBMA mouse 
model (184, 186). 17-AAG was the first Hsp90 inhibitor studied in clinical trials for cancer therapy; since 
Hsp90 is responsible for the stability of several signaling proteins, including mutated, chimeric, or 
overexpressed signaling proteins which enable cancer cell growth, survival or both, inhibiting Hsp90 could 
lead to inactivation, destabilization and eventually degradation of Hsp90 client proteins (187, 188). Despite 
its high potency, 17-AAG showed poor solubility and stability and demonstrated moderate toxicity in several 
clinical trials (189). This compound is able to increase the efficacy of other drugs, being for this reason in 
phase III of clinical trials (190). Since Hsp90 inhibitors showed to have a big potential, new synthetic 
inhibitors were designed (191, 192). Chemical compounds such as BIIB021 demonstrate to be more 
potent compared with 17-AAG (193); this compound is currently in phase II clinical trials for solid tumors. 
Other Hsp90 inhibitors identified include PU3, presenting better solubility than 17-AAG, but less potency 
(194) and NVP-AUY922, which entered clinical trials (phase I/II) and demonstrate early success in cancer 
field (195, 196). In fact, NVP-AUY922 was recently tested in HdhQ150 embryonic stem cells and showed to 
reduce the levels of soluble full-length mHtt (197). HSP990, another Hsp90 inhibitor, currently under 
clinical trials (phase I) in advanced solid tumors to test dosage, efficacy and tolerability, was shown to 
improve motor performance, aggregate load in a transgenic mouse model of Huntington disease (198). 
Recently, ethoxyquin (EQ), an antioxidant, was tested in peripheral neuropathy caused by paclitaxel, a 
common chemotherapeutic agent used in solid tumors (199). In this study the authors showed that EQ is 
able to inhibit Hsp90 activity and found that ataxin-2 is a client protein of this action. Furthermore EQ was 
shown to be neuroprotective in DRG cell cultures previously treated with paclitaxel (200). Based on these 
studies, Hsp90 seem to be a good therapeutic target for neurodegenerative disease; taking this, Ernst and 
colleagues suggested that Hsp90 inhibition should take in consideration the four different Hsp90 isoforms. 
Inhibition of the specific cytosolic isoforms (α and β) appears to be sufficient to reduce mutant huntingtin 
protein levels (201). Compounds that selectively inhibit Hsp90 (α and β) versus the endoplasmic reticulum 
(GRP94) and the mitochondrial (TRAP1) versions of this chaperone might confer a beneficial effect. This 
selectivity may also offer the opportunity to generate more well tolerated Hsp90 inhibitors (201)  
These studies provide good evidence of the beneficial role of increasing chaperone levels in polyQ 
diseases. 
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(ii) Ubiquitin-proteasome system (UPS) 
The UPS is an evolutionarily conserved pathway that controls the levels of critical proteins and is 
responsible for the degradation of misfolded or irreversibly damage proteins (reviewed in (202). This 
pathway is tightly regulated and involves two main steps: the selective polyubiquitylation of a given 
substrate and the indiscriminate proteolysis of the protein inside the proteasome core (203). Protein 
aggregates are a common feature of polyQ diseases (204, 205) and often these aggregated species are 
immunoreactive for ubiquitin, and for proteasome components (206-208). This co-localization led to 
subsequent studies regarding the involvement of UPS dysfunction in polyQ disorders. However, is still under 
debate whether UPS impairment is a cause or a consequence in neurodegenerative disorders. For example, 
a study suggested that accumulation of mutant htt in cells, transgenic mice and HD patients brains, drives 
the formation of aggregates as a consequence of age-related UPS dysfunction (209). Also, a decrease in 
synaptic UPS activity was shown in cell and mouse models of HD, suggesting the importance of the UPS in 
the synaptic dysfunction and selective neuropathology observed in HD (210). Supporting this, impairment 
of the UPS was shown in a cellular model, upon polyQ aggregation, even before inclusion formation (211). 
In contrast, more recent studies in different HD mouse models suggested that mutant htt does not impair 
the UPS (212) and globally no impairment of the UPS activity was found in the brain of the R6 (1 and 2) 
mouse models of HD (213). Also, in a mouse model of SBMA a well-preserved proteasome function was 
shown (185). 
Recently several studies were performed in an attempt to further explore the UPS involvement in 
polyQ diseases. For example, in MJD, it is thought that the UPS may be involved in the disease 
pathogenesis. Support to this theory is given by the interaction of ataxin-3 with parkin – an E3 ligase - (214, 
215), with the C terminus of Hsc-70-interacting protein (CHIP) (216), with valosin-containing protein (VCP) 
(217), as well as with proteasome components (218). It was suggested that mutant ataxin-3 has increased 
affinity for VCP, preventing the assembly of the VCP/Ufd1-Npl4 complex, responsible for the 
retrotranslocation of proteins from the endoplasmic reticulum to the cytoplasm, where ubiquitylated 
proteins are degraded by the proteasome (219). The ubiquitin ligase CHIP interacts with chaperones to 
promote the degradation of misfolded proteins (220). As mentioned before, ataxin-3 interacts with CHIP, 
although the functional meaning of this interaction is mostly unknown. Recently, it was shown that the 
ubiquitin-conjugating enzyme Ube2w is responsible for CHIP monoubiquitylation and that this ubiquitylation 
stabilizes the interaction of CHIP with ataxin-3 (216).  The dynamic interaction between ataxin-3 and CHIP 
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is disturbed in the context of expanded-polyQ ataxin-3, since mutant ataxin-3 has increased affinity for CHIP 
compared to wild-type ataxin-3 (221); this increased affinity may result in increased CHIP degradation and 
consequent impairment of protein quality control mechanisms. Accordingly, an increased affinity of mutant 
ataxin-3 for parkin – an E3 ligase responsible for a familial form of Parkinson disease (222) was 
demonstrated, resulting in increased parkin degradation (215), which correlated with decreased parkin 
levels found in a mouse model of the disease (223).  
Although the involvement of the UPS in polyQ diseases is still under debate, its modulation has 
been taken as therapeutic target for these pathologies. Amiloride and its derivate, benzamil, known to 
increase UPS activity, reduced polyQ aggregation and toxicity in HD models (224). As mentioned before, in 
a HD Drosophila model, Y-27632 - an inhibitor of the Rho-associated kinase p160ROCK lead to reduction in 
polyQ toxicity (122). Interestingly, this compound increased UPS activity and also increased 
macroautophagy; this particular effect of modulating the two main cellular degradation pathways, led to 
reduced levels and reduced aggregation of mutant huntingtin and ataxin-3 in cellular models (26). USP14 is 
a deubiquitylating enzyme (DUB) associated with the proteasome that blocks the degradation of 
ubiquitylated substrates. Mutations in specific ubiquitin-specific protease 14 (USP14) have previously been 
linked to neurodegenerative disease, and loss of USP14 leads to an ataxic neurological phenotype in mice 
(225). Supporting this, neuronal expression of USP14 was able to reverse the motor symptoms observed in 
ataxic mice (226). However, recent work described the inhibition of ubiquitin-protein conjugate degradation 
by USP14. In cellular models, a USP14 inhibitor, IU1, indirectly accelerated proteasomal degradation of 
proteins, such as tau and ataxin-3 (227). Because polyQ diseases are associated with accumulation of 
misfolded proteins, it has been proposed IU1 or other small molecule USP14 inhibitors may be used to 
increase the clearance of these toxicity-causative proteins and improve the prognosis in neurodegenerative 
diseases. 
 
(iii) Autophagy 
Macroautophagy, commonly referred as autophagy, is an important process for the bulk 
degradation of proteins and organelles and plays a major role in cellular stress conditions such as nutrient 
deprivation and infection (228). During nutrient starvation, increased levels of autophagy lead to the 
breakdown of non-vital components and the release of nutrients, ensuring that vital processes can continue 
(229). Autophagy it is also involved in neuronal and astrocytic cell survival and function, as demonstrated in 
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cerebral ischemia and/or reperfusion models, where physiological levels of autophagy, caused by mild 
hypoxia or ischemia, appear to be protective. In contrast, high levels of autophagy, caused by severe 
hypoxia or ischemia and/or reperfusion, may cause self-digestion and eventually neuronal and astrocytic 
cell death (230). Initiation of the process of autophagy begins with the formation of double-membrane 
structures called autophagosomes that fuse with lysosomes (autolysosomes) and lately degrade their 
contents by lysosomal hydrolytic enzymes (231, 232). Autophagy serves to recycle cytoplasmic proteins in 
normal conditions, and generate nutrients necessary under starvation status. Mice lacking Atg7 (autophagy-
related 7 gene) specifically in the central nervous system demonstrated behavioral deficits, such as 
abnormal limb-clasping and motor uncoordination, and died prematurely. Atg7 deficiency caused massive 
neuronal loss in the cerebral and cerebellar cortices. Polyubiquitylated proteins accumulated in the neurons 
of these mice as inclusion bodies which increased in size and number with ageing (233). Another study 
using mice deficient for Atg5 (autophagy-related 5 gene) specifically in neurons, showed that these animals 
developed motor deficits and it was possible to observe abnormal intracellular proteins that accumulated 
and formed aggregates and cytoplasmic inclusion bodies in neural cells. These results suggest the 
importance of basal autophagy for preventing the accumulation of abnormal proteins that can lead to 
neurodegeneration (234). 
The fact that accumulation of misfolded proteins in the cell is a common mechanism in several 
neurodegenerative disorders (235), makes autophagy a prominent target for the treatment of such 
diseases; these include Alzheimer disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis 
(ALS), Huntington’s Disease (HD), Machado-Joseph disease (MJD/SCA3) and other polyQ diseases (236-
248). Autophagy is modulated by several mechanisms, being directly regulated by the mammalian target of 
rapamycin (mTOR), as a negative regulator (249). Lentiviral vector-mediated overexpression of beclin-1, 
important for autophagosome formation,  was shown to be protective in neuronal culture and a lentivirus-
based rat model of SCA3 (246). Drugs that potentially modulate autophagy are increasingly being used in 
clinical trials, and screens are being performed for the discovery of new drugs that induce autophagy. 
Administration of rapamycin to different animal models of neurodegenerative disorders was demonstrated 
to be beneficial by enhancing autophagy function (231, 238, 245, 250, 251). Autophagy can also be 
regulated independently of mTOR, which can be achieved through lithium, sodium valproate and 
carbamazepine, compounds that lower myo-inositol-1,4,5-triphosphate levels (252, 253).  
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Another compound that is able to induce autophagy independently on mTOR is Rilmenidine, used 
in clinics as an anti- hypertensive agent (254, 255). Rilmenidine was shown to induce autophagy, attenuate 
the symptoms of disease observed in these mice and diminish the levels of mutant htt in a transgenic 
mouse model of HD (256). As rilmenidine is used chronically in hypertension, it is considered a safe 
compound for chronic use (257), which makes it a very interesting drug for therapeutic approaches in 
polyQ diseases. It is important to identify new safe autophagy inducers to be used in chronic treatments. As 
already mentioned, it was shown that trehalose has also the ability to induce autophagy independently on 
mTOR pathway, and enhance the clearance of autophagy substrates such mutant htt and mutant α-
synuclein (121). Recently a small molecule screen in yeast identified new molecules that are able to 
enhance autophagy (258, 259).  The authors identified small molecules that are suppressors of the effects 
of rapamycin – small-molecule inhibitors of rapamycin (SMIRs) – and enhancers of these effects – small-
molecule enhancers of rapamycin (SMERs). These molecules, were further tested in mammalian cells. 
From this screen, three SMERs (10, 18 and 28) appear to be interesting, since they could enhance the 
clearance of mutated α-synuclein in a cellular model. Furthermore, the combination treatment with these 
SMERs and rapamycin dramatically enhanced the effects of rapamycin (or the SMER) alone on mutated α-
synuclein clearance (259). 
 
1.3.3 Increasing histone acetylation 
 Transcriptional deregulation is a unifying feature of polyQ disorders (260-265); however, the 
relationship between polyQ-induced deregulation of gene expression and the ongoing degenerative 
processes remains unclear.  
 More than 20 nuclear proteins relevant to transcription are known to interact with polyglutamine 
disease associated-proteins (261, 266). Mutant polyQ proteins have been shown to interact abnormally with 
proteins involved in the transcription machinery, namely the CREB-binding protein (CBP), p300/CREBBP 
associated factor (PCAF), TATA-binding protein (TBP), TAFII130, and SP1 (261, 265, 267). Overexpression 
of some of these transcription regulators was shown to overcome polyQ toxicity, both in cellular models for 
MJD, SBMA, and HD (262, 267) as well as in vivo in a polyQ model in Drosophila (263). This suggests that 
expanded polyQ proteins may contribute for the depletion of key transcriptional regulators with toxic effects 
to the cell and reinforces the idea of an important role for transcription deregulation in polyQ pathogenesis. 
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 Many proteins that interact with polyglutamine disease associated-proteins are distributed around 
the core transcription machinery, which is now also known to exert DNA methylation, histone acetylation 
and RNA modification simultaneously (reviewed in (268)). CBP has attracted attention because it is a 
representative co-activator that possesses HAT (histone acetyltransferase) activity and interacts with 
numerous transcription factors, and its abnormal binding to disease proteins should affect the expression of 
a wide range of genes. Several polyQ-protein interactors have acetyltransferase activity. Acetylation of 
histones relaxes the DNA structure promoting transcription, whereas hypoacetylation represses gene activity 
(269). The equilibrium of histone acetylation/deacetylation is controlled by histone acetyltransferases and 
deacetylases (HDACs). HATs can be divided in two groups: HAT A and HAT B, based on cellular localization 
and mechanism of action. The proteins of the HAT A family are found in the nucleus where they transfer 
the acetyl group from Acetyl-CoA to an ε-NH2 group of histone N-tails after the assembly into nucleosomes, 
whereas the HAT B members are present in the cytoplasm and transfer the acetyl group from Acetyl-CoA to 
an ε-NH2 group of free histones prior to their deposition on the DNA (270). Many transactivation factors 
possess HAT activity. Mammalian HDACs are a family of 18 proteins divided in four classes based on 
structural and functional similarities: class I (HDACs:1, 2, 3, 8), Class IIa (HDACs: 4, 5, 7, 9), class IIb 
(HDACs: 6, 10), class III (sirtuins 1-7) and HDAC11 as the only member of class IV (271). 
 Thus, the current conceptual model is that polyQ proteins may be toxic by their direct inhibition of 
the acetyltransferase activity of transcription regulators, leading to diminished gene expression. The 
reactivation of the deregulated gene transcription, in particular by targeting histone acetylation using 
different compounds, albeit conceptually a very unspecific approach, is a growing field of research. In fact, 
treatment of polyQ disease models with HDAC inhibitors has been shown to ameliorate the disease 
phenotype and to decrease cell degeneration, with the increase of histone acetylation and consequent 
transcription activation (272-277).  
 Sodium butyrate (SB), an HDAC inhibitor, was tested in several polyQ diseases and shown to be 
beneficial (273, 275, 278). Pharmacological treatment using SB to modulate transcription significantly 
extended survival, improved body weight and motor performance, and delayed the neuropathological 
damage in a transgenic mouse model of HD, with an increase in histone acetylation (273). A transgenic 
mouse model of SBMA was also treated with SB and the authors were able to demonstrate an improvement 
in neurological phenotypes, as well as increased acetylation of nuclear histones in neural tissues. The 
therapeutic effects observed were obtained within a narrow range of SB concentrations (2, 4, 8, 16 and 40 
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g/L were tested and SB was only beneficial at 4 and 8 g/L), indicating the importance of the dosage used 
for this type of studies (278). Biochemical analysis of a DRPLA transgenic mouse model revealed 
hypoacetylation of histone H3 in brain tissue, indicating a global gene repression. Treatment of this mouse 
with SB rescued the histone hypoacetylation as well as the motor phenotype observed in this model; the 
treatment also extended lifespan of this transgenic mouse model (275). In a conditional pan-neuronal 
Drosophila model of SCA7, histone acetylation was found to be globally decreased and this mechanism of 
pathogenesis was further explored in primary neuronal cultures, where treatment with SB improved survival 
time of the neurons, indicating this small molecule as a good candidate for studies in higher models (279). 
Chou and colleagues demonstrated a hypoacetylation of H3 and H4 and a transcriptional downregulation in 
the cerebellum of a SCA3 mouse model when compared to wild-type animals (280). Recently, these 
authors used SB as therapeutic agent in this SCA3 mouse model, and observed that pre-symptomatic daily 
administration of SB was able to revert histone hypoacetylation as well as the transcription donwregulation. 
SB treatment also delayed the ataxic symptoms, improved neurological phenotypes and increased survival 
of SCA3 transgenic mice (276).  
Suberoylanilide hydroxamic acid (SAHA or vorinostat), is a potent HDAC inhibitor (acting 
preferentially on class I HDACs and HDAC6) that acts on gene expression and is an inducer of growth 
arrest, differentiation and/or apoptotic cell death in transformed cells, in vitro and in vivo (281-285). SAHA 
treatment of a transgenic mouse model of HD showed beneficial effects in the motor phenotypes observed 
in this model, and partial rescue of striatal neuron loss; the authors demonstrated that SAHA is able to 
cross the blood brain barrier, a common challenge in the field, and that it is able to increase acetylation in 
the brain (274). More recently, the same group demonstrated that SAHA is also a HDAC class IIa inhibitor. 
They showed that HDAC2 and HDAC4 were decreased after SAHA treatment in the cortex and brainstem at 
the protein level but not at mRNA level (286). The authors speculate that the mechanism by which SAHA 
reduces HDAC4 is through RANBP2-mediated proteasome degradation, as determined for cancer cell lines 
(286, 287). 
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Table 2. Summary of the most relevant side effects observed for compounds tested in non-human and human trials (drugs.com). The side effects presented in this table are the most 
common symptoms and might not occur in all population. Compounds currently in human clinical trials for polyQ diseases (clinicaltrials.gov). Date of search: June 2015. 
Pathway Compound Most common side effects Clinical trials (In polyQ) 
Inducing refolding/ 
degradation of 
mutant protein 
17-AAG Nausea, vomiting, fatigue and liver enzyme disturbances, ocular disturbances not yet 
17-DMAG Diarrhea, fatigue, headache, arthralgia, náusea not yet 
Amilorade Hyperkalemia, diarrhea; headache; loss of appetite; nausea; weakness. not yet 
Rapamycin Acne; constipation; diarrhea; headache; joint pain; nausea; stomach pain; dyspnea; hypertension not yet 
Lithium 
Drying or thinning of the hair; hair loss; mild hand tremor; mild loss of appetite; mild thirst; mild tiredness; ataxia; 
temporary, mild nausea and general discomfort at the beginning of treatment 
Phase II (SCA2, NCT00998634); Phase II/III 
(SCA3, NCT01096082); Phase I (SCA1, 
NCT00683943); Phase II (HD, NCT00095355) 
Carbamezapine Dizziness; drowsiness; dry mouth; nausea; unsteadiness; vomiting. not yet 
Valproate 
Change in appetite; constipation; diarrhea; dizziness; drowsiness; hair loss; headache; indigestion; mild pain 
or redness at the injection site; nausea; stomach cramps or pain; trouble sleeping; vomiting; weakness; 
weight changes. 
not yet 
Rilmenidine Very rare side effects not yet 
Trehalose gastrointestinal symptoms not yet 
Promoting 
histone acetylation 
Phenylbutyrate Bad taste in mouth; body odor; decreased appetite; absent or irregular menstrual periods. 
SCA3 (phase II, NCT01096095) and 
HD (phase II, NCT00212316) 
 
SAHA/vorinostat 
Constipation; cough; diarrhea; dizziness; dry mouth; fatigue; hair loss; headache; loss of appetite; muscle aches; 
nausea; taste changes; vomiting; weight loss 
not yet 
Mithramycin Anorexia, nausea, vomiting, diarrhea, and stomatitis, headache, fever, weakness, lethargy, malaise, and drowsiness not yet 
Rolipram 
Low blood pressure, dry mouth, constipation, altered sleep cycle, vomiting, headache, chest pain, 
afternoon drowsiness, reduction in alcohol tolerance, fainting, weight gain, orthostatic hypotension, 
sexual dysfunction, stiff neck, nausea, palpitations, sweating, chills, flushing, pallor and fear. 
not yet 
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Table 2 (continued). Summary of the most relevant side effects observed for compounds tested in non-human and human trials (drugs.com). The side effects presented in this table are 
the most common symptoms and might not occur in all population. Compounds currently in human clinical trials for polyQ diseases (clinicaltrials.gov). Date of search: June 2015. 
 
Pathway Compound Most common side effects Clinical trials (In polyQ) 
Neuroprotection 
Creatine Stomach pain; nausea; diarrhea and muscle cramping HD (phase III, NCT00712426) 
Co-enzyme Q10 Diarrhea; loss of appetite; nausea; stomach upset; trouble sleeping. HD (phase III, NCT00920699; NCT00608881) 
Nicotinamide Diarrhea; dizziness; headache; itching; nausea; stomach upset; temporary feeling of warmth or flushing of the skin. not yet 
TUDCA 
Constipation; diarrhea; dry skin; gas; headache; indigestion; metallic taste; muscle or joint pain; nausea; skin rash; 
stomach pain; swelling; tiredness. 
HD (phase I, NCT00514774) 
N-acetylcysteine Cold; clammy skin; drowsiness; fever; inflammation of the mouth or tongue; nausea; runny nose; vomiting. not yet 
Dantrolene 
Decreased grip strength; diarrhea; dizziness; drowsiness; general body discomfort; lightheadedness; 
muscle weakness; nausea; pain or redness at injection site; unusual tiredness; weakness. 
not yet 
Riluzole 
Abnormal skin sensations around the mouth; diarrhea; dizziness; drowsiness; headache; loss of appetite; 
muscle weakness; nausea; stomach pain; vomiting; weakness. 
HD (phase III, NCT00277602) 
Remacemide Lightheadedness, dizziness, vomiting, nausea and gastrointestinal disturbances HD (*) 
(*) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57:397–4. 
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Another histone deacetylase inhibitor, phenylbutyrate, improved survival, and attenuated gross 
brain atrophy and ventricular enlargement in N171-82Q HD transgenic mice (81). On the other hand, 
inhibition of histone H3 methylation by mithramycin lead to an increase of the lifespan and improvement in 
motor performance and striatal pathology of R6/2 mice (288). Another drug shown to alleviate the 
transcriptional dysfunction is the phosphodiesterase type IV inhibitor rolipram, proposed to act by 
increasing the phosphorylation and activity of CREB. R6/2 HD mice treated with rolipram showed an 
extension in lifespan as well as an improvement of the neuropathology and a slowed progression of 
neurological phenotype. Interestingly, the expression of BNDF, which is impaired in HD (289, 290), was 
induced in treated mice through restored function of CREB (291). In another study, it was shown that 
rolipram also prevented the sequestration of CBP into nuclear aggregates (292). HDACi 4b, that 
preferentially targets HDCA1 and HDCA3, was extensively tested in models of disease (reviewed in (293)). 
Early studies showed that HDCAi 4b was able to improve the body weight loss, strial volume reduction and 
motor impairments in the R6/2 mouse model of HD (294). Accordingly, later studies also showed that 
HDCAi 4b could improve the striatal volume loss and clasping behavior in two different model of HD (295). 
Combinatory treatment using HDCAi 4b and a related inhibitor (HDCAi 874) was shown to reduce mutant 
huntingtin aggregation in several brain regions (296). 
In spite of the promising results obtained using HDCA inhibitors in the context of polyQ diseases, 
this strategy lacks specificity (297-300) and knowledge on their actual mechanism of action is lacking; 
furthermore, not all HDCA inhibitors have the same protective activity. These issues hamper the translation 
of promising findings in the laboratory context, to the clinical application. Their chronic use in humans, 
using the currently available molecules, might be limited by the existence of several toxic effects (Table 2). 
Furthermore, since the specific targets of HDACs are not known, it will be very hard to restructure these 
compounds to reduce their toxicity. From a pharmacokinetic perspective, most of the HDAC inhibitors in 
clinical phase I studies have a short half-life in plasma (2-8 hours) and the collateral effects found included 
fatigue, somnolence, confusion and diarrhea, thus limiting therapeutical applications (301-304). 
Nevertheless, it is conceivable that, if one single therapeutic agent has limited potential because of its side 
effects, the combination of drugs might be a useful strategy in the attempt of obtaining maximal therapeutic 
effects at lower dosages, thus reducing undesired symptoms (305). Additionally, and given the increasing 
knowledge on HATs and their function in neuronal survival, the stimulation of acetyltransferase function 
emerges as a new therapeutic possibility in the fight against neurodegenerative disorders (306).  
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1.3.4 Neuroprotection 
Although progressive accumulation of specific protein aggregates is a defining feature of polyQ 
diseases (307), the specific mechanisms by which mutant proteins cause neuronal dysfunction and 
eventually cell death are not well understood. Evidence for mitochondrial deficits, oxidative stress and 
excitotoxicity, all of which might cause neuronal death have been found in different models of polyQ 
diseases. These three main mechanism may act separately or cooperatively to cause neurodegeneration 
(308).  
Metabolic deficits of neurons can be caused by mitochondrial neurotoxins, such as carbon 
monoxide, 3-nitroproprionic acid (3-NP), MA, MPTP and others. Neurons are highly energy-demanding cells 
and the synthesis of ATP occurs mainly in the mitochondria, therefore, mitochondrial poisoning results in 
ATP depletion, which can be cytotoxic. Evidence supporting these facts came from the study where 3-NP 
was administered systemically to rats causing cytotoxicity mainly in the striatum (309). Cerebral studies 
using F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) showed decreased cerebral 
metabolic rates for glucose, providing strong evidence for metabolic deficits in HD patients (310-313). 
Increased lactate levels were also detected in HD patients using imaging methods (314). Reduced 
concentrations of creatine and phosphocreatine have been observed in the basal ganglia of HD patients 
(315); there are also descriptions of a decrease in mitochondrial electron transport enzymes in HD 
postmortem tissue (316), such as cytochrome C oxydase I (317), reinforcing the idea that oxidative stress 
and mitochondrial dysfunction could be implicated in polyQ pathogenesis (318). Moreover, it was recently 
shown that mtDNA damage can be an early biomarker for HD neurodegeneration (319) since increased 
amounts of mtDNA deletion were observed in leucocytes of HD patients (320). Recently, a study using a 
transgenic mouse model of MJD also revealed a decreased mtDNA copy number in affected brain regions, 
that was aggravated with age, and also the accumulation of mtDNA 3867bp deletions, particularly in the 
initial stages of the disease (321). This is agreement with findings in MJD patients’ samples and in cells 
expressing mutant ataxin-3, which also showed decreased mtDNA copy number and an accumulation of 
mtDNA deletions (322).  
Several defects in the activities of the mitochondrial respiratory chain were also found in polyQ 
diseases. For example, defects in complex II/III were found in the striatum of HD patients (323). A 
proteomic approach in the striatum of R6/2 mouse model (324) and in the striatum of HD patients (325), 
has lead to the identification of reduced levels of aconitase due to increased oxidative damage. Aconitase is 
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vulnerable to free radicals and the decrease of aconitase activity is more prominent than the activity of the 
complex II/III when cells are exposed to stress. Furthermore, an important mediator of mitochondrial 
biogenesis, PGC-1α, was shown to be downregulated in HD patients and in animal models of the disease 
(326, 327). Abnormalities of mitochondrial permeability transition pore (mPTP) and calcium handling might 
be also relevant for polyQ pathogenesis. It was shown that mutant htt accumulates in mitochondrial 
membranes and that mitochondrial calcium is defective when normal mitochondria are incubated with a 
fusion protein containing a long polyQ tract (328). These results suggest that the polyQ tract, common to all 
polyglutamine diseases, is directly responsible by mitochondrial calcium-handling defects. It was also 
demonstrated that lymphocyte mitochondria from HD patients present a lower membrane potential (329) 
and depolarize at lower calcium loads than controls (330). Mitochondria isolated from striatum cells 
expressing mutant htt (331) and from muscle of R6/2 transgenic mice (332), showed induced mPTP 
opening and disruption of mitochondrial calcium homeostasis. PolyQ expansions cause multiple cellular 
alterations, leading to an early increased resistance to calcium in mitochondria, that undergo compensatory 
changes in calcium sensitivity (333) in an age-dependent manner. Comparing mitochondrial respiratory 
function from R6/2 mice with 12 weeks of age and transgenic animals with 12 months, the later shows 
higher respiratory control ratios and exhibits increased resistance to calcium loading; however when 
challenged with energy-demanding stimuli, the neurons from these old mice are more vulnerable to calcium 
deregulation (334). Dantrolene, a ryanodine receptor antagonist and clinically relevant Ca2+ signaling 
stabilizer, was shown to be beneficial in a transgenic mouse model of HD. After glutamate exposure in 
striatal cells, it was possible to observe an increase in Ca2+ release from intracellular stores; pre-treatment 
with dantrolene protected these cells from glutamate excitotoxicity. Feeding transgenic animals with 
dantrolene also improved motor deficits (335). This benefic effect was also possible to observe in models of 
other polyglutamine disorders, such as spinocerebellar ataxia type 3 and 2 (336, 337). Together, these 
studies indicate that mitochondrial impairment and energy dysfunction might play a role in HD and perhaps 
in the other polyQ disorders, and that any treatment that might serve to buffer intracellular energy stores 
may delay the onset and/or progression of HD pathogenesis.  
Oxidative stress might also play a role in polyQ disorders, given by the increased levels of 8-
hydroxydeoxyguanosine (8- OHdG), an oxidized DNA marker, in HD patients’ brains (323). Similar results 
were found in the striatum and forebrain of the R6/2 mouse model of HD at 12 and 14 weeks of age 
(338). Also, markers for lipid peroxidation were found to be increased in HD brains (339) and in the R6/2 
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mouse model (340). There are also observations of decreased antioxidant enzymes SOD and the oxidized 
form of glutathione in post-mortem HD brain (341). A reduction of Zn/Cu-superoxide dismutase (Cu/Zn-
SOD) was found in R6/1 HD transgenic mice at 35 weeks of age, when these animals present a severe 
phenotype (342). This reduction in Zn/Cu-SOD was also found in erythrocytes of HD patients (320). A study 
in MJD, using SK-N-SH and COS7 cells stably transfected with full-length ataxin-3 with 78 polyglutamine 
repeats demonstrated a significant reduction in the ratio of GSH/GSSG and total glutathione content (GSH 
+ 2x GSSG) in mutant MJD cells compared with the wild-type cells, under normal or stressful conditions. It 
was also shown in the same study that both cell lines had lower activities of catalase, glutathione 
reductase, and superoxide dismutase (322). Interestingly, another study showed that wild-type ataxin-3 and 
the forkhead box O (FOXO) 4 interact, activating the transcription of the SOD2 gene. Mutant ataxin-3 
demonstrated a reduced capability to activate FOXO4-mediated SOD2 expression, therefore compromising 
the antioxidant activity of cells (343). Conversely, some evidence suggests that oxidative stress could 
promote mutant huntingtin (htt) aggregation and cell death by impairing proteasomal function (344) and 
that this toxicity promoted by mutant htt could be suppressed by overexpression of Hsp27 in a cellular 
model of HD (345). This suggests that increased oxidative stress, metabolic deficits and mitochondrial 
abnormalities likely play a role in polyQ diseases. Therefore, therapeutic agents targeting these pathways 
could be beneficial for these patients. Several compounds have been tested and shown to have an impact 
in patients, and some of them are currently under clinical trials.  
Bioenergetic supplements, such as creatine, were shown to be beneficial for HD mice (346, 347), 
however a one-year study of creatine intake by HD patients did not improve functional or cognitive deficits 
(348). Another study, a phase II clinical trial of the safety and tolerability of creatine was performed in HD 
patients, in which biomarkers were assessed in the serum. This creatine supplementation study 
demonstrated that the levels of 8OH2’dG were normalized and that the dosage used (8g/day) was tolerable 
and safe to patients (349). Given the efficacy of creatine in this phase II trial, a phase III clinical trial has 
been approved and performed in several centers ClinicalTrials.gov Identifier: NCT00712426) that was 
terminated in March 2015 but no results are published yet. These results strongly support the effectiveness 
of creatine as a neuroprotector.  Two other supplements, coenzyme Q10 (CoQ10) and nicotinamide, were 
shown to be beneficial in the reduction of neurotoxicity of the metabolic poisons 3-NP and MA in rodents. 
Rats fed with CoQ10 showed less striatal lesion induced by MA and reduced lactate levels (350, 351). A 
NAD precursor, nicotinamide, is an electron acceptor which releases energy when it is re-oxidized during 
36 
 
General Introduction 
phosporylation of ADP to ATP and showed to be neuroprotector in MA lesions in rats (350, 351). Co-
treatment with nicotinamide and CoQ10, produces additional neuroprotection, since it was possible to 
reduce lesion volume, reduction in lactate levels and restoration of ATP levels (350, 351). A study with HD 
patients, however,  showed no beneficial effects with 300 mg of CoQ10 (352). Since the best balance 
between tolerability and blood levels achieved in HD patients was found for a dosage of 2,400 mg/day 
(353), a phase III clinical trial in currently ongoing using this higher dosage.  
Other antioxidants such as tauroursodeoxycholic Acid (TUDCA), BN82451 and N-acetylcysteine 
have been tested in animal models and showed several positive effects (354-356). Other potent 
antioxidants might be potential candidates: indole-3-proprionic acid (OXIGON) which is a β-amyloid fibril 
formation inhibitor and neuroprotector (357); and synthetic triterpenoids, which are able to upregulate 
genes involved in antioxidant and anti-inflammatory responses (358), reduce oxidative stress, improve 
motor problems and extend survival of a transgenic mouse model of HD (359). Also, Vitamin E, an 
antioxidant, also showed positive effects in vitro (360, 361) and in vivo (362, 363).  
Excitotoxicity can be defined as neuronal damage resulting from the toxic effects of the excessive 
action of excitatory amino acids. Glutamate is the major excitatory neurotransmitter, and in the central 
nervous system, the neuronal excitotoxicity is commonly referred to the damage and death arising from 
prolonged exposure to glutamate and the associated excessive influx of ions into the cell, resulting in 
calcium overload. This excessive glutamate is neurotoxic, leading to the activation of enzymes that degrade 
proteins, membranes and nucleic acids (364). Excitotoxicity may play a central role in HD, since the 
striatum receives glutamatergic input from the cortex (365). When excitotoxins are injected into the striatum 
the resulting neuropathology pattern is similar to that observed in HD (366, 367); therefore, it is not 
surprising that antagonists of the glutamate receptor NMDA can prevent striatal neurodegeneration (368). 
Additionally, NMDA antagonists may also protect against neuronal damage caused by other toxins, such as 
mitochondrial 3-NP and MA.  It has been shown that mutant htt enhances NMDA receptor activity and 
disturbs calcium signaling (369). Recently, expanded htt has been proposed to be able to enhance 
expression of different subunits of the NMDA receptor, NR1A and NR1B, perhaps inducing excitotoxicity 
(370). It is possible to establish an interplay between excitotoxicity, oxidative stress and mitochondrial 
function. Oxidative stress damages proteins, lipids and nucleic acids and is able to open the mPTP, that in 
turn, can stimulate ROS production, and consequently there is an energy failure and the release of 
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proapoptotic factors, such as cytochrome c into the cytoplasm (371). Ultimately, high levels of ROS and 
downregulation of antioxidant mechanism may lead to neuronal cell death (372).  
Deprivation of neurotrophic factors may also be involved in the pathogenesis of polyQ disorders. For 
example, both mRNA and protein levels of BDNF are decreased in patients and animal models of HD (373-
375) and the BDNF receptor TrkB is also reduced in a cellular model of HD (376). It seems reasonable to 
consider that increasing BDNF levels would be beneficial; indeed, BDNF, neurotrophin-3 (NT3) and NT4/5 
prevent neuronal cell death in an animal model of HD (377). BDNF seems to have positive effects in in HD 
pathogenesis; however, previous clinical trials showed several side effects of neurotrophins as well as poor 
penetration into the BBB (378). For this reason, there is a major effort ongoing to find compounds that 
upregulate BDNF. A traditional herbal medicine, tripterygium regelii extract (TRE) was shown to be able to 
increase BDNF levels in SH-SY5Y cells after a stressful stimulus. In addition to its effects on polyQ 
aggregation described before, riluzole also interferes with glutamatergic neurotransmission (379), thereby 
reducing excitotoxicity, enhancing neurite formation in damaged motor neurons and interestingly, increasing 
serum concentrations of BDNF (380, 381). Riluzole was shown to have promising results both in animal 
models and HD patients, and a phase III clinical trial is being now completed (382, 383).  
Remacemide, an NMDA glutamate receptor ion-channel blocker, seems to ameliorate the 
phenotype of a transgenic mouse model of HD (384). A pilot study demonstrated that remacemide is well 
tolerated in HD patients, as expected (385), since this compound is already used in the clinics as an 
anticonvulsant for the chronic treatment of epilepsy. However, a multi-center, randomized, placebo-
controlled, trial of remacemide in 347 HD patients has recently been completed which showed that the 30 
month treatment was ineffective at the doses used (200 mg/day and 600mg/day), and caused some 
secondary effects such as dizziness, nausea and vomiting (352). Very recently, the herbal formula B401 
was found to be neuroprotective in a mouse model of HD. This compound is widely used in traditional 
Chinese medicine. This formula B401 showed to reduce the levels of mutant huntingtin aggregates in the 
brain as well as the levels of TNF-α. Furthermore, B401 increased the levels of BDNF and VEGF expression 
in the brain of the R6/2 HD mice and was able to ameliorate brain atrophy. To complete this study, the 
survival of the animal was prolonged and the body weight loss ameliorated as well as mice performance in 
the rotarod (386) 
Further studies with neuroprotective molecules, ideally multi-target ones, may lead to improved 
effects on polyQ diseases.  
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1.3.5 Other treatment possibilities 
There are other emergent strategies for the development of an effective therapy for polyQ diseases 
such as stem cell, neural cell replacement and growth factor gene therapy. Although still in early 
experimental stages, these approaches are promising since the stimulation of endogenous stem cells in the 
brain could generate new and functional neurons (387), the replacement of dead and/ or dying neurons by 
new cells capable to connect and function appropriately (388) and the provision of neuroprotective trophic 
factors (389, 390) may provide neuroprotection and possibly promote neuroregeneration, restoring 
neuronal homeostasis.  
 
1.4 Machado-Joseph disease or Spinocerebellar Ataxia type 3 (MJD/SCA3): general oveview 
Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia 3 (SCA3), is the most 
common autosomal dominant ataxia worldwide (22). The disease was first described in families from the 
Azores Islands, being reported some years later in other countries and in families with no Portuguese 
ancestrality. This late-onset disorder was first described as an autosomal dominant ataxia in William 
Machado family and named as Machado disease (391). In the same year, another case was reported 
(Thomas family) with similar clinical symptoms, and this disease was entitled “Nigro-spino-dentatal 
degeneration with nuclear ophthalmoplegia” (392). Later on, in 1976 a “particular type of autosomal 
dominant hereditary ataxia” was described in the family of Antone Joseph, which was designated as Joseph 
disease (393).  
Two years later, after an intensive study in Azorean families and regarding the common features of 
the three families described above and the overlap with previously described Machado and Joseph families, 
a new “autosomal dominant system degeneration in Portuguese families of the Azores Islands” was 
introduced (394). In the 80’s, this disease was named Machado-Joseph disease (MJD) and some clinical 
criteria for diagnosis were introduced (395). The prevalence of this disease was from the beginning thought 
to be the highest among people of Portuguese/Azorean descendent. For immigrants of Portuguese Azorean 
ancestry in New England, the prevalence was described to be around 1:4000. The highest prevalence in 
the world, about 1:140, occurs on the small Azorean island of Flores (396). 
Later, however, researchers, based in DNA studies, have identified MJD cases in many ethnic 
backgrounds. Its relative frequency among the spinocerebellar ataxias is higher in Portugal (49%), China 
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(49%), Brazil (44%), the Netherlands (44%), Japan (43%), and Germany (42%); its relative frequency is lower 
in France (33%), the United States (21%), and Australia (12%); and it is rare in the United Kingdom (5%), 
India (3%), and Italy (1%) (50, 397-407).  
MJD patients suffer from a progressive neurodegenerative disorder appearing more frequently 
between the ages of 20 and 50 years, in which the intellect is preserved (394). The preservation of 
cognitive function is a key feature of MJD in its differential diagnosis among the vast group of 
spinocerebellar ataxias. MJD is characterized by motor uncoordination and gait ataxia, difficulty with speech 
and swallowing, spasticity, altered eye movements, double vision, and frequent urination. Some patients 
have dystonia (sustained muscle contractions that cause twisting of the body and limbs, repetitive 
movements, abnormal postures, and/or rigidity), others have peripheral neuropathy and loss of muscle 
strength or symptoms similar to those of Parkinson's disease. Twitching of the face or tongue, or peculiar 
bulging eyes due to lid retraction may also be present. The severity of the disease is related to the age of 
onset, an earlier onset being associated with a more severe and rapidly progressive form of the disease. 
Symptoms can begin any time between early adolescence and old age up to 70 years of age (396). MJD is 
also a progressive disease, meaning that symptoms accumulate and become worse with time. Life 
expectancy ranges from the mid-thirties, for patients with severe forms of MJD, to a normal life expectancy 
for those with mild forms. For patients who die early from the disease, the cause of death is often aspiration 
pneumonia due to immobility and poor coordination of swallowing and breathing. The clinical spectrum of 
SCA3 is highly pleomorphic and led to the definition of four clinical sub-phenotypes: type I, characterised 
by the dominance of pyramidal and extrapyramidal anomalies, in addition to ataxia and other signs, with an 
early age-at-onset and fast progression; type II, with typical cerebellar ataxia, progressive external 
ophtalmoplegia and pyramidal signs appearing at an intermediate age; type III, with late onset and slow 
progression of peripheral signs, such as loss of proprioception and muscle atrophies; and type IV, the 
rarest, characterised by the presence of Parkinsonic signs, associated to the core clinical features (394, 
395, 398). 
1.4.1 MJD pathology: a heterogeneous and complex disease 
The cerebellum and brainstem atrophy is well documented in MJD (408-411). Recent studies have 
shown that the neuropathology of this disease is not limited to cerebellum and brainstem, eventually 
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affecting the integrity of several functional and neurotransmitter systems resulting in severe and widespread 
neuropathology throughout the brain (412, 413) (Figure 2). 
The neuropathology of MJD includes severe neuronal loss in the anterior horn and Clarke’s column 
of the spinal cord and in restricted brain regions such as dentate nucleus (cerebellum), pontine nuclei and 
locus coeruleus (brainstem), substantia nigra (basal ganglia) and other regions such as the thalamus, as 
well as subthalamic, red and cranial nerve nuclei (414). It is also characterized by axonal neuropathy of 
peripheral motor and sensory axons (415). Also, post-mortem analysis revealed neuronal loss and gliosis in 
the substantia nigra, pontine and vestibular nuclei, as well as in cranial nerves, Clarke’s columns and 
anterior horns of the spinal cord (414). An additional finding in MJD brains is the fact that the brain weight 
of MJD patients is lower comparatively with healthy individuals, which by itself can be an indicator of brain 
atrophy (408). Most of the neuropathological studies in MJD were performed using routine pathoanatomical 
examination (4-6 µm thick sections) that might mask subtle pathological alterations in the patient’s brains. 
These studies restricted the neuropathology of MJD to the dentate nucleus, pallidum, substantia nigra, 
subthalamic, red and pontine nuclei, the anterior horn and the Clarke’s column of the spinal cord. Also, in 
these same studies, the involvement of the Purkinje cell layer of the cerebellum and the inferior olive is still 
controversial (85, 402, 416-418). Rüb and collaborators developed an unconventional examination of MJD 
patient’s brains, using 100 µm thick serial sections. The thickness of these brain sections due to their 
optical superposition allows the observation of more nerve cells than the conventional approaches used by 
neuropathologists (397, 401, 419-423). This new approach allowed the identification of new brain regions 
that suffers degeneration in MJD that might explain the heterogeneity of the symptoms observed in these 
patients. All these data is reviewed in (413). As a summary of these data, the authors found a more 
extensive damage affecting areas of the cerebellothalamocortical motor loop, the basal ganglia-
thalamocortical motor loop, and several other systems: visual, auditory, somatosensory, vestibular, 
oculomotor, ingestion-related brainstem nuclei, precerebellar brainstem, cholinergic and dopaminergic 
midbrain, and pontine noradrenergic systems (Figure 2) (413).  
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Figure 2. Neuronal circuits most affected in MJD. Illustration of cortico-pontine (PN)-cerebellar pathway (the red arrows 
correspond to cerebellar afferent system (corticopontine and pontocerebellar tracts)); the major basal ganglia loop (the green 
arrows correspond to the principal afferent and efferent fibers forming basal ganglia loops; it includes the dopaminergic 
projections from substantia nigra (SN) to caudate/putamen; and of the dentato(rubro)thalamocortical pathway (the blue arrows 
represent efferent projections of cerebellum that arise from dentate nuclei (DN) and continue their way to the motor cortex).  
 
The ataxin-3 protein (the MJD disease protein) is expressed ubiquitously and when it presents the 
expanded allele it tends to aggregate forming neuronal nuclear inclusion bodies (NNIs) in the brain (85, 
86). These NNIs are present in affected and non-affected brain regions, indicating that there is no direct 
correlation between the occurrence of these protein aggregates and disease pathology (399, 413, 424). 
Even so, the NIIs are ubiquitin positive and in their content it is possible to detect several proteins such as 
heat-shock proteins, proteasome subunits, transcriptions factors, among other proteins (86, 172, 425, 
426). Axonal aggregates were also found in human patients, and, as similar to intranuclear aggregates they 
were immunopositive for ubiquitin and p62; with this finding one can be hypothesize that axonal inclusions 
might be detrimental to axonal transport mechanisms, contributing to degeneration of nerve cells in SCA3 
(427). Despite the controversial topic on toxicity and/or protective role of NIIs (reviewed in (427)) they 
constitute an important morphological hallmark on MJD (86, 427), and are also present in the cytoplasm 
and in axons (399, 427, 428).  
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Figure 3. Neuropathology observed in MJD. Red marks indicate regions with more prominent dysfunction/degeneration in 
SCA3/MJD patients’ brains according to neuropathological studies, including the thalamus, pons, medulla oblongata and 
cerebellum. On the cellular model, it is possible to find the model of progressive alterations in protein control proposed by Seidel 
et al. Brown dots represent aggregated ataxin-3 that occurs in Stage 1 as granular cytoplasmic staining, progressing to diffuse 
nuclear staining (stage 2) and finally to neuronal nuclear inclusion (NNI) (stage 3). In stage 4 it is possible to observe 
proteasomal dysfunction observed by the red dots that only occurs in the presence of NNI. In stage 5, corresponding to a final 
dysfunction phase, is found the sequestration of chaperones into the NNI. It is also possible to observe astroglisosis and 
microgliosis in MJD brains as well as increased inflammatory cytokines. The neuropathologic findings in this illustration are 
relative to the pons of MJD patients. Furthermore, neuronal nuclear and axonal inclusions are a neuropathological finding in MJD 
brains. Adapted from (86, 427, 429).  
 
Positron emission tomography (PET) studies on the regional cerebral glucose metabolism revealed 
significantly decreased glucose utilization in the cerebellum, brainstem, striatum and whole cerebral cortex 
(430). Furthermore a decreased binding for dopamine transporter in these brain regions was also found in 
symptomatic MJD patients (431).  Although it is thought that white matter pathology in MJD is less 
pronounced when compared to grey matter, metabolic abnormalities were found in MJD brains white 
matter by magnetic resonance spectroscopy, suggesting axonal dysfunction (432). Recently, both white and 
grey matter were studied in 12 MJD patients using voxel-based morphometry to analyze tissue loss and 
tract-based statistics (TBSS) on diffusion magnetic resonance imaging (MRI) to structural pathology. The 
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authors correlated the structural changes in the brain and the symptoms severity given by the SARA score, 
and found that the white matter integrity of frontal, thalamic, brainstem and left cerebellar structures is 
negatively correlated with ataxia scores. Also, MJD patients demonstrated loss of both grey and white 
matter in the cerebellum, brainstem (including the pons) and in the thalamus. These results showed that 
the white matter pathology is evident in MJD patients and is correlated with ataxia severity (433). The most 
striking feature of brain pathology in MJD is the enlargement of the fourth ventricle that is clearly observed 
in MRI of patients. A comparative study between MJD, SCA1 and SCA6 showed that MJD and SCA1 
patients have severe atrophy in total brainstem, including midbrain, pons and medulla, total cerebellum, 
cerebellar hemispheres and cerebellar vermis, putamen and caudate nucleus. In this MRI study, the 
cerebellar cortex presented integrity in all disorders (434). There are some controversial findings regarding 
the progressive neuropathology and its correlation with patient’s age and CAG repeat length. Onodera and 
collaborators observed a close correlation between brainstem and cerebellar vermis atrophy with CAG 
repeat size and age in MJD patients (410). Another study, demonstrated that the cerebellum and brainstem 
atrophy is progressive and dependent on the length of the CAG tract and the age of the patients (435). 
Other study failed to demonstrate a correlation with patient’s age and progression of atrophy in a 
longitudinal study using volxel-based morphometry within one year (411). Consistent with this observation, 
Schulz and colleagues demonstrated a weak negative correlation with repeat length of the expanded allele 
and the volume of the brainstem, pons, caudate and putamen nucleus in MJD patients (434). Recently, 
Reetz and collaborators and the Ataxia Study group investigators undertook a longitudinal study using MRI 
at baseline and after a 2-year follow-up in MJD, SCA1 and SCA6 patients (436). The authors also 
determined the rate of volume loss and compared morphology changes and clinical features measured by 
different ataxia scales. The authors found the strongest volume loss change in the basal ganglia (specifically 
the caudate and putamen of the striatum), followed by the brainstem and found only mild atrophy in the 
cerebellum. The authors hypothesize that the strong atrophy of the brainstem and cerebellum at baseline 
could lead to a ceiling effect in the longitudinal study. Nevertheless, they proposed the involvement of the 
striatum in MJD. No correlation was found between neuropathology progression and CAG repeat length or 
disease duration (436).  
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1.4.2 Mouse models 
Rodents are the mammals of choice used in biomedical research, and extensive research has been 
performed using rats, mice, guinea pigs and hamsters. Among these rodents, and especially in those 
studies involving disease, mice are the most used. The big challenge faced by the mouse genetics field is 
the determination of the phenotype of each mutant (437) and three criteria are commonly used to validate 
a mouse model: (i) construct validity, stating that the animal model has to carry the same biological 
features that cause the human disease, such as the same genetic alteration or anatomical abnormality, (ii) 
face validity, that comprises a conceptual correspondence to the behavioral phenotype (symptoms) and 
endophenotype (physiological/anatomical alterations) of the human disease, and (iii) predictive validity, 
where the response to treatments (preventive or curative) should be analogous between mice and humans 
(438). Each model generated for a specific human disorder attempts to mimic some of its particularities, 
however, few replicate all the symptoms. MJD is not an exception. In the last 20 years, eight mouse models 
were generated for this disease (Table 3). 
 
1.4.3 MJD mouse models: phenotype overview 
The first MJD mouse model was generated in 1996 at Kakizuka’s lab. They were the first showing 
neurodegeneration and a neurological phenotype in a transgenic mouse model with an expanded CAG 
trinucleotide repeat within the ataxin-3 cDNA. This mouse was generated using truncated and full-length 
cDNAs of the ATXN3 gene (MJD1a isoform), with the L7 promoter directing expression specifically in 
Purkinje cells. In these constructs the cDNA encoded for Q79C, Q79, Q35C (truncated forms with or 
without C-terminal) or MJD79 (full-length context). The transgenic mice expressing truncated forms (Q79C, 
Q79) of the protein showed an ataxic phenotype (given by qualitative measures of wide-based hindlimb 
stance and falling down when moving), whereas the animals expressing the full-length protein (MJD79) or 
control individuals (Q35C) did not reveal any characteristic symptom of the disease. The onset of the 
symptoms in affected animals was around 4 weeks of age and the strong ataxic phenotype was more 
prominent in animals with a higher copy number of the transgene. This work showed that the expanded 
polyglutamine is responsible for neuronal loss and degeneration (15).  
Some years later, another mouse model was created in an attempt to properly mimic the temporal 
and spatial expression of the human disease gene, using yeast artificial chromosome (YAC) constructs 
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carrying the full-length ATXN3 gene with expanded polyglutamine tracts, containing all the enhancers and 
long-range regulatory elements needed for cell-specific expression at physiological levels. Two additional 
genes were also part of the cloned genomic region. Homologous recombination in the yeast host was used 
to generate three YAC constructs with 15, 76 and 84 repeats, corresponding to the human wild-type, 
intermediate and early-disease-onset MJD alleles, respectively. The mice carrying expanded alleles showed 
abnormal gait, tremor, hypoactivity, limb clasping, an inability to correct geotaxis, reduced grip strength, 
abnormal toe pinch responses, progressive loss of weight and balance deficits, but no premature death was 
observed. These symptoms aggravated with repeat length and with the gene dosage. Regarding the onset of 
the disease, homozygous mice showed an earlier onset, with faster and worse disease progression (223). 
Recently, a more extensive characterization of the motor phenotype of this model (YACMJD84.2 mice) was 
performed both in hemi and homozygous mice. Hemizygous animals showed a mild phenotype only 
detectable at 75 weeks of age (reduced locomotor and exploratory activity) and a reduced body weight, 
while homozygous mice developed an early motor deficit, gait problems and decreased locomotor and 
exploratory activity (439). 
In 2004, a third mouse model for MJD was published. This transgenic mouse expresses human 
mutant (Q71B and Q71C) or normal (Q20) ataxin-3 mjd1a under control of the mouse prion promoter, 
driving expression throughout the brain and spinal cord. Homozygous (Q71B and C) animals only displayed 
a phenotype that included progressive postural instability, gait and limb ataxia (footprinting analysis), loss of 
limb strength (Grip strength meter), motor uncoordination (Rotarod), weight loss and premature death only 
when the mutated protein was expressed above a critical concentration, only in their Q71C line. The 
heterozygous animals were indistinguishable in appearance and behavior from wild-type mice. This line also 
had problems in breeding, since homozygous animals were infertile (99).  
In 2007, a mouse model was generated using full-length ataxin-3 constructs (isoform 1, clone 
MJD1-1, with a third UIM at the C-terminus) containing 15, 70, or 148 CAG repeats under control of murine 
prion protein promoter. A nuclear signal (NLS) was also introduced as well as a nuclear export signal (NES) 
to transport ataxin-3 into the cytoplasm. Transgenic mice carrying 70 CAG repeats revealed a severe and 
rapidly progressive phenotype assessed in the SHIRPA protocol (tremor, wide-based hindlimbs to stabilize 
the body in a resting position as well as markedly reduced activity and grooming, resulting in a disheveled 
appearance). The footprinting analysis demonstrated mild disturbances early in life and at late stages they 
were almost unable to walk and died prematurely. This study demonstrated, not unexpectedly, that both the 
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size of the expanded CAG repeat length and the level of transgene expression are of major importance for 
disease onset and disease progression in mice. Mice with reduced expression of ataxin-3 with 70 CAG 
repeats developed a milder phenotype than lines with a stronger expression. Furthermore, transgenic mice 
with 148 CAG repeats merely survived the first months and had major problems to produce offspring, 
whereas mice with stronger expression of this transgene died very early without producing any offspring. 
More important, nuclear localization of ataxin-3 with 148 polyglutamine repeats accelerated and intensified 
the phenotype of transgenic mice even further, whereas the addition of a nuclear export signal ameliorated 
the phenotype (440).  
In 2008, another transgenic mouse model was created using cDNA of human wild-type ataxin-3-
Q22 or disease-causing ataxin-3-Q79 (ataxin-3 mjd1a isoform) under the control of mouse prion protein 
promoter. Mice from two ataxin-3-Q79 transgenic lines displayed various symptoms of motor dysfunction 
with an onset age of about 5–6 months, and the severity of neurological phenotypes progressively 
increased in the following months as assessed in the SHIRPA protocol. The symptoms included forelimb 
clasping, impaired motor coordination and shorter latency to fall in the rotarod behavioural test, less 
activity, incorrect body posture, ataxic gait (footprinting analysis), reduced weight and reduced pelvic 
elevation (280). In the same year, Torashima and collaborators generated a SCA3 mouse model (polyQ 
mice) that was suggested by the authors to constitute a great tool in viral-vector based screening of genes 
for therapeutic molecules that target the cerebellum, since the mutant ataxin-3 expression is directed to 
Purkinje cells. This model was generated using a truncated form of human ataxin-3 with 69 glutamines 
(ataxin-3 [Q69]). These mice presented a severe ataxic phenotype and disarrangement of the Purkinje cells 
(441). In order to analyze whether symptoms caused by ataxin-3 with an expanded repeat are reversible in 
vivo, a conditional mouse model of SCA3 with the full-length human ataxin-3 cDNA (isoform atxin-3c) with 
77 repeats was created using the Tet-Off system. When the expression of the expanded ataxin-3 was 
induced, transgenic mice developed a progressive neurological phenotype characterized by reduced anxiety 
and hyperactivity (given by the open-field test), impaired Rotarod performance and decreased gain of body 
weight. On the other hand, when ataxin-3 was turned off at an early symptomatic stage of the disease, the 
transgenic mice were indistinguishable from negative controls after 5 months of treatment (30). One year 
later, the same group published another MJD transgenic mice model expressing ataxin-3 (isoform ataxin-3c) 
with 148 CAG repeats under the control of the huntingtin promoter, resulting in ubiquitous expression 
throughout the whole brain. The model resembles many features of the disease in humans, including a late 
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onset of symptoms and CAG repeat instability in transmission to offspring. They observed a biphasic 
progression of the disease using the home cage activity and the open-field tests, with hyperactivity during 
the first months (not seen in human patients) and a decline of motor coordination given the rotarod test 
after about 1 year of age (442).  
In the same year, another transgenic mouse model (in our lab), using a human cDNA (isoform 1, 
MJD1-1 clone) carrying the repeat tract coding for 83 polyglutamines, under control of pCMV 
(cytomegalovirus) promoter was generated. From two different microinjections two female founders 
(background FVB/N) were obtained, A and B (94 and 83 CAG repeats, respectively). This novel transgenic 
mouse model for MJD has revealed some important features that recapitulate the disease. Namely, 
hemizygous transgenic animals developed a motor phenotype (rotarod test) in agreement with the 
dominant feature of the disease. Behavior studies revealed a number of findings in the mice from lineage A 
that differed from non-transgenic and transgenic from lineage B. We found that hemi and homozygous 
animals of lineage A displayed an uncoordination phenotype. Moreover, mutant mice tended to show a 
reduced locomotor activity in the rotarod test. In lineage A, which manifests MJD-like symptoms it was 
possible to establish a phenotype-genotype correlation: animals with higher CAG repeat tract spent less 
time on the rod (103). 
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Table 3. Summary of the MJD mouse models characterization at the phenotypic and pathologic levels. 
  
Ikeda et al, 
1997 
Cemal et al, 2002 Goti et al, 2004 
Bichelmeier et al, 
2007 
Chou et al, 2008 
Boy J et al, 
2009 
Boy J et al, 
2010 
Silva-
Fernandes et 
al, 2010 
General 
information 
Transgene 
cDNA MJD1a 
fragment with 79 
CAGs ;  cDNA 
MJD1a  full-length 
with 79 CAGs (no 
phenotype) 
All isoforms Isoform ataxin-3c Isoform ataxin-3c 
Isoform MJD1a HA-
tag 
Isoform ataxin-3c 
Isoform ataxin-
3c 
Isoform ataxin-
3c 
Promoter L7 (Purkinje cells) Human ataxin-3 (YAC) Mouse prion protein Mouse prion protein Mouse prion protein 
Hamster prion 
protein 
(conditional 
expression) 
Rat huntingtin 
(partial) 
CMV 
(CAG)n 79 64, 67, 72, 76 and 84 71 70 79 77 148 94 
Inclusions No description Yes Yes (homozigosity) Yes Yes Yes Yes No 
Cellular and 
subcellular 
transgene 
expression 
Purkinje cells 
Ubiquous (cytoplasmic 
and nuclear) 
Ubiquous but stronger 
in brain and spinal 
cord 
Ubiquous but 
directed to brain and 
spinal cord (NES and 
NLS artificial signals) 
Ubiquous but 
directed to brain 
and spinal cord 
Brain (stronger in 
the cerebellum, 
but only 
in glia cells) 
Ubiquous 
(cytoplasmic 
and nuclear) 
Ubiquous 
(cytoplasmic 
and nuclear) 
Neurodegenera
tion 
Purkinje cell 
degeneration and 
atrophic cerebellum 
Peripheral neuropathy 
with demyelination and 
degeneration of the 
DRGs; cell loss in the 
DCN and Purkinje cells; 
astrocytosis 
Substantia nigra: 38% 
decrease in TH-
positive neurons Q71-
C homozygotes 
Purkinje cell loss 
Purkinje cells with 
shrunken cell body 
and less dendritic 
arborization 
Purkinje cells 
darkly stained 
Purkinje cells 
darkly stained 
Astrogliosis in 
substantia nigra 
and vestibular 
nuclei; 
scattered dark, 
shrunken cells 
in pontine and 
dentate nuclei 
and thalamus 
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Table 3 (continued). Summary of the MJD mouse models characterization at the phenotypic and pathologic levels. 
 
 
 
  
Ikeda et al, 1997 Cemal et al, 2002 Goti et al, 2004 
Bichelmeier et 
al, 2007 
Chou et al, 2008 
Boy J et al, 
2009 
Boy J et al, 
2010 
Silva-
Fernandes et 
al, 2010 
 
Age at onset 
(weeks) 4 (ataxic phenotype) 
75 (heterozygous), 6 
(homozygous) (motor 
deficits) 
8 (tremor, hunchback, 
ataxic limbs) 
6 (tremor, 
reduced activity,  
wide-based 
hindlimbs to 
stabilize the 
body in a resting 
position) 
20 (motor deficits) 8 (limb clasping) 
48 (reduced 
balance and 
coordination) 
16 (motor 
deficits) 
Genetic 
background No description C57BL/6J (mixed?) 
B6C3F1/J 
(C57BL/6JxC3H/HeJ 
C57BL/6N 
(mixed?) 
FVB/N 
C57BL/6 
(mixed?) 
C57BL/6N C57BL/6J 
Phenotype 
  
+/- +/- +/+ +/- +/+ +/- +/- +/+ +/- +/- 
Phenotype 
parameters 
Ataxia Yes X X 
No 
phenotype 
Yes Yes Yes Yes X No 
Gait 
disturbance 
Yes Yes Yes (++) 
No 
phenotype 
Yes Yes Yes Yes X No 
Weight loss X Yes Yes (++) 
No 
phenotype 
Yes X Yes Yes X No 
Hypoactivity No Yes Yes (++) 
No 
phenotype 
Yes Yes Yes X X Yes 
Motor 
uncoordination 
X X Yes 
No 
phenotype 
Yes X Yes Yes Yes Yes 
Appearance Small Normal X Normal 
Moribund 
(32 weeks) 
Disheveled 
appearance (24 
weeks) 
X X X Normal 
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Table 3 (continued). Summary of the MJD mouse models characterization at the phenotypic and pathologic levels. 
 
  
Ikeda et al, 1997 Cemal et al, 2002 Goti et al, 2004 
Bichelmeier et 
al, 2007 
Chou et al, 2008 
Boy J et al, 
2009 
Boy J et al, 
2010 
Silva-
Fernandes et 
al, 2010 
Phenotype 
  
+/- +/- +/+ +/- +/+ +/- +/- +/+ +/- +/- 
Phenotype 
parameters 
Limb clasping X Yes Yes (++) No Yes X Yes Yes X No 
Tremors X Yes Yes (++) No Yes Yes X X X No 
Lowered pelvis X Yes Yes (++) No Yes X Yes X X No 
Limb strength 
deficit 
X Yes Yes No Yes X X X X No 
Other X X 
Excessive 
grooming 
X X X X 
Hyperactivity and 
spastic head 
movements 
(homozigoty) 
Hyperactivity X 
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1.4.4 MJD mouse models: neupathology overview 
Taking in consideration the heterogeneity and widespread neuropathology observed in MJD it has 
been difficult to establish a mouse model that mimics the brain pathology of MJD. In the model generated 
in 1996 by Ikeda and collaborators, expressing ATXN3 in Purkinje cells, the authors observed, in 8 weeks-
old mice, a severe atrophy of the cerebellum (the volume was one eighth less compared to littermate 
controls) and a massive loss of Purkinje cells (seen on calbindin staining). Also, the molecular and granular 
cell layers of the cerebellum were affected (H&E staining). The presence of NIIs was not reported in this 
study (15). In 2002, pathological examination of the brains of YAC-transgenic mice (12 months of age) 
showed degeneration and mild gliosis of the dentate and pontine nerve nuclei. The authors observed that in 
general the brain of transgenic mice were similar to controls. It was possible to observe that pontine 
neurons were abnormal, being hyperchromatic and shrunken and it were also seen scattered dark cells 
with pyknotic nuclei and eosinophilic cytoplasm (H&E staining). Quantitatively (quantification method not 
described), a 30% cell loss was observed in the pons and 40% in the dentate nucleus. In the dentate 
nucleus the cells showed grumose alterations. A slight increase in GFAP astrocytic marker was detected in 
the dentate nucleus, suggesting mild gliosis that may result from the cell loss observed in this brain region. 
Furthermore, Caldindin D-28k immunostaining showed Purkinje cell loss, shrinkage, cell body displacement 
and dendritic atrophy. The Purkinje cell loss increased with gene dose, suggesting that these cells are 
sensitive to the transgene dosage effects. These mice also had decreased myelin thickness in the dorsal 
root ganglia (DRG) and evidenced of de- and remyelination in the sciatic nerves at 9 months of age. It was 
possible to detect NIIs in neurons, but not in glial cells, mainly in the pontine and dentate nuclei. NIIs were 
not detected in cerebral cortex, hippocampus and striatum (223).  In 2004, a transgenic mouse model 
expressing human mutant (homozygous Q71) ataxin-3 under the control of the mouse prion promoter 
demonstrated a 38% decrease of dopaminergic neurons (tyrosine hydroxylase [TH]-positive neurons) in the 
substantia nigra (by the use of unbiased stereology) when compared to controls (Q20 transgenic mice) at 2-
3 months of age. Also, the authors quantified by stereology the number of Nissl-stained neurons in the 
dentate nucleus and found no statistical differences when compared to controls, although there was a 
tendency for a decrease. Finally, NIIs were evaluated and quantified (by light microscopy, counting three to 
six fields: 60 –120 neurons per brain region or spinal cord) in several brain regions. At 3-4 months of age 
the larger number of NIIs was found in deep cerebellar and pontine nuclei, spinal cord and to a lesser 
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extent in the olfactory bulb. In regions such as the frontal cortex, hippocampus, thalamus and cerebellum 
cortex NIIs were undetectable. At the age of 8 months, the number of NIIs increased in the regions 
analyzed and were detected also in thalamus and cerebellum cortex (very few) and not in the frontal cortex 
and hippocampus (99). Bichelmeier and colleagues have found Purkinje cell loss by immunostaining of 
cerebellar sections with anti-phosphorylated neurofilament antibody, which revealed condensed or empty 
baskets around Purkinje cells. Furthermore, electron microscopy analysis showed a clear pathology of 
Purkinje cells where it was possible to detect a shrinking of these cells to an extent of 50-80%, as well as an 
abnormal morphology. The granule cells of the cerebellum were not altered in this mouse. Brain sections 
were also evaluated for the presence of NIIs and it was possible to detect NIIs posite for both ataxin-3 and 
ubiquitin in several brain regions such as cerebellum (NIIs were absent in Purkinje cells), cortex, 
hippocampus, pons and cerebellar nuclei (440). Later on, Chou et al, focused their neuropathological study 
in the cerebellum by staining cerebellum sections of the mouse brain (10-11 months of age) with H&E and 
performed immunohistochemistry for NeuN (neuronal marker) or calbindin. The authors showed a 
tendency (not statistically significant) towards a decrease in the number of neurons in the dentate nucleus, 
granular, molecular and Purkinje cells of the cerebellum. Furthermore, calbindin staining of the Purkinje cell 
showed degeneration features, such as shrunken cell body and less dendritic arborization, although the 
authors could not find mutant ataxin-3 expression in these cells. NIIs were detected in the dentate and 
pontine nuclei as well as in the substantia nigra (280) at 12 months of age. Torashima also showed severe 
disarrangement of Purkinje cells in the polyQ mice already at 21 days of age, given by calbindin staining. 
Nuclear inclusions were also detected in the cerebellum of these mice (441). Also focusing the 
neuropathological study in Purkinje cells, Boy et al in 2009, showed that these cells presented an abnormal 
morphology by electronic microscopy in 20 months-old mice. Purkinje cells showed a dark staining that was 
considered “dark cell degeneration”. Since this model is a conditional transgenic, turning off the transgene 
expression it was possible to observe a reversion of this Purkinje cell degeneration. NIIs were detectable in 
cerebral cortex (very few); no other brain regions were reported has presenting NIIs (30). In accordance 
with these findings, the same authors, in 2010, described another model that also presented darkly stained 
Purkinje cells considered as a sign for degeneration in this mouse model at 20 weeks of age (442). 
However, this finding might be a little controversial, taking in consideration that many neuropathologists 
consider “dark neurons” as the most common histologic artefacts which can also be found in normal 
brains (443). Regarding NIIs, it was possible to detect in the pontine and cerebellar nuclei, red nucleus and 
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Purkinje cells (442). Also in 2010, Silva-Fernandes and co-workers observed neuronal atrophy in the 
pontine and dentate nuclei as well as astrogliosis in the vestibular nuclei and substantia nigra at 49 weeks 
of age. However, and in spite of its neurological phenotype, no cell death (apoptosis or necrosis) and no 
signals of microglial activation or neuroinflammatory response were observed in the brains of this 
transgenic mouse. Furthermore, it was possible to observe an abnormal cellular morphology in several 
brain regions, including thalamus, dentate and pontine nuclei. NIIs were not detected in this model (103). 
Taking advantage of lentiviral vectors, Gonçalves et al used C57Bl6 mice to produce another MJD-like 
model. They injected mutant and normal ataxin-3 in the striatum of these animals. These mice showed 
striatal pathology associated to mutant ataxin-3 overexpression, given by the reduction of DARPP32 staining 
and NeuN positive cells as well as increased pycnotic nuclei in the cresyl violet staining and mutant ataxin-3 
inclusions. Furthermore, these animals also showed decreased synaptophysin and MAP-2 staining and 
increased GFAP and CD11b staining, suggesting synaptotoxicity and astrogliosis, respectively (444). 
 
1.4.5 Pre-clinical trials in MJD mice 
Despite the existence of a variety of different MJD rodent models and their potentialities, only a few 
preclinical trials have been performed until now (see also table 4 and 5). These trials were carried out 
based in different approaches that will be discussed separately.  
(i) RNAi approaches and exon skipping (Table 4). RNA interference (RNAi) might be 
considered one the most notable discoveries in biomedical research. Indeed, specifically silencing the 
disease-causing genes (without interfering with the healthy allele and avoid off-target effects) would be the 
ideal therapeutic strategy. One of the major obstacles to the translation of this approach would be the 
delivery of the target RNAi in the human CNS. In the case of MJD, Alves et al have generated lentiviral 
vectors encoding siRNAs targeting a SNP (found in 72% of the population) that specifically silenced mutant 
ataxin-3 gene (when associated with that SNP-allele) and not the normal gene, and injected those vectors 
into the striatum of the rat (shAtaxMUT rat model). The non-allele-specific silencing in an acute rat model of 
MJD lead to a 80% reduction of mutant ataxin-3-positive inclusions and to the preservation of dopamine and 
cAMP-regulated phosphoprotein (DARPP-32)  expression in the striatum where the mutant protein was 
overexpressed, although it remains unclear whether this silencing improved behavior (52). Using the same 
model system, Nascimento-Ferreira et al (from the same lab), used lentiviral vectors-mediated 
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overexpression of beclin-1, and important protein involved the in nucleation step of autophagy. They have 
shown a reduction of ataxin-3 aggregates in the rat striatum that co-express mutant ataxin-3 and beclin-1, 
as compared to animals only expressing mutant ataxin-3, at 4 weeks post-injection, and this result was 
even more pronounced 8 weeks post-injection. Also, the authors have shown that beclin-1 overexpression 
led to a reduction in neuronal dysfunction, given by the DARPP-32 staining at 4 weeks post-injection, and 
again, this reduction was maintained at 8 weeks. Furthermore, beclin-1 overexpression reduced astrogliosis 
and microglial activation (445) . Together these results suggest autophagy activation as a promising 
strategy for MJD, as suggested by others (245, 446).  
Nóbrega et al, also from the same lab, used the polyQ mice (441) that expresses the mutant ataxin-
3 exclusively in the cerebellum. The same strategy as in (52) was used, but this different model, allowed 
the phenotypic evaluation after the injection of the shRNA targeting mutant ataxin-3. The authors were able 
to observe a reduction in ataxin-3 inclusions in the Purkinje cells of shAtx3-injected mice when compared to 
shGFP control animals. Furthermore, silencing ataxin-3 preserved the Purkinje cell layer as assessed with 
calbindin and DARPP-32 markers. The molecular and granular layers of the cerebellum were also larger in 
shAtx3-injected mice as compared to shGFP controls, and Golgi staining demonstrated increased 
arborization in the molecular layer of animals silencing mutant ataxin-3. Silencing mutant ataxin-3 improved 
significantly the performance of these mice in the rotarod, both at constant speeds and in the accelerating 
rod. The footprinting analysis also revealed improvement in animals upon silencing of ataxin-3, given the 
larger stride length and increased paw overlap. Finally, in the activity box, shAtx3-treated animals travelled 
longer distances and walked faster than control animals (447).  
In order to better understand the potentiality of RNAi approaches in a model system that more 
closely mimics the human disorder and the effects of this approach in a chronic situation, Costa and 
collaborators performed a RNAi therapy in the cerebellum of the YACMJD84.2 model (223). These authors 
used microRNAs (miRNAs) instead of shRNAs, due to their higher safety (448). A reduction of mutant 
ataxin-3 was observed in the cerebellum of the animals injected with miRATXN3 as compared to controls, 
and no toxicity was found in the brain, which led the authors to pursue with the chronic trial. In this study, a 
more detailed characterization of the YACMJD84.2 model was also performed, to complement the initial 
characterization conducted by Cemal et al. After an extensive behavioral and pathologic evaluation, the 
authors decided to use the homozygous animals in the RNAi therapy trial, since they presented a more 
marked phenotype when compared to heterozygous animals. The long-term administration of miRATXN3 
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failed to improve motor deficits of the treated SCA mice and had no impact in life expectancy. The authors 
showed that despite the widespread distribution of the miRATXN3 into the cerebellum and its apparent 
safety, it failed to rescue the phenotype of the SCA3 animals, suggesting that maybe the cerebellum is not 
the major origin of the motor problems observed in these mice (439). Thus, and as stated by the authors of 
these two last studies, the efficacy of RNAi approaches to suppress ATXN3  is highly dependent on their 
ability to silence ATXN3 throughout the brain regions affected in MJD (449).  
Melvin M. Evers and colleagues proposed a novel strategy for MJD treatment, proposing a protein 
modification approach for mutant ataxin-3 toxicity without affecting its normal function. This approach 
includes the removing of the toxic polyglutamine tract of ataxin-3 using antisense oligonucleotide-mediated 
(AONs) exon skipping, while keeping global levels of ataxin-3 unchanged.  In this study, the authors used an 
AON that removes simultaneously exon 9 and 10 (CAG repeat expansion is located at exon 10).  Since 
removal of exon 10 alone disrupts the reading frame, exon 9 is also removed to avoid this issue. The AONs 
designed were tested in human fibroblasts and the authors confirmed the exon skipping by sequencing. 
Afterwards, they tested if these AONs resulted in a modified protein. Indeed, the authors found a 37 kDa 
protein, corresponding to ataxin-3 protein lacking exon 9 and 10 in human fibroblasts. Furthermore, it was 
shown that the removal of these exons did not have a negative impact in the ubiquitin binding capacity of 
ataxin-3. To test the efficacy and safety of these AONs in vivo, the authors proceeded to a single intra-
cerebral ventricular injection of the AONs in the brain of wild-type mice. After 7 days, the skipping efficacy 
was measured in the cerebellum of the mice, which demonstrated a reduction in the levels of exon 9 and 
10 and not of the adjacent exons, suggesting the specificity of the AONs used (450). These results might 
indicate that exon skipping could be a novel therapeutic strategy for MJD. 
 
(ii) Pharmacological approaches (Table 5). Taking advantage of the model generated by 
Cemal et al in 2002, Chen and collaborators performed a chronic treatment to these mice using food 
supplemented with dantrolene. This compound is a ryanodine antagonist and clinically relevant Ca2+ 
signaling stabilizer, being a skeletal muscle relaxant commonly used to treat hyperthermia and muscle 
spasticity (451). Four groups of animals (WT and SCA3 treated and vehicle) were submitted to the beam-
walk test and the latency and the footslipages were measured. The authors observed that SCA3-vehicle 
mice have impairment in the beam walk test and that dantrolene had no effect in the WT group. The SCA3-
dantrolene group had an improved performance in the beams, taking less time to traverse the different 
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beams and that the number of foot slips was identical to WT. Interestingly, the authors also observed a 
crawling behavior in the SCA3-vehicle and to a less extent in the SCA3-dantrolene group. No crawling 
behavior was observed in WT groups. The authors also found significant improvement in the footprinting 
pattern of SCA3 group treated with dantrolene. To evaluate the neuroprotective effect of dantrolene, the 
brains of the four groups used were weighed and dantrolene-fed SCA3 mice had no improvement in this 
parameter. It was also shown that SCA3-vehicle animals have loss of NeuN positive cells in the pontine 
nuclei and of TH-positive cells in the substantia nigra; dantrolene food supplementation diminished this 
neuronal loss (336).  
In order to verify the therapeutic efficacy of autophagy induction in MJD, Menzies and colleagues 
used the model generated by Bichelmeier (440) which they chronically treated with an autophagy inducer – 
temsirolimus (rapamycin analog). Although the authors were not able to reproduce the phenotype 
previously described for this model (440), at the end of a 2 months preclinical trial they report that treated-
SCA3 animals performed better in the accelerating rod when compared to placebo-treated mice, and that 
this compound had no effect in WT animals in the rotarod. Also, temsirolimus was able to reduce the 
ataxin-3 aggregates in the motor cortex and the soluble cytoplasmic, but not nuclear, mutant ataxin-3 in 
total brain extracts. Finally, the authors performed a microarray study at basal conditions and after 
temsirolimus treatment. Overall, the transcriptional alterations found were very small, probably due to the 
absence of a clear phenotype in the SCA3 mice. Yet, it was possible to identify genes that were decreased 
in SCA3-placebo mice and increased after temsirolimus treatment; the opposite effect was not found (245).  
Previously, Chou and collaborators suggested that a global transcriptional deregulation was 
occurring in the cerebellum of a SCA3 transgenic model (280). More specifically, they have shown a 
generalized hypoacetylation of H3 and H4. In order to modulate these alterations in the transcriptome, the 
same authors treated their mouse model with sodium butyrate (SB), an HDAC inhibitor. They observed that 
daily administration of SB was able to revert histone hypoacetylation as well as the transcription 
donwregulation in the cerebellum. SB treatment improved motor performance of transgenic animals in the 
rotarod that is less evident in later stages. The ataxic symptoms quantified through the footprint pattern 
were also ameliorated with SB as well as the spontaneous locomotor activity (assessed in a Perspex box), 
body weight loss and survival (276). More recently, and using the same model (280), the same research 
group developed a preclinical trial using H1152, a Rho-kinase (ROCK) inhibitor. These authors tested 
several ROCK inhibitors in vitro and showed that H1152 was the most potent in reducing ataxin-3 protein 
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levels, by increasing proteasome activity. The same behavior tests used in the characterization of the model 
were used in this study (280). Daily intraperitoneal injections of H1152 in the SCA3 mice slightly improved 
motor coordination (rotarod) and locomotor activity deficits. Also, H1152 administration significantly 
decreased mutant ataxin-3 levels in the cerebellum, cerebral cortex, pontine nuclei and spinal cord as well 
as the cell death (reduction in NeuN positive cell) observed in the pontine nuclei of vehicle animals (452).  
Caffeine (a non-selective adenosine receptor antagonist) as well as the selective adenosine A2A 
receptor (A2AR) blockage has been shown to be neuroprotective in brain diseases, including Huntington’s 
disease (453-455). In a study by Gonçalves et al, caffeine was administered in the drinking water for 3 
months (maximum), in a dose (1g/L) corresponding to a human diary consumption of 5 cups of coffee. 
Chronic caffeine treatment rescued the striatal shrinkage observed in the water-drinking animals and 
slightly reduced the number of pycnotic cells. Also, caffeine was able to increase the loss of NeuN positive 
cells observed in the water-drinking animals. These data suggests that chronic caffeine treatment is 
neuroprotective towards ataxin-3 overexpression in the striatum. Furthermore, loss of DARPP-32 staining 
volume, astrogliosis and putative microgliosis were improved in the treated group. Finally, and intriguingly, 
caffeine-treated mice showed an increase in the number of nuclear inclusions when compared to water-
drinking animals. These observations might indicate that the final stage neuronal inclusions are protective 
rather than toxic. Nevertheless, the neuroprotective effects of caffeine might be of limited duration since the 
quantity of pycnotic cells remained in a high number. (444).  
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Table 4. Pre-clinical trials performed in MJD mouse models using RNAi approaches. 
  
 
    
Outcome 
 
 
Therapeutic 
molecule 
Model Target 
Treatment 
duration 
Route of 
administration 
Control groups Phenotype Pathology REF 
RN
Ai
 a
pp
ro
ac
he
s 
Recombinant 
lentiviral vectors 
encoding 
shAtaxMUT 
Alves S et al 
2008a (rat 
model) 
Mutant ataxin-
3 
- 
Intracranial 
injection in the 
striatum 
shGFP ND Striatal neuroprotection (52) 
Lentiviral vector-
mediated 
overexpression of 
belin-1 
Alves S et al 
2008a (rat 
model) 
Autophagy - 
Intracranial 
injection in the 
striatum 
ATX3-MUT and WT ND 
Clearance of ataxin-3 and 
ubiquitin positive 
aggregates, as well as 
oligomeric and soluble 
mutant ATXN3; 
decreased DARPP32 and 
NeuN depleted volume 
(445) 
Lentiviral vectors 
enconding shRNAs 
for mutant ataxin-3 
Torashima et 
al, 2008 
Mutant ataxin-
3 
- 
intracranial 
injection in the 
cerebellum 
shGFP 
rotarod and footprinting; 
locomotor activity 
ataxin-3 inclusions in 
Purkinje cells; preserved 
Purkinje cells, molecular 
and granular layers of the 
cerebellum; increased 
arborization of the 
neurons in the molecular 
layer; decreased 
Fluorojade B staining 
(447) 
anti-ATXN3 
RNAi (miRATXN3) 
Cemal et al 
2002 
Mutant ataxin-
3 
10 months 
(early post-
symptomatic) 
intracranial 
injection in the 
cerebellum 
AAV2/1-miRMis-
hrGFP; AAV2/1-miR-
hrGFP (YACMJD84) 
No improvement in the 
motor impairment and 
survival 
ND (456) 
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Table 4 (continued). Pre-clinical trials performed in MJD mouse models using RNAi approaches. 
 
  
 
    
Outcome 
 
RN
Ai
 a
pp
ro
ac
he
s Therapeutic 
molecule 
Model Target 
Treatment 
duration 
Route of 
administration 
Control groups Phenotype Pathology REF 
RNAi targeting 
human ATXN3 
3′UTR 
Cemal et al 
2002 
Mutant ataxin-
3 
2 months 
(post-
symptomatic) 
intracranial 
injection in the 
cerebellum (deep 
cerebellar nuclei) 
rAAV-CMV-hrGFP; 
rAAV-miR-Mis 
(YACMJD84) 
ND 
80% clearance of nuclear 
mutant ataxin-3 
inclusions in DCN and 
Purkinje neurons 
(457) 
Ex
on
 s
ki
pp
in
g antisense 
oligonucleotides to 
induce an in-frame 
exon skip in the 
ataxin-3 pre-mRNA 
WT C57Bl/6J 
ataxin-3 exon 9 
and 10 (CAG 
containing-
exon) 
7 days 
single intra-
cerebral 
ventricular (ICV) 
injection 
- ND 
Exon 9 and 10 were 
reduced in the 
cerebellum, without 
affecting the expression 
of other exons 
(450) 
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Table 5. Pre-clinical trials performed in MJD mouse models using pharmacological approaches 
     
 
  
Outcome 
 
 
Model 
Therapeutic 
molecule 
Target Treatment duration Dosage 
Route of 
administrati
on 
Control groups 
Phenotype 
improvement 
Pathology REF 
Ph
ar
m
ac
ol
og
ic
al
 a
pp
ro
ac
he
s 
Cemal et al 
2002 
Dantrolene 
stabilizer of 
intracellular Ca2+ 
signaling 
10 months  (started 
post-symptomatically) 
5 mg/Kg 
food 
supplementati
on 
wild-type animals (treated 
and vehicle); SCA3 mice 
vehicle 
beam walk test; gait 
deficits; 
restored brain weight 
loss; restored neuronal 
loss in PN; SN-TH 
neuronal cell loss is 
improved 
(336) 
Bichelmeier et al 
2007 
CCI-779 Autophagy inducer 
2 months (started pos-
symptomatically) 
20mg/Kg 
i.p injection 
(3x/week) 
wild-type animals (treated 
and vehicle)- data not 
shown; SCA3 mice 
vehicle 
Rotarod (no phenotype 
was detected in basal 
conditions) 
reduced aggregate 
number in the motor 
cortex; reduction in 
soluble ataxin-3 
(245) 
Chou et al 2008 
Sodium 
butyrate 
HDAC inhibitor 
(Class I) 
9 months (started pre-
symptomatically) 
400 or 800 
mg/Kg 
i.p injection 
(daily) 
SCA3 mice vehicle 
weight loss; rotarod; 
ataxic symptoms; 
hypoactivity; survival 
ameliorates mutant 
ataxin-3-induced 
degeneration of Purkinje 
neurons; restored 
hypoacetylation status in 
cerebellum 
(276) 
Chou et al 2008 H1152 
Rho-kinase (ROCK) 
inhibitor 
3 months (started pre-
symptomatically) 
10 mg/Kg 
i.p injection 
(daily) 
wild-type animals 
(treated); SCA3 mice 
vehicle 
rotarod; 
locomotor activity deficit 
reduction of ataxin-3 
levels in the cerebellum, 
cerebral cortex, 
pontine nuclei or spinal 
cord; prevention of 
neuronal loss in the 
pontine nuclei 
(452) 
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Table 5 (continued). Pre-clinical trials performed in MJD mouse models using pharmacological approaches 
     
 
  
Outcome 
 
Ph
ar
m
ac
ol
og
ic
al
 
ap
pr
oa
ch
es
 
Model 
Therapeutic 
molecule 
Target Treatment duration Dosage 
Route of 
administrati
on 
Control groups 
Phenotype 
improvement 
Pathology REF 
Lentiviral-vector 
mediated mouse 
model (striatum 
injections) 
Caffeine 
 
non-selective 
adenosine receptor 
antagonist 
3 months maximum 
(pre-symptomatically) 
1g/L drinking water 
C57Bl6 animals vehicle 
(expressing mutant and 
wild-type ataxin-3 in the 
striatum) 
ND 
ameliorates mutant 
ataxin-3 induced 
neurodegeneration; 
reduction in inclusions in 
the basal ganglia; reactive 
gliosis was reduced 
(444) 
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1.4.6 Clinical trials in MJD patients 
Currently, no disease modifying treatment exists for MJD. Yet, some symptomatic treatment is 
available, including genetic counseling, physical therapy programs, and speech and swallows evaluation. 
Symptomatic treatment for clinical findings such as parkinsonism, dystonia, cramps, depression, sleep 
disorders, and pain is important to improve the quality of life for those with MJD. The translation from 
model systems to human patients is an important and urgent issue. Considering the lack of information on 
the key aspects of the pathogenic mechanism(s), the clinical and molecular heterogeneity of MJD patients 
and the scarcity of human biological tissues available for research, the development of translational 
approaches is very difficult. Still, some clinical trials (very few) were performed for MJD (See table 6). The 
presence of undesired side effects is of major importance in clinical trials and must be taken in 
consideration (the known side effects of the compounds tested are summarized in the table 3). Most of 
these clinical trials were performed using very few MJD patients (less than 10) and only short-term effects 
were investigated, thus the outcome of these trials might be compromised. The combination of 
sulphamethoxazole and trimethoprim (Bactrim, a broad-spectrum antibiotic used in ear and urinary 
infections) was suggested to be effective in MJD in a small double-blind clinical trial using 8 patients. The 
authors observed mild improvements in some parameters evaluated, such as hyperreflexia of knee jerks 
and rigospasticity of the legs in the patients treated with Bactrim. It was also shown that the levels of 
biopterins and homovanillic were reduced in the cerebrospinal fluid (CSF) of MJD patients when compared 
with controls with other neurodegenerative diseases. The short-term treatment with Bactrim increased the 
levels of total and oxidized biopterins in the CSF (458). In the same year, another double-blind’ clinical trial 
was performed using Bactrim in 8 additional patients. In this study, three parameters were evaluated: 
subjective performance, neurological examination and timed tests. The treatment with Bactrim 
demonstrated an improvement on gait and coordination. The authors suggested that further clinical trials 
using Bactrim should be performed due to the promising results obtained with this small number of 
patients (459). Indeed, in 2001, a third double-blind clinical trial using Bactrim was performed in 22 MJD 
patients. In this trial, and in contrast to previous observations, chronic treatment with Bactrim had no effect 
in the parameters evaluated, such as ataxia ranking scale, self-assessment score, posturography and motor 
performance test. The visual system and mental health were also evaluated, but no effect was observed 
with Bactrim treatment (460).  
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The progression of MJD will confine the patients to a wheelchair and ultimately the patients will be 
bedridden. In this condition, and having in mind their cognitive preservation, the patients might suffer 
depressive symptoms. Furthermore, the serotoninergic system in the cerebellum seems to play a role in 
motor output, such as locomotion. Serotonergic system impairment in the cerebellum was demonstrated to 
induce cerebellar ataxia (461). The selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, are 
commonly used in the treatment of depression and present few side-effects (462). Taking this into account, 
Monte et al, performed an open-label trial in 13 molecularly confirmed MJD patients. After 6 weeks of 
treatment, fluoxetine had no overall effect on motor abilities measured by functional scales and had no 
beneficial effect on the other neuropsychological tests (463). Again, the outcome of the study may have 
been compromised by the small number of patients and short duration of the study. 
The use of 5-HT1A agonists has been controversial for the treatment of cerebellar ataxia, but 
several reports have suggested the efficacy of these agonist for the treatment of MJD (464-467). Indeed, 
Friedmann and collaborators have shown mild effects of buspirone in one MJD patient (468). Later, Takei 
et al, reported the positive effects of tandospirone, another 5-HT1A agonist, in one MJD patient. This patient 
showed improvement in ataxia, depression, insomnia, anorexia and leg pain (469). These positive effects 
lead the authors to pursue a larger clinical trial using 10 MJD patients. In this trial, the patients started 
tandospirone treatment at an initial dose of 15 mg/kg (as the previous case study) that was further 
increased to 30mg/kg for 7 weeks. The patients were examined using the international cooperative ataxia 
ranking scale (ICARS), the total length traveled (TLT) by stabolimetry test and the self-rating depression 
scale (SDS). All these parameters were alleviated with tandospirone treatment. Interestingly, all the 
symptoms aggravated after a transient stop of tandospirone, and improved when the therapy was restarted 
(470). These results suggested that 5-HT1A agonists could be effective in MJD, although more studies need 
to be performed to confirm these assumptions.  
The involvement of N-methyl-d-aspartate (NMDA)-mediated apoptosis in the pathogenic mechanism 
of formation of neuronal inclusions has been proposed (86, 471). It was recently shown that L-glutamate-
induced excitation of iPSC cells of MJD patients leads to Ca2+-dependent proteolysis of ATXN3 followed by 
the formation of insoluble aggregates. The formation of those aggregates was also dependent on Na+ and K+ 
channels as well as on voltage-gated Ca2+ channels (101). A pilot study was performed in 6 MJD patients 
using Lamotrigine (25mg twice a day during 9 weeks), a commonly used antiepileptic drug acting as a 
sodium channel-blocking agent that might be related to the reduction of NMDA-induced toxicity.  In this trial, 
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the patients were evaluated in the one leg standing test (OLST) and tandem gait index (TGI). Both OLST and 
TGI were improved during Lamotrigine treatment comparing the values obtained with the normal values for 
Chinese population. Furthermore, and given these positive results, the authors cultured lymphoblastoid 
cells of one MJD patient and treated those cells with lamotigrine. Mutant, but not normal ataxin-3 was 
reduced with lamotrigine in concentrations within the therapeutic range in humans. The mechanism 
underlying the reduction in mutant ataxin-3 levels was not investigated in this work (472).  
More recently, Zesiewicz and collaborators carried out a short-term clinical trial in 20 MJD patients 
using Varenicline (Chantix, 1mg twice a day for 9 weeks). Chantix is a medication used for smoking 
cessation, being a partial agonist of the α4β2 neuronal nicotinic acetylcholine receptors. Although the 
major components of the cholinergic system seem to be spared in MJD, which may be reflected in the 
absence of dementia in MJD patients, the midbrain cholinergic pars compacta of the pedunculopontine 
nucleus suffers cell loss in these patients with disease progression (413), contributing to REM sleep 
disturbances. Chantix was shown to be beneficial in SCA patients in some case studies (473-475). In this 
trial, the patients were evaluated at baseline and at the end of the treatment (after 8 weeks) primarily by the 
Scale for the Assessment and Rating of Ataxia (SARA scale) and secondary measurements consisted of a 
timed 25-foot walk, a 9-hole peg test, Beck depression inventory (BDI), Beck anxiety inventory (BAI), clinical 
global impression (CGI), patient global impression (PGI) and the Short-Form 36 (SF36) to evaluate daily 
living. Chantix was able to significantly improve some subscores of the SARA scale, such as gait and rapid 
alternating movements. Also, the timed 25-foot walk was ameliorated by Chantix treatment, as well as the 
BDI score. The BDI score improved in both groups (Chantix and placebo) probably because the patients 
that were enrolled in the trial became hopeful regarding new treatment possibilities. A problem concerning 
this study was a high rate of dropout in the placebo group (4 out of 10 patients), probably reflecting the 
difficulty of patients to reach the academic center. Regarding adverse events, it is possible to observe that 
Chantix caused, to a high extent, gastrointestinal-related events when compared to placebo patients. The 
mechanism by which Chantix improves ataxic symptoms was not evaluated in this study or elsewhere 
(476).  
More recently, Saute and colleagues conducted a phase II clinical trial in 62 MJD patients using 
Lithium Carbonate. Lithium is commonly used to treat bipolar disorder, and is also used adjunctively with 
mood stabilizers and antidepressants to enhance, prolong and facilitate treatment response and remission 
of mood disorders (477, 478). Lithium treatment was shown to have beneficial effects in several models of 
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different neurodegenerative diseases (479-483), by the inhibition of glycogen synthase kinase-3β (GSK-3β) 
and autophagy activation. Importantly, however, irreversible cerebellar toxicity, leading to ataxia, nystagmus 
and dysarthria has also been observed due to lithium intoxication. In this long-term clinical trial, Lithium (at 
therapeutic dosages of 0.5-0.8 mEq/L) was well tolerated by patients. After 48 weeks of follow-up, patients 
treated with Lithium did not show significant differences in disease progression, given by the results by 
Neurological Examination Score for the Assessment of Spinocerebellar Ataxia (NESSCA) and SARA scale. 
Nevertheless, the authors were able to observe that Lithium-treated MJD patients had a slower progression 
concerning the PATA test (word speed) and the Click test (finger-pointing coordination) as well as in the 
SCAFI (spinocerebellar ataxia functional index) and CCFS (composite cerebellar functional score), when 
compared to patients receiving placebo (484). They suggested that larger clinical trials should be performed 
in order to understand the value of Lithium in the treatment of MJD. 
There are many concerns regarding the clinical trials performed to date in MJD: (i) the small 
samples of patients, which might be difficult to overcome due to the fact that this is a rare disorder and also 
the collaboration of patients might represent a problem; (ii) the clinical heterogeneity of the patients could 
be a concern, and even if the patients have an homogeneous genetic background they could respond 
differently to the treatment; (iii) the short-term observation of the patients, that contrasts with the slow 
progression of the disease (except for the Lithium Carbonate trial, which had a duration of 48 weeks); (iv) 
the outcomes used for ataxia measurement which might be difficult to analyze due to the multisystem 
involvement in this disease and (v) lastly, the design of the studies as randomized double-blinded trials with 
quantifiable ataxia scales and non-ataxia measurements should be used, which was not often the case. 
Despite the existence of several scales to measure ataxia (reviewed in (485)), other non-ataxia scores 
should be applied to MJD patients since these patients also present non-ataxia symptoms, such as 
pyramidal and extrapyramidal signs as well as peripheral findings (486). 
The link to preclinical studies was also not evident in the trials performed to date, which lacked 
biological evidence for the therapeutic efficacy of the molecules being tested. This thesis aims to contribute 
to the field by providing preclinically validated candidate therapeutic molecules for MJD.  
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Table 6. Clinical trials performed in MJD patients.  
Therapeutic molecule Design 
Treatment 
duration 
Number 
of 
patients 
Mean 
age 
(years) 
Mean 
repeat 
length 
Dosage Known collateral effects Results REF 
Trimethoprim and 
sulfamethoxazole (Bactrim) 
doubled-
blinded 
4 weeks 8 NA NA NA 
nausea, vomiting, anorexia, rash, 
and urticaria 
Mild effect; mild improvements of 
hyperreflexia of knee jerks and of 
rigospasticity of the legs. Increased levels of 
biopterins in the CSF after Bactrim 
treatment. 
(458) 
Trimethoprim and 
sulfamethoxazole (Bactrim) 
doubled-
blinded 
NA 8 NA NA NA 
nausea, vomiting, anorexia, rash, 
and urticaria 
Beneficial effect on gait and 
coordination; subjective performance, 
neurological examination and timed tests 
(459) 
Trimethoprim and 
sulfamethoxazole (Bactrim) 
doubled-
blinded 
24 weeks 22 NA NA 
160 mg + 800 mg 
twice a day in the 
first 2 weeks; 80 
mg + 400 mg twice 
a day for 5.5 
months 
nausea, vomiting, anorexia, rash, 
and urticaria 
No overall effect; Ataxia ranking scale, 
self-assessment score, static posturography, 
and results of motor performance testing. 
Effects on the visual system. Physical and 
mental health were documented using the 
Medical Outcomes Study 36-Item Short-
Form Health Survey. 
(460) 
Fluoxetine Open-label 6 weeks 13 41±13 75±3 20 mg/day 
nausea, diarrhea, dry mouth, 
headache, dizziness, sexual 
dysfunction 
No effect; functional capacity, standardized 
neurologic and cognitive ratings. The 
Montgomery-Asberg depression rating scale 
was used to control depressive symptoms. 
463) 
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Table 6 (continued). Clinical trials performed in MJD patients.  
 
Therapeutic 
molecule 
Design 
Treatment 
duration 
Number 
of 
patients 
Mean 
age 
(years) 
Mean 
repeat 
length 
Dosage Known collateral effects Outcome REF 
Buspirone Case-study 15 weeks 1 NA NA 12,5mg/day 
dizziness, drowsiness and 
headache, nausea, diarrhea, 
increase in appetitte 
Mild effect;improved gait and balance; 
Clinical rating scale for ataxia was used 
(468) 
Tandospirone Case-study 8 weeks 1 51 NA 30mg/day 
dizziness, drowsiness, headache, 
dry mouth, insomnia 
Strong effect; ataxia, depression, 
insomnia, anorexia, and 
leg pain were improved; ICARS(1) and 
SDS(2) scales were used. 
(469) 
Tandospirone 
Open-
labeled 
7 weeks 10 50.6±12 NA 
30mg/day  
15 mg/day 
dizziness, drowsiness, headache, 
dry mouth, insomnia 
Strong effect; ataxia, depression, 
insomnia, anorexia, and 
leg pain were improved; ICARS(1) and 
SDS(2) scales were used. 
(470) 
Lamotrigine 
Open-
labeled 
9 weeks 6 27 78±2 
25 mg 
twice a day 
Blurred vision, 
    changes in vision, 
    clumsiness or unsteadiness, 
    double vision, 
    poor coordination, 
    skin rash 
Positive effect; OLST(3) and TGI(4) 
tests were performed and improved 
(472) 
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Table 6 (continued). Clinical trials performed in MJD patients. 
 
Therapeutic 
molecule 
Design 
Treatment 
duration 
Number 
of 
patients 
Mean 
age 
(years) 
Mean 
repeat 
length 
Dosage Known collateral effects Outcome REF 
Varenicline 
(Chantix) 
doubled-
blinded 
8 weeks 20 50.6±11 NA 1 mg twice a day 
Abnormal dreams, change in 
taste, dry mouth, flatulence, 
headache, lack or loss of strength, 
nausea, sleeplessness, stomach 
pain, trouble sleeping, unusual 
tiredness or weakness 
Positive effect; SARA(5) scale, a timed 
25-foot walk and 9-hole peg test, 
measurements 
of mood and anxiety, and adverse events. 
476) 
Lithium 
carbonate 
doubled-
blinded 
48 weeks 62 40±9 75±3 
Weekly lithium 
doses were given 
until a target of 
0.5 to 0.8 
milliequivalents 
per liter (mEq/L) 
Confusion, poor memory, or lack 
of awareness, fainting 
    fast or slow heartbeat, frequent 
urination, increased thirst, 
irregular pulse, stiffness of the 
arms or legs, troubled breathing 
(especially during hard work or 
exercise), unusual tiredness or 
weakness, weight gain, intentional 
tremor 
No overall effect; NESSCA (6) and SARA 
scale, 9-hole peg test, 8 Meter Walking 
Time, Click Test 
and PATA-rate, Composite Cerebellar 
Functional Score, Quality-of-Life 
Questionnaire, Beck Depression Inventory, 
Clinical Global Impression of Change 
(487) 
 
NA – not applicable
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Objectives 
 
Considering the lack of knowledge on pathogenic mechanisms underlying MJD and the 
currently inexistent therapies for this disorder, this thesis work has its main focus on hypothesis-based 
pharmacological pre-clinical trials, using the CMVMJD135 mouse model. Bearing this in mind we aimed 
to test the therapeutic efficacy of: 
1. Inducing the load of molecular chaperones in the cell, using an Hsp90 inhibitor, 17-DMAG; 
2. Increasing the autophagy process, using lithium chloride or a combination of lithium chloride 
and temsirolimus (CCI-779); 
3. Targeting the ER stress response, using tauroursodeoxycholic acid (TUDCA), also known to 
have multiple actions in the cells (anti-apoptotic, anti-inflammatory, chemical chaperone) 
contributing to neuroprotection. 
4. Increasing the energy status in the cell, using a natural nutrient, creatine. 
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Chapter 2 
Chronic treatment with 17-DMAG improves balance and coordination in a new mouse 
model of Machado-Joseph disease 
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Abstract Machado-Joseph disease (MJD) or spinocerebellar
ataxia type 3 (SCA3) is a neurodegenerative disease currently
with no treatment. We describe a novel mouse model of MJD
which expresses mutant human ataxin-3 at near endogenous
levels and manifests MJD-like motor symptoms that appear
gradually and progress over time. CMVMJD135 mice show
ataxin-3 intranuclear inclusions in the CNS and neurodegen-
erative changes in key disease regions, such as the pontine and
dentate nuclei. Hsp90 inhibition has shown promising out-
comes in some neurodegenerative diseases, but nothing is
known about its effects in MJD. Chronic treatment of
CMVMJD mice with Hsp90 inhibitor 17-DMAG resulted in
a delay in the progression of their motor coordination deficits
and, at 22 and 24 weeks of age, was able to rescue the
uncoordination phenotype to wild-type levels; in parallel, a
reduction in neuropathology was observed in treated animals.
We observed limited induction of heat-shock proteins with
treatment, but found evidence that 17-DMAG may be acting
through autophagy, as LC3-II (both at mRNA and protein
levels) and beclin-1 were induced in the brain of treated
animals. This resulted in decreased levels of the mutant
ataxin-3 and reduced intranuclear aggregation of this protein.
Our data validate this novel mouse model as a relevant tool for
the study of MJD pathogenesis and for pre-clinical studies,
and show that Hsp90 inhibition is a promising therapeutic
strategy for MJD.
Keywords Polyglutamine . animal models . ataxia .
behavior . therapy . autophagy.
Introduction
Machado-Joseph disease (MJD), also known as
spinocerebellar ataxia type 3 (SCA3), is caused by a CAG
repeat expansion (>55) [1] in the protein coding region of the
ATXN3 gene, located in chromosome 14q32.1 and encoding
the protein ataxin-3. The main clinical features of MJD are
ataxia and ophthalmoplegia, which can be associated to a
variable degree with peripheral amyotrophy, intention
fasciculation-like movements of facial and lingual muscles,
rigidity, spasticity, dystonia and palpebral retraction, leading
to the appearance of bulging eyes [2]. Ataxin-3 harboring the
expanded polyQ tract has a strong tendency for aggregation,
leading to the formation of inclusions in the nucleus and
cytoplasm of neuronal cells, including axonal tracts [3, 4],
the pathogenic relevance of which remains unclear.
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Molecular chaperones are crucial for the maintenance of
native protein conformation, and recent research has shown
that defective chaperone action may have pathogenic conse-
quences [5, 6]. Several studies demonstrated the involvement
of the heat shock proteins in MJD [7–10]; co-localization of
Hsp70, Hsp40 and Hsp90, but not other chaperones (Hsp27,
Hsp60 and Hsp110) with aggregates formed bymutant ataxin-
3 has been described, which might result in a depletion of
these protective molecules [7, 9]. In order to promote the
correct refolding of the pathogenic protein(s) and to reduce
the formation of toxic aggregated forms, the use of com-
pounds that promote increased expression of heat shock pro-
teins (HSPs), leading to improved protein folding and/or
clearance of the mutant protein by the ubiquitin proteasome
system or through autophagy, has been proposed [11, 12].
Hsp90, by itself and/or associated with multichaperone com-
plexes, is a major repressor of HSF-1 acting in a feedback
regulation mechanism [13]. Pharmacologic inactivation of
Hsp90 leads to the overexpression of several molecular chap-
erones, activating the heat-shock response (HSR) via the
persistence of HSF-1 action [13, 14]. Potent Hsp90 inhibitors,
such as 17-AAG or 17-DMAG, have been shown to reduce
aggregate load and toxicity in cell, fly, nematode and mouse
models of several neurodegenerative diseases, dependently on
HSF-1 [15–20]. Concerning polyQ diseases, these two com-
pounds have been shown to have beneficial effects only for
SBMA [19–21]. Despite its high potency, 17-AAG showed
poor solubility and stability and demonstrated moderate tox-
icity in several clinical trials [22]. In contrast, 17-DMAG is a
more potent analog of 17-AAG [23], is more water soluble
than 17-AAG and can be administered orally [24], which
could be advantageous for clinical purposes.
Although mouse models have been a remarkable tool in
human disease research, several criteria have to be achieved in
order to validate a genetically manipulated mouse as a model
of a disease [25]. Therapeutic trials need to be performed in
animal models showing significant similarities to the human
diseases, in order to better evaluate the therapeutic benefit of a
specific compound. Although several transgenic mouse
models have been generated for the study of MJD, it has been
difficult to find in one single model the main features of this
disorder (reviewed in [26]).
In this work, we generated a new transgenic mouse model
expressing ATXN3 with 135 glutamines under the control of
the CMV promoter. These mice develop a progressive neuro-
logical disease overlapping with the core clinical features of
MJD and show relevant neuropathology as well as ubiquitin-
positive ataxin-3 intranuclear inclusions in regions of the brain
known to be involved inMJD, including the pontine and deep
cerebellar nuclei. We used this model in a pre-clinical trial to
validate Hsp90 inhibition as a therapeutic strategy for MJD,
with encouraging results that suggest that this approach
should be pursued.
Results
CMVMJD135 Mice Express the Expanded Human Ataxin-3
in the CNS
We have generated transgenic mice expressing the ATXN3c
cDNA variant of the ATXN3 gene carrying a repeat tract with
the sequence (CAG)2CAAAAGCAGCAA(CAG)129, coding
for 135 glutamines, under the regulation of the CMV promoter
(Fig. 1A). Transgene mRNA quantification demonstrated that
one lineage (hereafter designated CMVMJD135), expressed the
human ATXN3 protein in the brain (Fig. 1B). This lineage,
possessing two copies of the transgene, expressed the human
ATXN3 mRNA at near-endogenous levels in the cerebellum,
brainstem, forebrain and spinal cord (Fig. 1C). When breeding
these animals we observed intergenerational CAG repeat length
variation, mostly towards contraction (Supplementary Fig. 1)
(maternal meioses (n=24): mean=−1.46±2.74; range=[−7, +4];
paternal meioses (n=42): mean=−0,71±1,61; range=[−5, +1]).
We chose to study animals with repeat lengths over 129. All the
comparisons for the genotype factor were performed between
CMVMJD135 mice and wild-type littermates since it has been
previously shown that transgenic mice expressing human
ataxin-3 carrying a normal CAG repeat tract did not display
any differences in the phenotype or neuropathology in compar-
ison with wild-type (wt) [27–30]. In addition, our previous data
have shown that even expression of ataxin-3 with 83 glutamines
under the CMV promoter caused no phenotype change [31].
CMVMJD135 Transgenic Mice Display Progressive
Neurological Deficits
At 4 weeks of age, transgenic and control littermates were
indistinguishable in their home cage; however, at 16 weeks of
age transgenic animals started to present a visibly abnormal
gait and at 40 weeks of age they showed an unhealthy appear-
ance, an abnormal body posture, limb clasping and limb tonus
deficit (Fig. 1D).
Female CMVMJD135 transgenic and control mice gained
weight at a similar rate until 19 weeks of age (Fig. 1E);
however, transgenic males showed a significantly lower body
weight gain compared with control males at 19 weeks of age,
and since this age, all transgenic animals demonstrated a
decline in body weight, whereas their wt littermates continued
to gain weight until 40 weeks of age (male: genotype x age,
F2,61=35.067, p<0.000; female: genotype x age, F2,61=5.211,
p=0.008).
In the balance beam test, CMVMJD135 mice showed a
significantly worse performance already at 10 weeks of age
traversing the medium square beam (male: genotype, F1,40=
30.845, p=2×10-6, age, F1,40=6.356, p=0.014; female: geno-
type, F1,44=10.754, p=0.002) (Fig. 2B), as well as the medi-
um (male: genotype, F1,34=22.023, p=4.3×10
-5; female:
434 Silva-Fernandes et al.
genotype, F1,37=4.859, p=0.034) (Fig. 2D) and the small
round beams (male: genotype, F1,31=18.486, p=1.58×10
-4;
female: genotype, F1,34=11.487, p=0.002, age, F1,34=5.618,
p=0.024) (Fig. 2E). With disease progression, CMVMJD135
mice demonstrated a higher frequency of foot slips and a
flattened body posture in the beams. By 40 weeks of age,
transgenic mice failed to maintain balance on the beams and
fell off.
Footprint patterns of wt (41 weeks of age) and
CMVMJD135 transgenic mice at 14, 28 and 41 weeks of
age are illustrated in Fig. 3A. Dragging of the feet was
observed in transgenic animals already at 14 weeks of age,
progressing through age and becoming increasingly more
severe (41 weeks: p=2.44×10-4) (Fig. 3B). Additionally, be-
ginning at 16 weeks of age, transgenic mice displayed a
reduced paw overlap when compared with control animals,
indicating an altered uniformity of step alternation (genotype,
F1,11=5.184, p=0.044) (Fig. 3C) as well as a significant
decrease in the stride length (genotype, F1,11=36.086,
p=8.8×10-5) (Fig. 3D).
CMVMJD135 mice swam significantly slower than con-
trol littermates at 22–25 weeks of age (genotype, F1,21=
17.927, p=3.71×10-4) and more so at 40 weeks (genotype,
F1,15=42.466, p=1.0×10
-5) (Fig. 4A). In addition, they
displayed abnormalities in their swimming movements,
adopting a twisted posture, and kicked in an uncoordinated
Fig. 1 Generation of a transgenic mouse model of MJD carrying the
expandedATXN3with 135 CAGs. (A) Schematic diagram of the plasmid
CMVMJDAT3Q135_1.5 used for the generation of cDNA MJD trans-
genic mice. (B) Western blot anti-ATXN3 in different CNS regions
(cerebellum, forebrain and brainstem) of CMVMJD135 mice with 14–
16 weeks of age. In all lanes, the endogenous mouse ataxin-3 (Atxn3) is
detected at about 42 kDa. An approximately 80-kDa protein correspond-
ing to expandedATXN3 is detected in transgenic animal lysates. (C) qRT-
PCR analysis of human ATXN3 and murine Atxn3 mRNA expression
levels. Values are presented as mean ± SEM (n=4). (D) CMVMJD135
mice at 40 weeks of age presenting body posture deficit with lower pelvic
elevation and hunchback (2), limb clasping (4) and reduced hindlimb
tonus (6) in comparison with wt animals (1,3,5). (E) Assessment of body
weight with age (n=11–12 for each group). Asterisks indicate significant
differences between wt control and CMVMJD135 transgenic mice.
*p<0.05, **p<0.01, ***p<0.001
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manner with both hind- and forelimbs. In the rotarod para-
digm, significant differences were observed from the age of 20
weeks (genotype, F1,21=4.879, p=0.038) (Fig. 4B). At 40
weeks of age, transgenic animals showed a dramatic deterio-
ration in their rotarod performance compared with littermate
controls, both in the accelerating rod (genotype,F1,17=20.234,
p=3.17×10-4) and at constant speeds (8 rpm: p=0.004;
15 rpm: p=0.002; 20 rpm: p=0.003; 24 rpm: p=0.002)
(Fig. 4C).
At the first age of assessment with the SHIRPA protocol
(7 weeks) CMVMJD135 transgenic mice revealed significant
differences in performance in the hanging wire grip test, that
became worse with age (male: genotype x age, F1,42=30.331,
p=2.0×10-6; female: genotype x age, F1,41=36.955,
p<0.000) (Fig. 5A). At 19 weeks of age, a significant
percentage of transgenic animals developed loss of hindlimb
tonus resistance (male: p=1.07×10-4; female: p=0.002)
(Fig. 5B), a decrease in forelimb strength (male: p=0.003;
female: p=0.006) (Fig. 5C) and hindlimb clasping (male:
p=1.07×10-4; female: p=0.006) (Fig. 5D). Furthermore, 40-
week-old animals demonstrated a dramatic deterioration of
the neurological symptoms observed at 19 weeks of age in
the SHIRPA protocol, namely, the loss of hindlimb tonus,
the tremors and the decreased locomotor and exploratory
activity, among others (Supplementary Fig. 2A–D). From 40
weeks of age onwards, most CMVMJD135 mice were not
able to traverse the beams or stay in the rotarod and their
footprinting pattern was difficult to measure due to the
severe dragging, which led us to halt the phenotype
evaluation.
Fig. 2 Body balance impairment
in CMVMJD135 mice. Balance
beam test performance of wt and
transgenic animals using square
(A,B) and round beams (C–E) is
depicted at 10 and 22 weeks of
age. Values are presented as
mean ± SEM (n=8–13 for each
genotype and gender). *p<0.05,
**p<0.01, ***p<0.001
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A group of wt (n=9) and transgenic animals (n=13) were
followed through life until they had to be sacrificed due to
established humane endpoints (93 weeks of age). Although
transgenic mice showed a progressive deterioration of the
motor phenotype, no differences were observed in survival
rate between both genotypes until this age, in the laboratory
conditions used, which included lowering the food to an ac-
cessible level and hydrating it at ages when transgenic animals
had difficulty reaching the food and drink compartments.
For cognitive assessment, the Morris Water Maze test was
performed at 10 weeks of age, before the motor symptoms
would interfere excessively with testing, and no differences
were found (Supplementary Fig. 2E,F).
CMVMJD135 Mice Exhibit Reduced Brain Weight, Reduced
Volume and Total Cell Number in Pontine Nuclei
and Intranuclear Ataxin-3 Inclusions
The total brain weight of CMVMJD135 mice was slightly
reduced (5 %) in comparison with control littermates at late
stages of the disease (42–43 weeks) (p=2.74×10-4) (Fig. 6A).
However, we did not observe differences in brain weight in
animals sacrificed at 20 weeks of age, suggesting that the
motor phenotype begins before marked neuronal loss. Stereo-
logical evaluation of CMVMJD135 mice brains at 60 weeks
of age revealed a significantly reduced volume as well as a
decrease in total cell number in pontine nuclei indicating
neuronal demise in this region, known to be affected in MJD
(Fig. 6B). Interestingly, transgenic mice showed a significant
volume reduction without cell loss in the dentate nuclei. In
contrast, no differences were found in the locus coeruleus and
in the substantia nigra (SN), although hyperchromatic cells
and astrogliosis were observed in SN (Fig. 6C; Supplementary
Fig. 3).
Immunohistochemistry showed the presence of ataxin-3
inclusions in the nucleus of neuronal cells in different regions
of the CNS of CMVMJD135 mice at 20–35 weeks of age
(Fig. 6C) including the pontine nuclei, reticulotegmental nu-
cleus of the pons, spinal cord neurons, the facial nuclei,
anterior olfactory nuclei, ventral tenia tecta, inferior olive,
Fig. 3 Abnormal footprint pattern in transgenic mice. (A) Representative
walking footprint patterns of 14-, 28- and 41-week-old CMVMJD135
mice. Qualitatively, the patterns generated clearly differ, showing that
transgenic mice display foot-dragging. At late stages CMVMJD135 mice
also demonstrate shorter strides and an irregular left–right step pattern as
compared with the wt control mice. (B) Quantitative analysis of foot-
dragging. Quantitative analysis of the footprint patterns of wt and trans-
genic mice, based on measurements of (C) distance between front and
hind footprint overlap and (D) stride length through age. Values are
presented asmean ± SEM (n=7 and 10 for wt and transgenic, respectively).
*p<0.05, **p<0.01, ***p<0.001
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the dentate nuclei, locus coeruleus and the cuneate nuclei. The
evaluation of cell morphology by cresyl violet staining at 24
weeks of age showed an increased abundance of seemingly
atrophic and hyperchromatic neurons in the pontine nuclei of
CMVMJD135 mice (Fig. 6C,g–j).
17-DMAG Chronic Treatment Improved Several Features
of the Motor Phenotype Observed in CMVMJD135 Mice
Given previous results suggesting that Hsp90 inhibition could
be a useful therapeutic approach for polyQ disease, our own
finding with 17-DMAG in a nematode model of MJD [32],
and the lack of studies in vertebrate models of this disorder,
we tested the effect of 17-DMAG in the CMVMJD135
mouse. All analyses in this pre-clinical trial were performed
using male mice.
A pilot study was performed in wt animals in order to
determine the effective dose of 17-DMAG which induces
Hsp70 in the brain. Previous studies have shown increased
oral availability of 17-DMAG in comparison with 17-AAG;
however, above 10 mg/kg 17-DMAG has been described to
be toxic in mice [33]. It has also been demonstrated that i.p.
17-DMAG administration leads to a better bioavailability than
the oral route [24]. In our dose–response study using three i.p.
injections per week on alternate days, with 17-DMAG at 5, 10
or 25 mg/kg, we observed that, 12 hours post-last injection,
only with the dose of 25 mg/kg was the expression of Hsp-70
significantly induced in the brain, this dosage being thus
selected for the chronic therapeutic study (Supplementary
Fig. 4). With systemic administration of this dosage, the
concentration of 17-DMAG in the brain 1 hour after treatment
was 42 ng/g (drug quantity/brain weight) with a plasma/brain
ration of 0,2.
Fig. 4 Motor incoordination on the rotarod and in the swimming tank in
CMVMJD135 mice. (A) 22–25- and 40-week-old wt and CMVMJD135
male mice (n=7–15) were tested for motor coordination in the swimming
tank, by assessing the latency to swim over a 60-cm distance to a visible
escape platform. Transgenic mice displayed swimming impairments giv-
en by a significant increase in the time spent to cross the 60-cm distance.
Rotarod analysis of CMVMJD135 and wt animals were tested in (B) an
accelerating rod (4–40 rpm) and (C) at constant speeds. The mean±SEM
of the latency to fall at each speed level was recorded. Rotarod deficit was
present at 20 weeks of age and older (shown for 40 weeks);
CMVMJD135 transgenic mice displayed a progressive decline in perfor-
mance on the rotarod with increasing rotation speed. *p<0.05, **p<0.01,
***p<0.001
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In the therapeutic assay, we used four groups of animals:
17-DMAG- and vehicle-treated wt (n=10; n=10, respectively)
and CMVMJD135 animals (n=10; n=12, respectively). In the
motor swimming test, 17-DMAG treatment had a highly ben-
eficial effect, being able to improve the phenotype of the
transgenic animals almost to the performance level of wt
animals at 16, 22 and 24 weeks of age (genotype x treatment,
F1,38=19.912, p=0.00007); this effect was lost at 30 weeks of
age (Fig. 7A). 17-DMAG treatment also had a positive effect
in the rotarod performance of CMVMJD135 animals, which
was comparable to that of wt animals at 22 weeks of age
(15 rpm: genotype x treatment, F1,33=6.378, p=0.017); this
Fig. 5 Phenotype of CMVMJD135 mice detected in the SHIRPA pro-
tocol. (A) Strength and fine motor coordination evaluation in the hanging
wire grip test, measured by the latency to fall off the grid. Values are
presented as mean ± SEM (n=11–12 for each group). (B) At 19 weeks of
age animals demonstrated hindlimb tonus alterations, (C) a decrease in
forelimb grip strength and (D) a higher percentage of animals displaying
clasping of the hindlimbs when compared to controls. Values are present-
ed as percentage of animals with different scores in the SHIRPA protocol
(n=11–12 for each group). *p<0.05, **p<0.01, ***p<0.001
17-DMAG Improves MJD Mouse Phenotype 439
effect was no longer statistically significant at 24 and 30 weeks
of age (Fig. 7B). At 22 and 24 weeks of age 17-DMAG-treated
CMVMJD135 mice had a better performance in the balance
beam test (Fig. 7C; Medium square 24 weeks—genotype:
F1,37=6.228, p=0.017; treatment: F1,37=6.903, p=0.012.
Small circle 22 weeks—genotype: F1,37=7.45, p=0.01;
Fig. 6 Neuropathology of CMVMJD135 mice. (A) Brain weight analy-
sis at 42–43 weeks of age of wt (n=5) and CMVMJD135 male mice (n=
4). (B) Volume and total cell number quantification in different brain
regions of transgenic (n=9) and control (n=5) male animals using stereo-
logical methods. (C) Anti-ataxin-3 immunohistochemistry (rabbit anti-
MJD1.1) of wt (a-c) and CMVMJD135 mice (d-f) at approximately 20–
35 weeks of age. CMVMJD135 mice exhibited nuclear and cytoplasmic
inclusions positive for ataxin-3 in different regions of the CNS, namely,
pontine nuclei (d), reticulotegmetal nucleus of pons (e) and spinal cord
neurons (f); Cresyl violet brain sections in the pontine nuclei of wt (g) and
in CMVMJD135 (i) mice. Higher magnification of neuronal cells in the
wt (h) and transgenic mice (j). Images are representative of the results
obtained for six animals per genotype, three each female and male. Scale
bar: 20 μm
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treatment: F1,37=10.385, p=0.003. Small circle 24weeks—
genotype: F1,36=8.50, p=0.006; treatment: F1,36=7.346, p=
0.01), which was not maintained at 30 weeks of age, suggest-
ing that 17-DMAG treatment is delaying the manifestation of
loss of balance in these animals. Moreover, 17-DMAG was
able to delay the onset and progression of the foot-dragging
phenotype, since at any age the percentage of CMVMJD135
animals treated with 17-DMAG showing foot-dragging was
less than in those not receiving treatment (p<0.05) (Fig. 7D).
In summary, 17-DMAG chronic treatment was able to delay
the motor deficits in the rotarod, motor swimming and balance
beam test by approximately 8 weeks, which represents approx-
imately 9 % of the median C57Bl/6 normal lifespan [34]
(600 days), and to a lesser extent the foot-dragging (6 weeks,
7 % of the lifespan).
17-DMAG treatment failed to ameliorate other manifesta-
tions of the disease evaluated in the SHIRPA protocol, name-
ly, those more related to weakness/hypotonia (hanging wire,
hindlimb tonus), tremors and abnormal reflexes (limb
clasping). Although we did not detect any improvement in
the hanging wire test, in the total number of rears and body
weight, the sample size we used (n=10–12) would be suffi-
cient to detect an improvement of 50 % at several time points
(see Supplementary Table). For the number of squares trav-
elled in the arena, the required sample size for the observed
mean difference to be significant would be much larger than
the one we used (see Supplementary Table).
17-DMAG Treatment Reduces Neuropathology in the CNS
of CMVMJD135 Mice
Transgenic vehicle-treated animals demonstrated the presence
of shrunken and morphologically abnormal cells in the ponti-
ne nuclei. In contrast, 17-DMAG treated animals showed
normal cell morphology, shrunken cells being almost unde-
tectable in this brain region at 30 and 16 weeks of age
(Supplementary Fig. 5). Quantification of the ataxin-3 nuclear
inclusions present in the pontine nuclei of CMVMJD135 mice
revealed a significant reduction of the number of cells con-
taining these inclusions, also reflected in a reduced number of
inclusions per area, in 17-DMAG-treated transgenic animals
when compared to vehicle-treated ones (p=0.009) (Fig. 8A).
Mutant Ataxin-3 Levels are Reduced Through Autophagy
in 17-DMAG-Treated CMVMJD135 Mice
No differences were found in ataxin-3 expression at mRNA
level in the brainstem between the treatment groups, which
allow us to conclude that 17-DMAG treatment is not affecting
expression of ataxin-3 at the transcription level (Fig. 8B).
Interestingly, however, the protein levels of mutant human
ataxin-3 in the brainstem were dramatically reduced in 17-
DMAG-treated animals at 16 (p=0.033) and 30 weeks of age
(p=0.019), suggesting that this treatment is promoting mutant
ataxin-3 degradation rather than refolding (Fig. 8C).
In an attempt to dissect the mechanism of action of the drug
we analysed the levels of molecular chaperones in treated
animals. Unexpectedly, at 20 weeks, mRNA expression levels
of molecular chaperones Hsp-70 and −40 were not signifi-
cantly increased upon 17-DMAG treatment in transgenic
mice, while there was a trend towards increase in the controls
(Fig. 9A). Hsp70 quantification in the forebrain at 16 and 30
weeks of age in CMVMJD135 mice demonstrated that chron-
ic treatment with 17-DMAG led to a statistically non-
significant trend towards increase in Hsp70 expression in this
brain region in transgenic mice at 16 weeks of age, whereas at
30 weeks the opposite trend was present (Fig. 9B). These
results suggest that HSR induction by chronic administration
of 17-DMAG at 25mg/kgmay be compromised in the disease
state, particularly at later stages. Since it was previously
shown that 17-AAG and its analogue 17-DMAG are able to
activate macroautophagy in different model systems [35–37],
we also assessed activation of this pathway. We observed an
increase in the beclin-1 protein levels in the brainstem of 16-
and 30-week-old mice and of the LC3-II/LC3-I ratio at 30
weeks of age, after chronic 17-DMAG treatment (p=0.008,
p=0.017, respectively) in transgenic mice but not in controls,
confirming the specificity of this activation (Fig. 9C,D).
Discussion
The pathogenic mechanism of MJD, as well as of other polyQ
disorders, is not well understood, and these disorders remain
incurable to date. In this work, we have generated a new
transgenic mouse model expressing at near the same cDNA
variant of ataxin- 3 as in our previous CMVMJD94 model,
ATXN3c- which corresponds to the most predominant variant
of the protein in the brain [38], but with an increased number
of glutamine residues (135Q). Moreover, we tested a potent
Hsp90 inhibitor, 17-DMAG, that was able to improve the
motor phenotype and the neuropathological features of
CMVMJD135 mice.
Our results show that the CMVMJD135 mouse is a pow-
erful model for pre-clinical trials in MJD. The behavioral
evaluation of CMVMJD135 mice revealed the presence of
several phenotypic abnormalities that gradually appear and
progress during a lifespan of over one and a half years,
namely, balance and motor coordination deficits, loss of limb
strength, decreased locomotor and exploratory activity, abnor-
mal gait and tremors, with many parameters assessable by
objective tests. The first sign of neurological disease in the
CMVMJD135 model was the presence of balance and grip
abnormalities at 6 weeks of age. Cerebellar ataxia is one of the
first clinical manifestations seen inMJD patients, and is due to
unsteadiness or impaired balance. Although behavioral
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alterations suggestive of loss of coordination in CMVMJD135
mice were observed at 4 and 8 weeks of age, at these ages
animals were indistinguishable from their wt littermates by
simple observation in their home cage. At 16 weeks of age,
however, signs of neurological abnormality were already ob-
servable in CMVMJD135 mice in their home cage, in partic-
ular a clearly abnormal gait. The footprinting pattern evalua-
tion of CMVMJD135 mice clearly demonstrated foot-
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dragging and, at later stages of the disease, a shortened step
length and a decrease in the hind/ frontlimb overlap. Trans-
genic animals also showed a significant deficit in the acceler-
ating rod at 20 weeks of age, which was further aggravated at
40 weeks of age, in the constant and accelerating rod. In the
motor swimming test, the abnormal posture and inappropriate
kicking movements exhibited by CMVMJD135 contrasted
markedly with the coordinated synchronized paddling move-
ments shown by wt mice.
The analysis of CAG repeat number through the genera-
tions of CMVMJD135 mice revealed that CAG tract length
varied in approximately 54–79 % of the transmissions, fre-
quently towards contractions. The genescan profile of the
CAG tract obtained from mouse tail revealed that somatic
mosaicism was also present. Thus, our new model seems to
replicate this feature of the human disease as well.
The histological evaluation of CMVMJD135 mouse brains
frequently revealed abnormal cell morphology in the pontine
nuclei as well as gliosis in the substantia nigra at clearly
symptomatic ages (24 weeks of age). The stereological anal-
ysis of pontine nuclei of CMVMJD135 brain at late stages
(60 weeks of age) revealed a reduced volume and total cell
number in this region and reduced volume in the dentate
nuclei, two regions of high involvement in human patients.
Moreover, we observed a total brain weight decrease, but only
at late stages of the disease (42–43 weeks of age), which
supports the hypothesis that major cell loss only occurs at
these advanced stages. These results suggest that the early
motor phenotype observed in our model is mostly attributable
to dysfunction of the brain regions affected in MJD, clearly
preceding neuronal cell death. In order to validate this hypoth-
esis, it will be necessary to perform a longitudinal neuropa-
thology analysis of the brain regions affected in MJD, to
Fig. 8 17-DMAG treatment
reduced the levels of human
ataxin-3 and the aggregate load in
CMVMJD135 mice brain. (A)
Neuronal inclusions were counted
in the pontine nuclei of 30-week-
old animals treated with vehicle
or 17-DMAG (n=3 for each
condition). Four slides of each
animal were used for the analysis.
(B) qRT-PCR analysis of human
ATXN3 mRNA expression levels
(n=4). (C) Anti-ataxin-3 western-
blot (rabbit anti-MJD1.1) of 30-
week-old CMVMJD135 mice,
either vehicle or treated with 17-
DMAG (n=4 for each condition),
were performed in the brainstem.
Mutant human ataxin-3
has a molecular weight of
approximately 80 kDa. Values are
presented as mean ± SEM;
*p<0.05, **p<0.01, ***p<0.001
Fig. 7 17-DMAG improves motor coordination of CMVMJD135 mice.
(A) Motor swimming test was performed at 16, 22, 24 and 30 weeks of
age (n=10–12 animals for each tested group) and the mean latency of the
third day test was analyzed. Transgenic mice displayed swimming
impairments, given by a significant increase in the time spent to swim
across 60 cm distance, and 17-DMAG treatment improved their
performance. (B) Rotarod test was performed at 22 and 30 weeks of
age (n=10–12 for each tested group) to evaluate motor coordination at
constant speed in the rod (8, 15, 20, 24 and 31 rpm). 17-DMAG treatment
was able to rescue this phenotype at 22 weeks of age. (C) Balance beam
test was performed at 14, 16, 22, 24 and 30 weeks of age (n=10–12 for
each tested group. 17-DMAG treatment significantly improved balance
deficits at 22 and 24 weeks of age. Values are presented as mean ± SEM.
(D) Quantitative analysis of the percentage of animals showing foot-
dragging. 17-DMAG treatment delays the onset and progression of this
symptom. *p<0.05, **p<0.01, ***p<0.001
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establish correlations between the phenotype here defined and
the neurodegeneration pattern.
An important feature of MJD, as well as of other polyQ
diseases, is the presence of neuronal inclusions containing the
mutant protein. Our previous results have shown the presence
of motor symptoms in a transgenic mouse model of MJD in
the absence of intranuclear inclusions, suggesting that these
are not essential for disease manifestation [31]. However, the
nature and relevance of intermediate species of the aggrega-
tion process remains to be elucidated in this disorder. In this
new transgenic mouse, intranuclear inclusions were present in
the cells of affected brain regions, such as the pontine and
deep cerebellar nuclei, but also in regions that are spared, such
as the anterior olfactory nuclei and ventral tenia tecta. This is
concordant with what is seen in human MJD patients, where
neurodegeneration was not clearly correlated with the occur-
rence of ataxin-3 immunopositive inclusions [39]. Moreover,
neuronal inclusions were observed already at 20 but not at 16
weeks of age, when several motor symptoms were already
clearly present. This is in agreement with previous results
obtained in other transgenic mouse models of MJD, in which
symptoms appear before the detection of the inclusions [40].
Although the role of intranuclear inclusions, the end-
product of the aggregation process in MJD pathogenesis,
remains to be clarified, the presence of this pathological
hallmark of disease in our model indicates that it successfully
replicates the full aggregation process that happens in humans.
The combination of clinical and neuropathologic features of
Fig. 9 17-DMAG is able to induce autophagy in CMVMJD135 animals.
ELISA assays, western blots and qRT-PCR analysis of HSR and autoph-
agy markers were performed in the brainstem or forebrain of 16-, 20- or
30-week-old wt and CMVMJD135 mice (n=4–5) treated with vehicle or
17-DMAG (25 mg/kg), 12 hours after the last treatment. (A) Hsp70,
Hsp40 mRNA expression levels were normalized for the housekeeping
gene HPRT. (B) ELISA assay for Hsp70 quantification. Anti- Beclin-1
(C) and anti-LC3 (D) western-blots. LC3-II was normalized both for
tubulin and LC3-I; Beclin-1 was normalized for tubulin. Values are
presented as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001
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CMVMJD135 mice prompted us to start pre-clinical trials
using different compounds, targeting different potential path-
ogenic mechanisms for MJD.
The chaperone machinery has the potential to neutralize the
toxicity caused by misfolded and aggregated proteins, making
the activation of molecular chaperones an attractive therapeu-
tic strategy [21, 41]. Treatment of CMVMJD135 mice with
17-DMAG markedly improved motor performance, given by
the results in the motor swimming, rotarod and beam balance
tests, reduced the expression levels of human ataxin-3 at
protein level and reduced the nuclear aggregate load in the
pontine nuclei. Regarding neuropathology, 17-DMAG also
led to a visible amelioration in cell morphology in affected
brain areas, such as the pontine nuclei, at 16 and 30 weeks of
age. Intriguingly, however, 17-DMAG had no beneficial ef-
fect in other neurological symptoms, for instance, limb weak-
ness, tremor and abnormal reflexes, and the beneficial effects
of 17-DMAG treatment were not maintained throughout dis-
ease progression. At 30 weeks of age, CMVMJD135 mice
treated with 17-DMAG started to present MJD symptoms
similar to those of mice treated with saline. Data from preclin-
ical toxicity studies for 17-DMAG in animal models have
recently become available [33], leading us to believe that it
is possible to further increase 17-DMAG dose (higher than
25mg/kg) while keeping outside its toxicity range; this should
be tested in future studies.
In our study, and in spite of the therapeutic effects ob-
served, the chronic administration of 17-DMAG failed to
induce the HSR in CMVMJD135 mice, particularly at later
stages of the disease. This is in agreement with what was
recently described in a Huntington’s disease mouse model
treated with an Hsp90 inhibitor [42]. These authors tested
the effectiveness of HSF-1 dissociation from the Hsp90 com-
plex, its translocation to the nucleus and consequent
hyperphosphorylation, features interfering with HSF-1
trimerization and its ability to induce HS gene expression
[43], and concluded that all those processes were occurring
normally upon treatment, suggesting that the problem was at
the level of transcriptional activation of HSF1 targets due to
excessive chromatin condensation. A similar phenomenon
appears to be taking place in CMVMJD135 mice.
Since it was previously shown that 17-AAG and its ana-
logue used in this study—17-DMAG—are able to activate the
autophagy process in different model systems [35–37], and
given that our results suggested degradation of ataxin-3 was
occurring, we assessed known autophagy markers in 17-
DMAG-treated animals. Our results suggest that autophagy
is activated by the drug specifically in diseased animals. This
is confirmed by an increase in the protein levels of Beclin-1
and LC3-II , detected only in 17-DMAG-treated
CMVMJD135 mice. Although we could not observe an in-
duction of HS genes at the age tested (20 and 30 weeks of
age), this induction might still happen earlier in life, being no
longer seen in later disease stages, when autophagy starts
taking place as a compensatory mechanism. In addition to
improving the major symptoms of disease, 17-DMAG re-
duced mutant protein levels and aggregate load in
CMVMJD135 mice, which is a good additional proof of its
beneficial effects. 17-DMAG is currently in Phase I of clinical
trials for advanced solid tumors (www.clinicaltrials.gov), to
t e s t d o s a g e , t o x i c i t y, p h a rma co k i n e t i c s a n d
pharmacodynamics. So far, the most frequently observed
collateral effects of this compound were fatigue, nausea,
diarrhea and headache [44]. Although the effects of
continuous activation of HSF-1 are not well understood, and
it was suggested to be detrimental in some situations [45], our
data show that 17-DMAG is a promising compound and
Hsp90 an interesting molecular target for MJD therapy. There
is a need to better understand the impairment of the HSR
during aging in mice (since this study is not easy to perform
in humans) which will help in the development of new drugs
that can act synergistically with 17-DMAG in the improve-
ment of proteostasis.
Materials and Methods
Generation of Transgenic Mice, Breeding, Genotyping, CAG
Repeat Sizing and Mouse Maintenance
To generate transgenic MJD mice, we converted the ATXN3a
cDNA variant carrying a repeat tract ((CAG)2CAAAAGCA
GCAA(CAG)124), coding for 130 glutamines (plasmid
pF25B3.3::AT3Q130::YFP) in the ATXN3c variant [18] into
the pCMV vector (Fig. 1A). This plasmid, designated
pCMVAT3Q135_1.5, was linearized by total digestion with
PaeI (Fermentas), the fragment of interest (3150 bp) was then
purified from an agarose gel using the QiaQuick gel extraction
system (Qiagen, Hamburg, Germany) and microinjected into
fertilizedmurine oocytes of the C57Bl/6 mouse strain (QTRN,
Canada). To establish the lineage CMVMJD135, founder C
was bred with C57Bl/6 females and the hemizygous progeny
were bred with littermate wt animals to generate the experi-
mental groups. DNA extraction, animal genotyping, transgene
copy number and CAG repeat size analyses were performed
as previously described [31].
All animal procedures were conducted in accordance with
European regulations (European Union Directive 86/609/
EEC). The animals were anesthetized with a mixture of keta-
mine hydrochloride (150 mg/kg) plus medetomidine
(0.3 mg/kg). Animal facilities and the people directly involved
in animal experiments (ASF, SDS, ANC) were certified by the
Portuguese regulatory entity—Direcção Geral de Veterinária.
All of the protocols performed were approved by the joint
Animal Ethics Committee of the Life and Health Sciences
Research Institute, University of Minho, and the Institute for
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Molecular and Cell Biology, University of Porto. Health mon-
itoring was performed according to FELASA guidelines [46],
confirming the Specified Pathogen Free health status of sen-
tinel animals maintained in the same animal room.
Behavioral Analysis
CMVMJD135 phenotypic characterization was performed
during the diurnal period in groups of five animals per cage
including CMVMJD135 hemizygous transgenic mice and wt
littermates (n=11–15 per genotype and gender). The mean
repeat size (±SD) for all mice used was (133±1). Animals
were evaluated monthly in the rotarod [31] (beginning at 4
weeks of age until 40 weeks of age), by the modified SHIRPA
protocol [31] (at 7, 19 and 40 weeks of age), using the balance
beam test [47] (at 10 and 22 weeks of age) and the motor
swimming test [47] (between 22–25 and 40 weeks of age).
Rotarod tests and footprinting pattern were performed as
previously described [31] as was the SHIRPA protocol, with
the addition of the hanging wire grip test. To evaluate the
severity of foot-dragging through age the footprinting patern
of CMVMJD135 (n=10) and wt controls (n=7) was
classified at each time point considering six consecutive steps
(0=absent/mild, up to three steps; 1=moderate, more than
three steps out of six; 2=severe, all steps out of six).
Hanging Wire Grip Test Each mouse was placed on a wire
cage top, which was slowly inverted and suspended at ap-
proximately 30 cm to the floor. The time it took each mouse to
fall from the cage top was recorded. Any mouse still gripping
the cage top after 60 seconds was removed.
Balance Beam Test Motor coordination and balance of mice
were assessed by measuring the ability of the mice to traverse
a graded series of narrow beams to reach an enclosed safety
platform as previously described [47]. The beams consisted of
long strips of PVC (1 m) with a 27- and 11-square cross-
section or a 28-, 15-, or 10-mm round diameter. During
training, mice were placed at the start of the 11-mm square
beam and trained over 3 days (3 trials per day) to traverse the
beam to the safe platform.
Motor swimming test [47] and Morris water maze were
performed as previously described [48, 49].
Western Blot
Protein isolation from mouse tissues and western blot were
performed as previously described [31] homogenized in cold
RIPA buffer and a mixture of protease inhibitors (Complete;
Roche). The blots were blocked overnight at 4 °C with the
primary Ab: rabbit anti-ataxin-3 serum (kindly provided by
Dr. Henry Paulson) (1:10000); mouse anti-Hsp70 (1:2000
StressGene), rabbit anti-LC3 (1:500 Cell Signaling), rabbit
anti-Beclin1 (1:1000 Cell signaling) and mouse anti-alpha-
tubulin (1:100, DSHB). Band quantification was performed
using ImageJ software according to the manufacturer’s in-
structions using alpha-tubulin as the loading control.
qRTPCR
Total RNA was isolated from CMVMJD135 mice tissues
using TRIZOL (Invitrogen, Calrsbad, CA, USA) according
to the manufacturer’s protocol. First-strand cDNA, synthe-
sized using oligo-dT (Bio-rad), was amplified by quantitative
reverse-transcriptase PCR (qRT-PCR) as previously described
[31]. Human and mouse ataxin-3 primers were used for trans-
gene expression quantification [31]: HSP40 (F: 5’CGCCGG
ACGGGTATATAGAG3’; R: 5’GGCCCAGCGTCTGATA
GTAG3’), HSP70 (F: 5’CCAACGCTGTCACTCAAACC
3’; R: 5’GCCCTTGTCCAGAACTCTCC3’) and LC3 (F:
5’TTCTTCCTCCTGGTGAATGG3’; R: 5’GTGGGTGCCT
ACGTTCTCAT3’).
Neuropathology and Immunohistochemistry
Transgenic and wt littermate mice were deeply anesthetized
and transcardially perfused with PBS followed by 4 % para-
formaldehyde (PFA) in PBS. Brains were postfixed overnight
in fixative solution and embedded in paraffin. Slides with
4-μm-thick paraffin sections were stained with cresyl violet
or processed for immunohistochemistry with rabbit GFAPAb
(DAKO Corporation, Carpinteria, CA) (1:500) or rabbit anti-
MJD1.1 [50] (1:40) or anti-ubiquitin (1:500) [31]. Ataxin-3
positive inclusions in the pontine nuclei of 30 weeks old
animals either vehicle or 17-DMAG treated (n=3–4 for each
condition, three slides per animal) were quantified and normal-
ized for total area using the Olympus BX 51 stereological
microscope and the Visiopharma integrator system software.
Stereological Analysis Neuronal number and volume were
obtained by systematic random sampling in pontine nuclei
from Bregma level −3.80 mm through 4.60 mm; substantia
nigra from Bregma level −2.46 mm through 4.04 mm; locus
coeruleus from Bregma level −5.34 mm through 5.80 mm and
dentate nuclei from Bregma level −5.68 mm thourh 6.36,
according to the Paxinos and Franklin mouse brain atlas of
2001. Every second section containing the region of interest
was selected to obtain a sample in a systematic uniform and
randommanner (section sampling fraction; ssf = 0.5). Volume
estimation was obtained according to Cavalieri’s principle
[51]. Each known area was multiplied by the represented
thickness (30 μm x 2 sections). Average cell numbers were
estimated using the optical fractionator method [52]. The area
(a) of the counting frame was 400 μm2 (20 μm x 20 μm), the
area sampling fraction (asf) = a (frame)/ a (step length) was
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0.004. The height (h: 15 μm) of the optical dissector was
equivalent to the thickness of the section (t: 30 μm).
The measurements were performed using The Visiopharm
Integrator System, version 2.12.3.0 and a camera (Pixelink PL-
A622) attached to a motorized microscope (Olympus BX51).
17-DMAG Dose Determination
Wt animals were injected with 17-DMAG (InvivoGen) at
different concentrations (5, 10 and 25 mg/kg, n=4 per dose)
three times per week on alternate days, and 12 hours after the
last injection the animals were sacrificed. Another set of
animals (n=4) was injected with vehicle (saline NaCl 0,9 %)
and sacrificed at the same time. The protein levels of Hsp70
were measured by western blot in the muscle and in the brain.
Determination of Blood/Plasma Ratio to Estimate 17-DMAG
brain exposure
A total of six C57Bl/6 mice at approximately 6 months of age
were used, in which two were injected intraperitoneally three
times in a week with saline—0.9 % NaCl and four animals
with 17-DMAG 25 mg/kg. Animals were anesthetized 1 hour
post-injection and the blood was removed from the inferior
vena cava, and after perfusion with PBS brains were dissected,
weighted and immediately frozen at −80ºC. Brain tissue was
homogenized in acetonitrile:H20 (4:1 v/v). After centrifuga-
tion, plasma and brain supernatants were harvested and sam-
ples were frozen at −80 °C until bioanalysis. Brain and plasma
samples were analysed for content of drug by use of
UltraPerformance LC® (UPLC®) chromatography followed
by tandem-MS (MS/MS) detection.
Hsp70 ELISA Assay
An Hsp70 ELISA kit (ADI-EKS-700B from ENZO life sci-
ences, UK) was used to measure the Hsp70 concentration in
brain tissue frommice. The analysis was carried out according
to the manufacturer’s instructions. Briefly, forebrain tissue
protein extracts were obtained as described above and extrac-
tion reagent (ELISA kit) with phosphostop and protease in-
hibitor cocktail was added. The homogenate was spinned
down at 20,000 g for 10 min and the supernantant was kept
at −80 °C until analysis. The protein concentration was deter-
mined using a standard BCAProtein assay (Thermo scientific,
Denmark), and upon ELISA analysis, 100 μg of protein was
analysed per well according to the standard protocol. The
developed plates were measured with a Spectramax 340PC
(Molecular Devices Inc., USA) at 450 nm (reference 540 nm).
Hsp70 concentration was calculated based on the standard
curve and expressed as ng of Hsp70 per ml.
17-DMAG Treatment and Behavioral Assessment
CMVMJD135 and littermate mice (n=10−12 for each group)
were intraperitoneally injected three times a week since 5
weeks of age (one week before the onset of symptoms) with
17-DMAG at 25 mg/kg (for a mean mouse weight of 25 g) or
with a 0.9 % saline solution. The animals were evaluated every
two weeks in the balance beam test and using the SHIRPA
protocol since 6 weeks of age. Foot-dragging was evaluated as
described above and at the age of 16, 22, 24 and 30 weeks the
animals were also tested in the rotarod and in the motor swim-
ming test. Behavior analysis methods were described above.
Statistical Analysis
Power analysis was used to determine the sample size [53].
Considering the different variables under study, such as weight,
time held in the hanging wire, rotarod and swimming latency,
assuming a power of 0.8 and a significance level of 0.05,
different required sample sizes were obtained, depending on
the specified smallest detectable difference and the variability
within the four populations under study (wt vehicle, wt 17-
DMAG, tg vehicle and tg 17-DMAG). Based on these calcu-
lations and bearing in mind that as the age of the animals
increases also the mean differences increase and, possibly, the
standard deviations, a sample size ranging between five and ten
animals was obtained and, therefore, a sample of ten animals
was chosen. Sample size calculations of each behavioral test
were also assessed assuming a power of 0.8 and a significance
level of 0.05 (Supplementary Table). The effect size was cal-
culated taking into account an improvement of 50 %, using
mean and standard deviation values previously obtained for
transgenic and control groups for the different behavioral tests.
Behavioral data were analyzed by the non-parametric
Mann–Whitney U-test when variables were non-continuous
or when a continuous variable did not present a normal
distribution (Kolmogorov-Smirnov (K-S) test p<0.05). Con-
tinuous variables with normal distributions (K-S test p>0.05)
were analyzed with the Student’s t-test and two-way ANOVA
(factors: genotype and age for basal behavioral characteriza-
tion of the CMVMJD135 mice; factors: genotype and treat-
ment in the 17-DMAG preclinical trial). For the motor swim-
ming test, repeated-measures ANOVAwas performed consid-
ering two factors: genotype and treatment. All statistical anal-
yses were performed using SPSS 22.0 (SPSS Inc., Chi-
cago, IL). A critical value for significance of two-tailed
p<0.05 was used throughout the study.
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Supplementary material 
 
 
 
Supplementary Fig. 1. Intergenerational instability of the CAG repeat in MJD mice. (A) Representative Genescan tract 
diagrams showing the variation of the CAG repeat tract in maternal and paternal meioses of CMVMJD135 mice. (B) 
Differential pattern of CAG repeat variation in CMVMJD135 male (n = 42) and female meioses (n = 24). Values are presented 
as frequency (%).  
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Supplementary Fig. 2. Evaluation of the progression of the disease at 40 weeks of age in the SHIRPA protocol. Spatial 
cognitive performance in CMVMJD135 mice at 10 weeks of age. (A) Exploratory behavior given by the number of rears was 
dramatically decreased in CMVMJD135 mice as well as the spontaneous locomotor activity (B). In addition, at 40 weeks of 
age animals demonstrate severe tremors (C) and hindlimb tonus resistance decrease (n = 7–10) (D). (E) Morris water 
maze test (MWM) was performed in wt (n = 7) and CMVMJD135 mice (n = 20) in five consecutive days and the time and 
distance travelled was recorded. (F) To exclude a motor influence in this spatial memory task the open-field test was 
performed one week after the MWM test and no differences were found between controls and transgenic animals indicating 
that the cognitive function is preserved in this model, as in MJD patients. MWM testing at later ages was not possible due to 
motor impairments. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Supplementary Fig. 3. Neuropathology of substantia nigra in CMVMJD135 mice. Anti-GFAP immunohistochemistry in the 
substantia nigra of wt (A) and CMVMJD135 (B) mice (n = 3–4). Scale bar: 50 μm. Cresyl violet staining of the susbtantia 
nigra in wt (C) and transgenic mice (D). Scale bar: 20 μm.  
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Supplementary Fig. 4. One-week of 17-DMAG treatment increases Hsp70 protein levels in the muscle (A) and in the 
brain (brainstem) (B) in a dose-dependent manner. Male wt mice were injected three times during a week with different 
concentrations of 17-DMAG: 5, 10 and 25 mg/kg (n = 4 for each dosage). 12 hours after the last injection mice were 
sacrificed and Hsp70 proteins levels were measured. In brain tissue, as in muscle, there was a dose-dependent response in 
Hsp70 induction by 17-DMAG, although the increase in expression was only statistically significant at 25 mg/kg (p < 0.05) 
which we selected for the therapeutic study. With systemic administration of this dosage, the concentration of 17-DMAG in 
the brain 1 hour after treatment was 42 ng/g (drug quantity/brain weight) with a plasma/brain ratio of 0,2. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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Supplementary Fig. 5. Decreased neuropathology in CMVMJD135 mice treated with 17-DMAG. Comparative sections of 
pontine nuclei of male CMVMJD135 mice treated with vehicle (A and C) or 17-DMAG (B and D) at 16 weeks of age (A 
and B) and 30 weeks of age (C and D) stained with cresyl violet (n = 3 for each group); 17-DMAG-treated mice present a 
decrease in the number of pyknotic cells in the pontine nuclei at both ages. Scale bar: 20 μm.  
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Supplementary Table 1. Sample size calculations for each behavioral test assuming a power of 0.8 and a significance level of 0.05. 
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Abstract The accumulation of misfolded proteins in neurons,
leading to the formation of cytoplasmic and nuclear aggre-
gates, is a common theme in age-related neurodegenerative
diseases, possibly due to disturbances of the proteostasis and
insufficient activity of cellular protein clearance pathways.
Lithium is a well-known autophagy inducer that exerts neu-
roprotective effects in different conditions and has been pro-
posed as a promising therapeutic agent for several neurode-
generative diseases. We tested the efficacy of chronic lithium
(10.4 mg/kg) treatment in a transgenic mouse model of
Machado-Joseph disease, an inherited neurodegenerative dis-
ease, caused by an expansion of a polyglutamine tract within
the protein ataxin-3. A battery of behavioral tests was used to
assess disease progression. In spite of activating autophagy, as
suggested by the increased levels of Beclin-1, Atg7, and LC3-
II, and a reduction in the p62 protein levels, lithium adminis-
tration showed no overall beneficial effects in this model
concerning motor performance, showing a positive impact
only in the reduction of tremors at 24 weeks of age. Our
results do not support lithium chronic treatment as a promising
strategy for the treatment of Machado-Joseph disease (MJD).
Keywords Polyglutamine .Spinocerebellarataxia .Lithium .
Autophagy . Therapy . Triplet repeats
Introduction
Lithium, a monovalent cation and a FDA-approved drug with
the ability to cross the blood–brain barrier, has been used in
the past 6 decades for the treatment of bipolar disorder(BD)
and also adjunctively with mood stabilizers and antidepres-
sants to enhance, prolong, and facilitate treatment response
and remission of mood disorders [1, 2]. Although its thera-
peutic mechanisms remain unclear, strong in vivo and in vitro
evidence suggests that lithium has neurotrophic/
neuroprotective properties toward a wide range of insults,
and also in neurodegenerative diseases [3, 4]. Lithium inhibits
glycogen synthase kinase-3 [5, 6] and increases the protein
levels of the brain-derived neurotrophic factor (BDNF) [7, 8],
leading to an enhanced cell survival. Lithium also regulates
calcium homeostasis and suppresses calcium-dependent acti-
vation of pro-apoptotic signaling pathways [9], and it can
protect against endoplasmic reticulum (ER) stress [10], asso-
ciated with impaired synaptic plasticity and pathology in
neurodegenerative conditions, such as Alzheimer’s disease
(AD) [11]. In order to be effective, lithium requires long-
term treatment, and its effects are not reverted immediately
after discontinuation. For this reason, it is thought that lithium
acts at the gene expression level. Indeed, lithium is able to
upregulate the expression of important molecules such as
HSP70 [12, 13], BCL-2 [9, 14, 15], BDNF [7, 8, 16], HSF1
[13], and CREB [4], among others. Moreover, lithium
decreases inositol 1,4,5-trisphosphate by inhibiting
phosphoinositol phosphatases [17, 18]; this was proposed as a
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novel mechanism to induce autophagy [19–21].
Macroautophagy, commonly referred to as autophagy, is an
important process for the degradation of proteins and organelles
and plays amajor role in cellular stress conditions [22]. It is also
involved in neuronal and astrocytic cell survival and function
[23]. The process of autophagy begins with the formation of
double-membrane structures called autophagosomes that fuse
with lysosomes (autolysosomes) and lately degrade their con-
tents by lysosomal hydrolytic enzymes [24, 25]. Autophagy
recycles cytoplasmic proteins in normal conditions and recycles
nutrients when necessary, for instance, under starvation. The
accumulation of misfolded proteins in cells is a common feature
in aging and in several neurodegenerative disorders [26], which
makes autophagy a prominent target for the treatment of such
diseases; these include amyotrophic lateral sclerosis (ALS),
Parkinson disease (PD), AD, Huntington’s disease (HD), and
Machado-Joseph disease (MJD) [27–37]. Drugs that potentially
modulate autophagy are increasingly being used in clinical
trials, and screens are being performed for the discovery of
new compounds that induce autophagy. Autophagy is modu-
lated by several signaling pathways and is directly inhibited by
the serine/threonine protein kinase mammalian target of
rapamycin (mTOR) [38]. Administration of rapamycin has
been demonstrated to be beneficial in different animal models
of neurodegenerative disorders, by enhancing autophagic func-
tion [24, 29, 36, 39, 40]. Autophagy can also be regulated
independently of mTOR, which can be achieved through lith-
ium, sodium valproate, and carbamazepine, compounds that
lower myo-inositol-1,4,5-triphosphate levels [20, 41]. Lithium
acts as an autophagy enhancer or inhibitor, depending on the
dosage. At higher doses, it inhibits GSK3β, which suppresses
autophagy [42]; in contrast, at lower doses, it inhibits IMPAse,
inducing autophagy [20].
Chronic lithium treatment was tested in several models
of neurodegenerative diseases. Lithium was shown to
have beneficial effects in patients and also in an ALS
mouse model [43, 44]. The study in the mouse model
demonstrated neuroprotection by lithium, which delayed
disease onset and duration and increased lifespan. In the
clinical trial, a randomized study of adults with ALS
showed that none of the patients treated with lithium died
during the 15 months of the follow-up, and the disease
progression was markedly attenuated [44]. In a mouse
model of HD, this treatment had variable effects; lithium
improved the motor performance and reduced depressive-
like behavior, but only when administered post-
symptomatically [45]; furthermore, it had no effect on
survival in this model [45]. Chronic treatment with lithi-
um also improved neurological function and hippocampal
dendritic arborization in a mouse model of SCA1 [46].
More recently, chronic lithium treatment was shown to
ameliorate the phenotype of a MJD Drosophila model,
partially by inhibiting GSK3β [47].
Taking into account the beneficial effects of lithium and its
autophagy induction properties, and considering that little is
known about its possible effects in MJD, we performed
chronic lithium treatment in the CMVMJD135 mouse model
[48]. Our results show limited beneficial effects of lithium
treatment; although it subtly improved a few of the symptoms
observed at specific time points, it was not able to globally
improve motor function in this model. These findings do not
support the idea that lithium is a good candidate to treat MJD.
This is of clinical relevance, since one may avoid the collateral
effects of trying lithium therapy in MJD patients.
Material and Methods
Transgenic Mice We used the CMVMJD135 mice [48],
which express an expanded version of the human MJD1-1
cDNA (the 3 UIMs-containing variant of ATXN3) under the
regulation of the CMV promoter (ubiquitous expression) at
near-endogenous levels. All animals were maintained under
standard laboratory conditions: an artificial 12-h light/dark
cycle (lights on from 8:00 to 20:00 h), with an ambient
temperature of 21±1 °C and a relative humidity of 50–60 %;
the mice were given a standard diet (4RF25 during the gesta-
tion and postnatal periods, and 4RF21 after weaning,
Mucedola SRL, SettimoMilanese, Italy) and water ad libitum.
All procedures were conducted in accordance with European
regulations (European Union Directive 86/609/EEC). Animal
facilities and the people directly involved in animal experi-
ments (S.D.S, A.N.C) were certified by the Portuguese regu-
latory entity—Direcção Geral de Veterinária. All the protocols
performed were approved by the joint Animal Ethics Com-
mittee of the Life and Health Sciences Research Institute,
University of Minho. Health monitoring was performed ac-
cording to FELASA guidelines [49], confirming the Specified
Pathogen Free health status of sentinel animals maintained in
the same animal room. Humane endpoints for experiment
were defined (20 % reduction of the body weight, inability
to reach food and water, presence of wounds in the body,
dehydration), but not needed as the study period was con-
ceived to include ages at which animals do not reach these
endpoints.
Mouse Genotyping The progenies produced by mating MJD
transgenic with wild-type animals were genotyped at weaning
by PCR, as previously described [50].
Drug Treatment and Behavioral Tests Male micewere used in
the study since they show less variability than females in
behavioral tests, due to the more variable hormonal female
status. Transgenic and non-transgenic, drug- and vehicle-
treated animals were housed at weaning in groups of five
animals per cage. The experiment started at 4 weeks and
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ended at 24 weeks of age. At 4 weeks of age, we screened the
overall status of the animals by the SHIRPA protocol before
starting the treatment with lithium chloride (LiCl, Merck,
Massachusetts, USA). The treatment started at the asymptom-
atic age of 5 weeks, 1 week before the previously observed
onset of symptoms [48].
We used a total of 40 animals, which were housed accord-
ing to the drug administered, since the experiment was carried
out by a single experimenter, which was only blind to the
genetic status of the animals. The animals were intraperitone-
ally injected three times per week, except in the week of
behavioral tests. Transgenic and non-transgenic littermates
(n=10 for each genotype) were treated with 10.4 mg/kg of
lithium chloride as previously described [44, 45]. Control
littermate animals were given a vehicle injection of buffer
(0.15 M NaCl, 5 % Tween-20, and 5 % PEG 400) with the
same frequency. The animals were evaluated at 20 and
24 weeks of age in the BeamWalk Balance test. The SHIRPA
protocol was performed at all ages tested. For a detailed
description of behavioral testing, see below.
BodyWeight All mice were weighed a week before the start of
the drug treatment (4 weeks) and then at 5, 6, 8, 9, 10, 12, 13,
14, 16, 17, 18, and 20 weeks of age.
BeamWalk Balance Test The beamwalk balance test assesses
balance but is also sensitive to fine motor coordination. This
test measures the ability of the animal to stay upright and to
walk on an elevated beam without falling to the cushioned
pads below, or slipping to one side of the beam. The beams are
70 cm long and made of smooth wood with a square (12 mm
wide) or a round (11- and 17-mm diameter) shape. The beam
is placed at the height of 50 cm. The test has different levels of
difficulty obtained by varying the shape and width of the
beams. The animals were trained during 3 days in the square
beam (12 mm). In the fourth day, they were tested in the
training beam and also in two round beams (17 and 11 mm).
The animal is placed on one end of the beam and then
allowed to walk along the beam and reach the opposite end
(which has a “safe” dark box). At the end of the training days,
the animals should be capable of performing the task in less
than 20 s. By day 4, animals were tested using two beams of
different width and shape (square and round). If the animal fell
or turned around in the beam, this was considered one failed
trial. Each animal had the opportunity to fail two times in each
beam. The time the animal took to cross the beam was count-
ed, and time was discounted if the animal stopped in the beam.
SHIRPA Protocol We established a protocol for phenotypic
assessment based on the primary screen of the SHIRPA pro-
tocol, which mimics the diagnostic process of general neuro-
logical and psychiatric examination in humans [51]. Each
mouse was placed in a viewing jar (15-cm diameter) for
5 min and transferred to a 15-labeled-squares arena (55×
33×18 cm), and then a series of anatomical and behavioral
features were registered. The full details of the SHIRPA
protocol are available at the site http://empress.har.mrc.ac.
uk/browser/?sop_id=10_002_0. In addition, we included the
footprint pattern test (see below) to assess gait [52] and the
counting of rears over 5 min in the viewing jar, as a measure of
spontaneous vertical exploratory activity. The protocol was
adjusted in order to minimize animal handling and to generate
uniformity in waiting times between the tests [53].
Footprint Pattern The footprint test was used to evaluate the
foot dragging of the animals. To obtain footprints, the
hindpaws and forepaws of the mice were coated with black
and red non-toxic paints, respectively. A clean rectangular
paper sheet was placed on the floor of the runway for each
run. The animals were then allowed to walk along a
100 cm long×4.2 cm width×10 cm height corridor in the
direction of an enclosed black box. Each animal was allowed
to achieve one valid trial per age. To evaluate the presence of
foot dragging through age, the footprinting pattern of
CMVMJD135 and wild-type (wt) vehicle- and lithium-
treated (n=10 per group) was analyzed at each time point
considering six consecutive steps (absent, no dragging; pres-
ent, at least one step out of six shows dragging).
Assessment of Autophagy Activation The animals that were
chronically treated with LiCl for 19 weeks and were killed 12 h
after the last injection as previously described [48], and the
brain and muscle tissue were immediately frozen in dry ice. We
also injected wild-type animals with LiCl (10.4 mg/kg) three
times in 1 week in alternate days and performed the killing at
different time points after the last injection: 6, 14, 16, 18, and
24 h for determination of acute effects. Another set of animals
was injected with the vehicle and killed at the same time points.
Western Blot Brain tissue was homogenized in cold 0.1 M
Tris–HCl, pH 7.5, 0.1 M EDTA, and a mixture of protease
inhibitors (Complete, Roche, Swiss) and was sonicated for
10 s. Protein concentration was determined using the Bradford
assay (Biorad, CA, USA). Samples were heated for 5 min at
100 °C and microfuged for 10 s before loading. For each
sample, 15 μg of total protein was loaded into SDS-PAGE
gels and then transferred to nitrocellulose membranes
(Amersham GE Healthcare, UK). After incubation with the
primary antibodies—rabbit anti-LC3 (1:1,000 Novus Biolog-
icals, Littleton, CO), rabbit anti-IMPA1 (1:1,000, Abcam,
Cambridge, UK), rabbit anti-p62 (1:50, Abcam, Cambridge,
UK), rabbit anti-Beclin-1 (1:1,000, Cell signaling, Beverly,
MA), rabbit anti-Atg7 (1:1000, Cell signaling, Beverly, MA),
mouse anti-alpha-tubulin (1:100, DSHB, University of Iowa,
Iowa), and mouse anti-beta-actin (1:100, DSHB, University of
Iowa, IA)—the secondary antibodies were incubated at the
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following dilutions: anti-rabbit (1:10.000, Santa Cruz, Dallas,
TX, USA) and anti-mouse (1:10.000, Santa Cruz, Dallas, TX,
USA). Antibody affinity was detected by chemiluminescence
(ECL kit, Santa Cruz, Dallas, Texas, USA). Band quantifica-
tion was performed using the ImageJ software according to
the manufacturer’s instructions, using alpha-tubulin as the
loading control.
Determination of Lithium Plasma Levels The plasma lithium
levels were measured applying the LITH assay using the
Dimension Vista® System (LITH Flex® reagent cartridge)–
SIEMENS.
Statistical Analysis Power analysis was used to determine the
sample size [54]. Considering the different variables under
study, such as weight and time held in the hanging wire,
assuming a power of 0.8 and a significance level of 0.05,
different required sample sizes were obtained, depending on
the specified smallest detectable difference and the variability
of the experimental groups. Based on these calculations and
bearing in mind that as the age of the animals increases, also
the mean differences increase and, possibly, the standard
deviations, a sample size ranging between five and ten ani-
mals was obtained, and therefore, a sample of ten animals was
chosen. For specific behavioral tests and time points of anal-
ysis, see Supplementary Table S1.
Continuous variables with normal distributions (K-S test
p>0.05) were analyzed with the Student’s t test or two-way
ANOVA (factors: genotype and treatment). Behavioral data
were subjected to the non-parametric Mann–Whitney U test
when variables were non-continuous or when a continuous
variable did not present a normal distribution (Kolmogorov-
Smirnov test p<0.05). Categorical variables in the SHIRPA
protocol were analyzed by contingency tables (Fisher’s exact
test). All statistical analyses were performed using SPSS 22.0
(SPSS Inc., Chicago, IL). A critical value for significance of
p<0.05 was used throughout the study.
Results
In the CMVMJD135 transgenic mouse model, mutant ataxin-
3 expression is close to the endogenous levels and the MJD-
like symptoms are progressive in life, as observed in human
patients [48]. In the current study, we confirmed the onset of
the neurological phenotype at 6 weeks of age, with loss of grip
strength, measured using the hanging wire test. At 20weeks of
age, the animals showed a deficit in balance on the beam test.
It was also possible to observe tremors, foot dragging, and
limb clasping. Furthermore, they exhibited decreased locomo-
tor and exploratory behavior late in life. This model does not
show premature death, allowing long-treatment periods—in
the present case, treatment was administered for 19 weeks,
i.e., until the age of 24 weeks, when animals display overt
symptoms and a full-blown neurological phenotype.
Autophagy Is not Altered in the Brain of CMVMJD135 Mice
At basal conditions, autophagic activity in 24-month-old
CMVMJD135 mouse brains did not differ from that of litter-
mate controls (Fig. 1a). Autophagy was assessed by the mea-
surement of protein levels of LC3-II (Fig. 1b), an
autophagosome marker; of Beclin-1 (Fig. 1c), a protein in-
volved in the nucleation step of autophagy; of Atg7 (Fig. 1d)
involved in the elongation step of this process; of p62
(Fig. 1e), an autophagy substrate; and of IMPA1 (Fig. 1f), an
enzyme responsible for the provision of inositol required for
synthesis of phosphatidylinositol and polyphosphoinositides.
Our results suggest that autophagy is neither impaired nor
over-activated in this transgenic mouse model of MJD.
Lithium Chloride Induces Autophagy in the Mouse Brain
In order to verify if lithium chloride could induce autophagy at
the dosage we planned to administer (10.4 mg/kg), similar to
that used by Fornai et al. [44 and Wood and Morton 45], we
used a group of wild-type mice, injected them with lithium
chloride [45] three times per week, and measured the levels of
autophagy markers in the brain at different time points after
the last injection (6, 14, 16, 18, and 24 h post-injection). In
these mice, in which the mean plasma lithium concentration
achieved was 0.3±0.09 mmol/L, we were able to observe an
increase in the LC3-II/LC3-I ratio (Fig. 2a) and a decrease in
IMPA1 (Fig. 2b), an enzyme whose expression is directly
inhibited by lithium. According to the Guidelines for the use
and interpretation of assays for monitoring autophagy in
higher eukaryotes [55], LC3 is the only marker for
autophagosomes, but in mammalian cells, total LC3 protein
levels may not be altered after a cellular challenge; the most
probable finding is the increase in the conversion of LC3-I to
LC3-II. LC3-I is abundant and stable in the central nervous
system, which is a parameter to take in consideration in this
type of measurements [55]. Importantly, the LC3-II/LC3-I
ratio was increased at the protein level in the brain of
lithium-treated mice (Fig. 2a). We also found an increase in
LC3-II/LC3-I ratio in muscle tissue (data not shown). Consis-
tently, Beclin-1, a protein involved in the nucleation step of
the autophagosome formation [56], was also increased in
animals treated with LiCl, supporting autophagy induction
by this treatment (Fig. 2b). Furthermore, the levels of Atg7,
a protein involved in the elongation step of autophagosome
formation, were also increased in the LiCl-treated animals
(Fig. 2c). The decrease in p62 levels confirms that autophagy
was occurring without blockage (Fig. 2d). The levels of
IMPA1 were, as expected, decreased (Fig. 2e).
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To complement these analyses, we measured the levels of
autophagy markers in the brain of the transgenic animals that
were chronically treated with LiCl, namely, the LC3-II/LC3-I
ratio (Fig. 3a), as well as protein levels of Beclin-1 (Fig. 3b),
Atg7 (Fig. 3c), p62 (Fig. 3d), and IMPA1 (Fig. 3e), and the
results were similar to those observed for the acute LiCl
treatment, confirming that autophagy remains induced in the
chronically treated animals.
Intriguingly, and despite the efficacy of LiCl to induce au-
tophagy, it did not reduce the protein levels of mutant human
ataxin-3 in the brain of LiCl-treated animals, which were com-
parable to those of vehicle-treated mice (Supplementary Fig. S1).
LithiumDid not Improve BodyWeight Loss in CMVMJD135
Mice
We assessed the phenotype of the mice from 4 to 24 weeks of
age (Fig. 4a). Animals were weighed at 4 (before the treat-
ment) 5, 6, 8, 9, 10, 12, 13, 14, 16, 17, 18, and 20 weeks of
age. One of the known collateral effects of lithium treatment in
human patients is weight gain [57], but we did not observe this
in our study. Chronic administration of LiCl had no effect on
body weight in wt animals, compared with wt animals treated
with vehicle. At 12 weeks of age, vehicle-treated
CMVMJD135 mice started to lose weight compared to the
vehicle-treated wt animals (p=0.024) as previously observed
for this model [48] (genotype: F1,40=9.919; p=0.003) and as it
is known to occur in human patients [58]; this body weight
reduction was progressive in time, as shown in Fig. 4b. No
differences were found between vehicle- and lithium-treated
transgenic animals, i.e., lithium treatment did not improve this
body weight reduction.
Lithium Treatment Had no Major Effect on Neurological
Deficits Present in CMVMJD135 Mice
We analyzed all the animals using the SHIRPA protocol [51]
before the treatment onset, at 4 weeks of age, and no
Fig. 1 Autophagy basal levels in
CMVMJD135 mice. a
Representative Western blot
probed with LC3, Beclin-1, Atg7,
p62, IMPA1, and tubulin
antibodies. At least three technical
replicates were performed. b–f
LC3-II, Beclin-1, Atg7, p62, and
IMPA1 protein levels were
measured in brain lysates of
CMVMJD135 mice (n=5) and
their littermate wild type (n=5) at
24 months of age. LC3-II protein
levels were normalized both for
LC3-I and α-tubulin; Beclin-1,
Atg7, p62, and IMPA1 were nor-
malized for α-tubulin.
*p<0.05; **p<0.01;
***p<0.001 (Student’s t test)
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differences were found between wt and CMVMJD135 ani-
mals (data not shown), meaning that at this time point, the
transgenic animals did not show any symptoms of disease.
The first disease manifestation in the CMVMJD135 model
is the loss of limb strength given by the hanging wire test,
which measures the time the mouse is able to hold a grid with
its hindlimbs and, mostly, forelimbs, before falling. Whereas
wild-type animals—treated and vehicle groups—were almost
always able to complete the task (hanging in the grid for the
maximum time, 2 min), transgenic animals—both LiCl- and
vehicle-treated groups—showed a decreased latency to fall
from the grid, worsening with age (genotype: F1,39=324.589;
p=1.6628×10−20) (Fig. 4c).
At 16 weeks and subsequent ages, CMVMJD135 vehicle-
treated animals showed a decrease in exploratory behavior,
given by the infrequent rearing behavior, which progressed to
Fig. 2 Autophagy induction by
acute lithium treatment. a Anti-
LC3 Western blot of brain lysates
of wild-type animals injected with
vehicle (n=4) or lithium
10.4 mg/kg (n=4 for each time
point); b Beclin-1 Western blot of
brain lysates of wild-type animals
injected with vehicle (n=4) or
lithium 10.4 mg/kg (n=4 for each
time point); c Atg7 Western blot
of brain lysates of wild-type
animals injected with vehicle (n=
4) or lithium 10.4 mg/kg (n=4 for
each time point); d p62 Western
blot of brain lysates of wild-type
animals injected with vehicle (n=
4) or lithium 10.4 mg/kg (n=4 for
each time point); e anti-IMPA1
Western blot analysis of brain
lysates of wild-type animals
injected with vehicle (n=4) or
lithium 10.4 mg/kg (n=4 for each
time point); lithium-injected
animals were killed at different
time points as shown in the
graph; vehicle animals were
killed 6 h post-injection. Alpha-
tubulin or beta-actin was used as
loading control. *p<0.05;
**p<0.01; (Student’s t test)
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almost no rearing at the age of 24 weeks (p<0.05). At 8 weeks
of age, lithium-treated CMVMJD135 animals showed an
increase in exploratory behavior when compared with
vehicle-treated CMVMJD135 animals, given by the increase
in number of rears in the viewing jar (p=0.026). This activity
reached that of the vehicle-treated wt animals at this age, but at
later stages, the improvement was no longer seen (Fig. 5a). To
further test exploratory locomotor activity, we counted the
number of squares travelled in the arena used in the SHIRPA
protocol. CMVMJD135 treated with vehicle showed a de-
crease in the number of squares travelled in the arena at 20
and 24 weeks of age (p=0.003 and p=0.002, respectively),
which was not improved by chronic lithium treatment
(Fig. 5b).
Fig. 3 Autophagy induction by
lithium in chronically treated
transgenic mice at 24 weeks of
age. a Anti-LC3 Western blot of
brain lysates of transgenic
animals injected with vehicle
(n=4) or lithium 10.4 mg/kg
(n=4); b Beclin-1 Western blot of
brain lysates of transgenic ani-
mals injected with vehicle (n=4)
or lithium 10.4 mg/kg (n=4); c
Atg7Western blot of brain lysates
of transgenic animals injected
with vehicle (n=4) or lithium
10.4 mg/kg (n=4); d p62 Western
blot of brain lysates of transgenic
animals injected with vehicle (n=
4) or lithium 10.4 mg/kg (n=4); e
anti-IMPA1 Western blot analysis
of brain lysates of transgenic
animals injected with vehicle (n=
4) or lithium 10.4 mg/kg (n=4);
alpha-tubulin or beta-actin was
used as loading control. *p<0.05;
**p<0.01; (Student’s t test)
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We also performed qualitative analysis of the gait in the
open arena as described by Rogers et al. [51]. We scored the
animals with 0 when their gait was normal, 1 when the animal
had a fluid stepping but an abnormal walking, and 2 when the
animal had limited walking [51]. CMVMJD135 animals
started to have significantly worse gait scores at the age of
20 weeks (p=0.029), and at 24 weeks of age, 100 % of the
animals had a visibly abnormal gait (80 % of the animals were
scored as 1, 10 % as 2, and 10 % as 0, p=0.000017) (Fig. 5c).
There was a trend toward improvement with lithium treat-
ment, but only at 24 weeks of age (80 % of the vehicle
transgenic animals were scored as having abnormal gait, in
contrast with 67% of the treated transgenic animals, p=0.054)
(Fig. 5c). Additionally, we performed a semi-quantitative
analysis of the foot dragging observed in the mice (Fig. 5d).
We found no significant differences in the footstep measure-
ments between the four groups at the ages tested, but it was
possible to observe that CMVMJD135 animals presented foot
dragging at 12 weeks (p=0.00002) and that this symptom
progressed in severity with age (p<0.05). At 20 weeks of
age, all CMVMJD135mice (100%, p=2×10−5) dragged their
feet while walking. Lithium was not able to rescue this
phenotype.
When mice are picked up by the tail and suspended toward
a surface, their normal reflex is to extend all the four paws to
anticipate the ground [59]. The paw clasping phenotype, in
which the animals contract the paws instead of extending
them, is observed in several mouse models with damage in
the cerebellum [60, 61] or in the basal ganglia [62, 63], and
also in models of AD [64–66]. In CMVMJD135 mice, this
paw clasping phenotype was detected at 24 weeks of age (p=
2×10−6), whereas wt animals never presented this abnormal
reflex (Fig. 6a). Lithium treatment was not able to rescue this
aspect of the phenotype (Fig. 6a).
Fig. 4 Effect of lithium treatment
on body weight and strength of
CMVMJD135 and wt mice. a
Schematic timeline for the
behavioral analysis of lithium pre-
clinical trial. b The body weight
in grams between 8 and 20 weeks
of age was depicted for wt and
CMVMJD135 mice treated with
LiCl or vehicle (n=10 for each
group). c Hanging wire test—all
transgenic animals display a
worse performance in holding the
grid with age (from 8 to 24 weeks
of age). A maximum time of
2 min was given to each animal
and the time that they took to fall
was registered (n=10 for each
group). Symbols represent mean ±
SEM of the different groups.
*p<0.05; ***p<0.001, for
genotype factor (two-way
ANOVA)
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We also observed an increase in the percentage of trans-
genic animals presenting tremors through age, starting at
16 weeks of age (p<0.05), which was, surprisingly, amelio-
rated with lithium treatment, this improvement being signifi-
cant only after a long period of administration (24 weeks of
age, p=0.02) (Fig. 6b).
Lithium Fails to Rescue Balance and Fine Motor Deficits
in CMVMJD135 Mice
The balance beam test depends on the mouse’s ability to
maintain balance while traversing a narrow beam to reach a
safe platform [67] and was used to test the balance and fine
motor coordination capabilities in CMVMJD135 and wt
animals, treated with LiCl or with the vehicle. At 20 weeks,
CMVMJD135 animals were slower to traverse the round
beams with 17 mm (genotype: F1,31=8.96; p=0.005; geno-
type×treatment: F1,31=5.260; p=0.029) and 11 mm of diam-
eter (genotype: F1,36=4.447; p=0.042), but not significantly
slower in the 12-mm square beam, in which they had been
trained; the difficulty in performing this task was confirmed at
24 weeks of age, when transgenic animals were slower in
traversing the 12-mm square beam (genotype: F1,37=6.412;
p=0.016), the 17-mm round beam (F1,30=5.315; p=0.028),
and the 11-mm round beam (genotype: F1,33=5.041; p=
0.032) (Fig. 7). In the 11-mm round beam, transgenic mice
showed a “crawling behavior” (when the animal’s thorax and
abdomen are in contact with the beam surface) and dragged
Fig. 5 Effect of lithium treatment upon spontaneous exploratory activity
and gait quality. a Transgenic animals display decreased vertical locomo-
tor activity at 16 weeks of age and subconsequent ages (n=10 for each
group); b Transgenic animals travel less in the arena than wild-type
animals at 20 and 24 weeks of age; lithium treatment had no effect in
this phenotype (n=10 for each group). c CMVMJD135 animals have
abnormal gait at 20 and 24 weeks of age (qualitative assessment) that is
slightly reverted by LiCl at 24 weeks, although not statistical significant
(n=10 for each group). d Quantitative analysis of the foot dragging:
Presence/absence of dragging demonstrated that transgenic animals drag
their feet since 12 weeks of age, which was not ameliorated by LiCl (n=
10 for each group). *p<0.05; **p<0.01; ***p<0.001
Cerebellum (2014) 13:713–727 721
themselves across the beam. Lithium had no significant effects
in the performance in the beam of either wt or CMVMJD135
mice.
Discussion
One promising therapeutic strategy in diseases associated with
misfolded protein accumulation is the stimulation of cellular
degradation pathways such as macroautophagy. Here we have
tested the effect of authophagy activation by lithium in a
mouse model of MJD, beginning at a pre-symptomatic age.
In this study, we confirmed the progressive neurologic
phenotype of the CMVMJD135 mouse model, through ob-
servation of the group of vehicle-treated animals, which be-
haved as previously described [48]. Chronic lithium treatment
was, however, not able to rescue the neurological phenotype
of these mice. The disease-causing polyQ CAG repeat
Fig. 6 Effect of lithium treatment
on limb clasping and tremors. a
Limb clasping is observed in
transgenic animals—treated and
non-treated—at 24 weeks of age
(n=10 for each group). b
CMVMJD135 mice presented
tremors since 16 weeks of age;
LiCl is able to decrease tremors in
transgenic animals at 24 weeks of
age (n=10 for each group).
*p<0.05; **p<0.01;
***p<0.001 (Fisher’s exact test)
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expansion in ataxin-3 might cause neurotoxicity both through
a toxic gain of function and a loss of the wild-type ataxin-3
normal function(s) [68]. Several molecular pathways might be
involved in MJD neuropathology, although the precise path-
ogenic mechanism(s) is (are) not known [69, 70]. Decreased
autophagy is a cellular process that might be included in these
mechanisms [36, 37, 71]. An autophagy impairment was
recently proposed to occur in a mouse model of MJD, as well
as in the brain of MJD patients [37]. MJD pathogenesis has
been modeled through the expression of mutant ataxin-3 that
causes aggregate formation and toxicity, in cell models and
in vivo [72], and autophagy has been shown to be an effective
cellular strategy for the clearance of these aggregated proteins
[73, 74]. Menzies and colleagues demonstrated that autopha-
gy induction by rapamycin could improve rotarod perfor-
mance in a transgenic mouse model of MJD [36]; however,
the MJD model used in this study presented a very mild
phenotype (not significantly different from control mice from
a statistical standpoint), and the authors proposed that this
hypothesis should be further confirmed in a model with more
marked phenotype. Also, in this study, the authors suggest that
it would be of great importance to test other compounds that
can induce autophagy, such as lithium. Here, we provide a
complete behavioral analysis of the CMVMJD135 mouse
model chronically treated with lithium chloride.
At basal conditions, it was not possible to observe signif-
icant differences in protein levels of LC3-II, Beclin-1, Atg7,
p62, and IMPA autophagy markers when comparing
CMVMJD135 with wild-type animals at 24 weeks of age
(when they have a well-established phenotype), suggesting
that, in spite of the neurodegenerative changes they show [48],
the autophagy process is functioning normally in the brain of
these mice. This is in contrast with the findings in another
transgenic mouse model of MJD, characterized by more
marked overexpression of ataxin-3 and a faster disease pro-
gression [75], where it has been proposed that autophagy was
over-activated but functional only at early stages of the disease
[37].
Given the previous results in other related neurodegenera-
tive diseases and our own results with 17-DMAG, which
delayed disease progression the CMVMJD135 mouse and
induced autophagy [48], we reasoned that even if autophagy
is normal in these mice, it might be useful to boost the cells’
capacity to eliminate toxic ataxin-3 aggregates; hence, we
proceeded with chronic li thium treatment in the
CMVMJD135 mice. In this study we selected to use a dosage
Fig. 7 Effect of lithium treatment on balance and motor coordination.
Each bar corresponds to the mean of two consecutive trials in each beam.
The time to traverse the beam was videotaped and then measured by the
same experimenter. Ten to 12 animals were used for each condition.
*p<0.05 for genotype factor (two-way ANOVA); #p<0.05 for
genotype×treatment factor (two-way ANOVA)
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at the lower limit of the therapeutic range in order to avoid
cerebellar toxicity as much as possible. The efficacy of lithium
as an autophagy inducer in the brain was validated by the
decrease in protein levels of IMPA-1, induction of Beclin-1
and Atg7 protein levels, increased LC3-II/LC3-I ratio, and
decrease in p62 in treated CMVMJD135 mice. Our reason for
studying treatment of the CMVMJD135 mice before onset of
the symptoms was to have the strongest effect possible in the
disease progression and to see if we could prevent or delay the
onset of the disease rather than treat it once established, as
mechanistically, we anticipated that it would be harder to
remove the larger nuclear inclusions than smaller cytoplasmic
aggregates. Considering the availability of a genetic test for
MJD patients, this early stage treatment design could be
feasible for mutation carriers even before they present clinical
symptoms.
At the phenotypic level, LiCl treatment did not rescue the
loss of body weight observed in CMVMJD135 animals. Pro-
gressive weight loss is observed in MJD patients [58], despite
a normal appetite [76] and also in HD patients [77]. It has been
reported previously that treatment with LiCl pre-
symptomatically caused loss of body weight in a HD mouse
model, whereas a gain of body weight was observed when
LiCl treatment was performed in post-symptomatic animals
[45]. We have not observed loss or gain of body weight as
result of the treatment here performed, which was initiated
1 week before symptom onset. Intriguingly, at 8 weeks of age,
lithium-treated CMVMJD135 animals showed an increase in
exploratory behavior when compared with vehicle-treated
CMVMJD135 animals, given by the increase in number of
rears in the viewing jar. This activity reached the levels of
vehicle-treated wt animals. We believe that this apparent (and
transient) amelioration might have been due to an improved
reaction to the novelty of the test (i.e., an effect in mood) and
not because lithium was having benefic effects at the motor
level, since this rescue of hypoactivity was not manifested in
other motor parameters and was not maintained through life.
The tremors observed in CMVMJD135 mice were amelio-
rated with lithium treatment, this improvement being statisti-
cally significant only after a long period of lithium adminis-
tration. This is an intriguing finding because tremors are often
observed in BD patients taking lithium for long periods [78],
being a side effect of this drug. Additionally, tremors are not a
major symptom in MJD patients, but rather a rare manifesta-
tion [79–81] that can be treated with levodopa or dopamine
agonists [82]. Thus, the tremor rescue by lithium treatment
that we observed in CMVMJD135 mice at one of the time
points of analysis might not have a major impact in human
patients.
Gait analysis was performed using qualitative analysis,
given by the “the way animals walk” in the arena—scored
by the experimenter, as part of the SHIRPA protocol [51]—
and by the footprinting analysis [52], respectively. In the
qualitative gait analysis, vehicle-treated CMVMJD135 ani-
mals showed visible deficits in gait at 20 and 24 weeks of
age. In the last time point of analysis (at 24 weeks), LiCl
treatment appeared to improve the visible quality of gait, but
this effect was not statistically significant.
Regarding balance (balance beam test), abnormal reflexes
(limb clasping), and strength/fine motor coordination (hang-
ing wire test), it was also not possible to observe any amelio-
ration of CMVMJD135 mice with lithium treatment. Of no-
tice, the number of animals used in the study allowed detec-
tion of a 50 % effect size for all tests for at least one age, with
the exception of the medium square and small circle beams in
the balance beam test and the exploratory locomotor activity
in the SHIRPA protocol (Supplementary Table S1).
Lithium was shown to have beneficial effects in motor
performance (given by rotarod analysis) in a transgenic mouse
model of SCA1 [46] but had no effect inmotor performance in
a HD mouse model when administered pre-symptomatically
[45]. The current study demonstrates that long-term peri-
symptomatically initiated lithium treatment had no major
effects in a mouse model of MJD. Depending on the concen-
tration, lithium has well-established collateral effects. At least,
in mice, these side effects may be the result of differences in
the ability of some individual mice to clear LiCl from the
plasma. In humans, at a dose of 1.5 mEq/L the side effects are
considered mild, but anorexia [83], tremors [84], nausea,
diarrhea, vertigo, confusion (American Psychiatric Associa-
tion 2002), and cognitive impairment can occur [85]. Of
relevance to this pathology, irreversible cerebellar toxicity
due to lithium intoxication has long been recognized and can
lead to ataxia, nystagmus, and dysarthria [86]. The pathophys-
iology of lithium-related ataxia appears to be related with loss
of Purkinje cells in the cerebellum, with sparing of the sur-
rounding basket cells [87]. Clinicians are aware of these risks
and monitor lithium plasma levels of the patients’ closely.
Side effects need to be carefully analyzed since lithium can
cause cerebellar toxicity even at so-called therapeutic levels
[88].
While completing the experiments for this article, a human
clinical trial with lithium carbonate was performed in MJD
patients (http://clinicaltrials.gov/ct2/show/record/
NCT01096082). This study demonstrated that lithium (at a
dose of 0.5–0.8 mEq/L) was safe and well tolerated by
patients during the trial period, but the disease progression
was not improved after 48 weeks of follow-up, given by the
Neurological Examination Score for the Assessment of
Spinocerebellar Ataxia (NESSCA) and the Scale for the As-
sessment and Rating of Ataxia (SARA) scales. However, the
authors were able to show that the patients treated with lithium
had a slightly slower progression concerning two quantitative
ataxia assessment tools, the mean PATA rate and the Click
Test, as well as in the spinocerebellar ataxia functional index
(SCAFI) and composite cerebellar functional score (CCFS),
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when compared to patients receiving placebo. Considering
this minor improvement in a few ataxia measures, the authors
proposed that a larger number of patients should be enrolled in
a new clinical trial to clarify these results [89]. Although the
dosage used in our study is considerably lower than that used
in the human study, and our treatment was initiated 1 week
before symptom onset, this clinical trial is in accordance with
the present study, where we could not find improvement by
chronic LiCl treatment in the coordination and ataxia mea-
surements, although some behavioral parameters, such as
tremors and gait quality, were slightly ameliorated. Further-
more, we used similar doses as those administered in studies
showing beneficial effects in mouse models of ALS and HD
[44, 45] and confirmed that this dosage induced the expected
biological effects, namely concerning autophagy induction.
Conclusion
In conclusion, the present study, demonstrates that chronic
lithium treatment is not able to rescue the CMVMJD135
mouse phenotype; our results do not support lithium treatment
as a good approach for MJD, particularly as the above men-
tioned side effects must be taken in consideration.
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Supplementary material  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1: Levels of human ataxin-3 in LiCl-treated animals. Anti-ataxin-3 western-blot of brain lysates of 
transgenic animals injected with vehicle (veh) (n = 4) or lithium chloride (LiCl) 10.4 mg/Kg (n = 4) at 24 weeks of age. Actin 
was used as loading control (test-t student).
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Supplementary Table 1. Sample size calculations for each behavioral test assuming a power of 0.8 and a significance level of 0.05.  
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Combined therapy with LiCl and CCI779 causes neurotoxicity 
Abstract 
A major pathological hallmark in several human neurodegenerative disorders, like Parkinson's 
disease (PD) and polyglutamine (polyQ) disorders, including Machado-Joseph disease (MJD), is the 
formation of intra-neuronal protein aggregates. MJD is an inherited neurodegenerative disease, caused 
by a CAG repeat expansion in the ATXN3 gene, resulting in an abnormal protein, which is prone to 
misfolding and forms cytoplasmic and nuclear aggregates within neurons, ultimately inducing 
neurodegeneration.  
Treatment of proteinopathies with drugs that up-regulate autophagy, like rapamycin, has shown 
promising results in cell, fly and mouse models of polyQ diseases. Temsirolimus (Cell Cycle inhibitor-
779, CCI-779) is an analogue of rapamycin that inhibits the mammalian target of rapamycin (m-TOR), 
while lithium chloride acts by inhibiting inositol monophosphatase (IMPase), reducing free inositol and 
IP3 levels, both compounds being able to induce autophagy.  
We have previously shown that chronic treatment with lithium chloride (10.4 mg/Kg) had 
limited effects in a transgenic MJD mouse model. Also, others have shown that temsirolimus had mild 
positive effects in a different mouse model of the disease. It has been suggested that the combination 
of mTOR-dependent and –independent autophagy inducers could be a more effective therapeutic 
approach. To further explore this avenue towards therapy, we treated CMVMJD135 transgenic mice 
with a conjugation of temsirolimus and lithium, both at concentrations known to induce autophagy and 
not to be toxic. Surprisingly, this combined treatment proved to be deleterious to both wild-type and 
transgenic animals, failing to rescue their neurological symptoms and actually exerting neurotoxic 
effects. 
These results highlight the possible dangers of manipulating autophagy in the nervous system 
and suggest that a better understanding of the potential disruption in the autophagy pathway in 
SCA3/MJD are required before successful long-term autophagy modulating therapies can be developed.  
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Introduction 
Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia type 3 (SCA3), is the 
most common autosomal dominant ataxia worldwide (1), and is caused by a CAG repeat expansion 
within the coding region of the ATXN3 gene (2). The clinical severity and the age at onset of the disease 
depend on the length of the expanded repeat (3, 4). MJD is characterized by motor uncoordination and 
amyotrophy, spasticity, gait ataxia, difficulty with speech and swallowing, altered eye movements, 
double vision, and frequent urination (5, 6).  
MJD shares many features with other polyglutamine diseases, such as the formation of 
cytoplasmic and nuclear inclusion bodies within neurons by the mutant protein (7, 8). It is assumed 
that the common toxic gain-of-function mechanisms for the polyglutamine-containing protein depend on 
aggregation and deposition of misfolded proteins leading to neuronal dysfunction and eventually cell 
death (9).  
Despite the well-described clinical and pathological phenotypes, the molecular and cellular 
events underlying neurodegeneration in these disorders are still poorly understood. Compelling 
evidence points to major aetiological roles for interference with transcriptional regulation, protein 
aggregation and clearance, the ubiquitin-proteasome system and alterations of calcium homeostasis in 
the neuronal loss observed during the neurodegenerative process. These pathways could act 
independently or, more likely, interact and enhance each other, triggering the accumulation of cellular 
damage that eventually leads to dysfunction and death (10). This suggests that simultaneous targeting 
of several pathways may be therapeutically necessary to prevent neurodegeneration and preserve 
neuronal function. Understanding how dysregulation of these pathways mediates disease progression is 
leading to the first attempts of obtaining effective therapeutic strategies in vivo, which may prove 
beneficial in the treatment of polyQ diseases. One such pathway is autophagy, a process that 
encompasses lysosomal degradation of cytoplasmic material, such as defective organelles and 
unfolded/aggregated proteins. Autophagy is morphologically defined by the appearance of numerous 
cytosolic autophagosomes, which are formed by the assembly and expansion of double layered, 
membrane bound structures of unknown origin around whole organelles and isolated proteins. The 
autophagosomes encapsulate cytosolic materials and subsequently dock and fuse with lysosomes or 
other vacuoles, resulting in the degradation of their contents (11). In several neurological diseases, the 
pathological accumulation of autophagosomes/ autophagosome-like structures and abnormalities in the 
endosomal-lysosomal pathway has been documented by electron microscopy (EM) in human post 
mortem brain tissue (12-16). While initially this was interpreted as evidence of death triggered by 
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autophagy, the currently predominant perspective is that this vesicle accumulation reflects impaired 
autophagy completion, which is emerging as a common element to several neurodegenerative disorders 
(17, 18). Autophagy induction has therefore been advanced as a promising therapeutic strategy for 
these diseases (19, 20), and in the particular case of MJD, genetic approaches in lentiviral 
overexpression models have supported this conclusion (21). 
The mammalian target of rapamycin (mTOR) kinase is a master negative regulator of autophagy 
(22). mTOR is a central sensor of energy status, growth factors and nutrient signals, and can be 
inhibited by rapamycin (23) and related small molecules (24). Besides this pathway, autophagy can 
also be regulated independently of mTOR (25). Inhibition of inositol monophosphatase (IMPase) 
reduces free inositol and IP3 levels, which leads to an upregulation of autophagy. Rapamycin has been 
shown to reduce aggregation of expanded polyQ in transfected cells (26), to protect against 
neurodegeneration in a fly model of Huntington disease (HD), and to improve motor performance and 
decrease aggregate formation in a mouse model of HD (27). Lithium, an mTOR-independent autophagy 
inducer has been shown to improve motor performance and depressive-like behavior in a mouse model 
of HD, as well as to improve neuropathology and motor function in a SCA1 mouse model (28, 29). We 
have recently shown that 19 weeks of lithium chloride (10.4 mg/Kg) treatment in the CMVMJD135 
mouse model (30), had limited effects on the motor phenotype of these animals, despite its ability to 
induce autophagy both in the chronic and acute treatment (30). Temsirolimus (cell cycle inhibitor-779), 
a less toxic rapamycin analogue, was recently approved by the Food and Drug Administration (FDA) for 
the treatment of renal cell carcinoma (31, 32). This drug was shown to reduce mutant ataxin-3 levels 
and toxicity, as well as ameliorate the disease symptoms in a transgenic mouse model of MJD (19). 
Additionally, Menzies and colleagues suggested that the use of combined lithium and temsirolimus 
would be an interesting approach to explore (33). The theoretical basis for this combinatory approach 
would be the fact that lithium can act both as autophagy inducer or inhibitor, depending on the dose 
used (25, 34). At higher dosages lithium is actually able to inhibit GSK3, which suppresses autophagy 
via phosphorylation of mTOR (34, 35); thus, a combinatory therapy with another mTOR-dependent 
autophagy inducer could counteract this effect. The main goal of this work was to test the potential of 
this combinatory treatment in a MJD. We treated MJD transgenic animals (36, 37) chronically with a 
combination of temsirolimus and lithium – LiCl+CCI-779 (m-TOR-dependent and independent 
pathways, respectively). We show that the combinatory treatment using lithium and temsirolimus 
improved locomotion defects of a transgenic C.elegans model of MJD. However, our results show that 
the simultaneous administration of LiCl and CCI-779 was ineffective in rescuing the motor impairments 
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of CMVMJD135 mice and had deleterious effects both in CMVMJD135 and wild-type (wt) animals at the 
doses used in this pre-clinical trial. 
 
Material and methods 
 
Nematode strains and general methods. Standard methods were used for culturing and 
observing C. elegans (38). Briefly, nematodes were grown on nematode growth medium (NGM) plates 
seeded with Escherichia coli OP50 strain at 20°C. The transgenic AT3q130 strain used in this work 
was previously described by Teixeira-Castro et al (37). All assays were performed at room temperature 
(20 ºC) on 4-days old synchronized animals grown at 20ºC.  
 
C. elegans drug treatment and motility assay. AT3q130 animals were grown in liquid 
culture in a 96-well plate format, with the combination of lithium and CCI779. Four day old animals 
were transferred from the 96-well plates onto an unseeded NGM plate (equilibrated at 20°C). Plates 
were allowed to dry for 1 hour before starting the assays. Motility assays were performed at 20°C as 
previously described (37, 39). Animals remaining inside a 1-cm circle after one min were scored as 
locomotion defective. Motor behavior assays were run in triplicates or quadruplicates (n=3 or 4), with a 
total of at least 150 animals tested per compound concentration. Compound preparation: Stock 
solution of 200 mM LiCl (1.05679-0100, Merck) was prepared in water. CCI779 (T8040, LC-
laboratories) 48.5 mM stock solution was prepared in EtOH. 
 
Ethics statement. All procedures with mice were conducted in accordance with European 
regulations (European Union Directive 2010/63/EU). Animal facilities and the people directly involved 
in animal experiments (S.D.S, A.N.C) were certified by the Portuguese regulatory entity — Direcção 
Geral de Alimentação e Veterinária.  
All of the protocols performed were approved by the Animal Ethics Committee of the Life and 
Health Sciences Research Institute, University of Minho. 
 
Mouse strains, maintenance and general methods. Male CMVMJD135 mice 
(background C57BL/6) (40) were used in the study since they were expected to show less variability 
than females in behavioral tests, due to the hormonal female status. Transgenic and non-transgenic 
drug- and placebo- treated animals were sequentially assigned and housed at weaning in groups of 5 
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animals in filter-topped polysulfone cages 267 × 207 × 140 mm (370 cm2 floor area) (Tecniplast, 
Buguggiate, Italy), with corncob bedding (Scobis Due, Mucedola SRL, Settimo Milanese, Italy) in a 
conventional animal facility. The progeny produced by mating MJD transgenic with wild-type animals 
were genotyped at weaning by PCR, as we previously described (41). The experiment started at 4 
weeks and ended at 24 weeks of age. All animals were maintained under standard laboratory 
conditions: an artificial 12 h light/dark cycle (lights on from 8:00 to 20:00 h), with an ambient 
temperature of 21±1 °C and a relative humidity of 50–60%; the mice were given a standard diet 
(4RF25 during the gestation and postnatal periods, and 4RF21 after weaning, Mucedola SRL, Settimo 
Milanese, Italy) and water ad libitum. Health monitoring was performed according to FELASA guidelines 
(42), confirming the Specified Pathogens status of sentinel animals maintained in the same animal 
room. Humane endpoints for experiment were defined (20% reduction of the body weight, inability to 
reach food and water, presence of wounds in the body, dehydration), but not needed in practice as the 
study period was conceived to include ages at which animals do not reach these endpoints. The 
animals were sacrificed by decapitation. The timeline used in this study is shown in Fig. 2A. 
Drug treatment. In order to conduct this pre-clinical trial we used a combination of two FDA-
approved compounds, lithium (LiCl, Merck) and temsirolimus (CCI-779, LC Laboratories). Mice were 
allocated to vehicle and LiCl+CCI-779-treated groups. The final numbers of animals in each group were: 
vehicle-treated CMVMJD135, n = 12; LiCl+CCI-779-treated CMVMJD135, n=10; vehicle-treated wt, n = 
12; LiCl+CCI-779-treated wt, n=15. The treatment started at the asymptomatic age of 5 weeks. Animals 
were intraperitoneally injected three times a week in the testing room and immediately placed in their 
home cage, except in the week of behavioral tests. Transgenic and non-transgenic animals were treated 
with 10.4 mg/kg of lithium and 20 mg/kg of temsirolimus (doses and routes as previously described by 
(27-30)). Lithium stock solutions were prepared at a concentration of 25mg/kg in 0.15 M NaCl, 5% 
Tween-20 and 5% PEG 400 and Temsirolimus at 50 mg/kg in absolute ethanol. Control animals were 
given a placebo injection of buffer (0.15 M NaCl, 5% Tween-20 and 5% PEG 400) with the same 
frequency. 
Body weight. All mice were weighed a week before the start of the drug treatment (4 weeks) 
and then at 8, 12, 16, 20 and 24 weeks of age.  
Behavioral tests. The behavioral tests herein shown were performed as previously described 
(30). At 4 weeks of age we tested the motor performance and screened the overall health status of the 
animals using the SHIRPA protocol (43), before starting the treatment with the combined compounds. 
The SHIRPA protocol was applied at 4, 8, 12 and 16, 20 and 24 weeks of age (protocol details are 
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available at the site: http://empress.har.mrc.ac.uk/browser/?sop_id=10_002_0). In addition, we 
included the footprint pattern test (44). The protocol was adjusted in order to minimize animal handling 
and to generate uniformity in waiting times between the tests (45). To analyze the foot dragging 
phenotype (at 8, 12 and 20 weeks of age), six consecutive steps were evaluated and the presence or 
absence of foot dragging phenotype was registered as previously described (30). 
The beam walk test, which assesses balance but is also sensitive to motor coordination was 
performed as previously described at 20 and 24 weeks of age (30). The time animals took to 
cross the beam was counted, and time was discounted if animals stopped in the 
beam. 
 
Western-blot 
Mouse brain tissue was homogenized in cold 0.1 M Tris-HCl, pH 7.5, 0.1 M EDTA, in the 
presence of a mixture of protease inhibitors (Complete; Roche, Swiss). Protein concentration was 
determined using the Bradford assay (Biorad, California, USA). Samples were heated for 5 minutes at 
100°C, and microfuged for 10 seconds before loading. For each sample, 50 micrograms of total 
protein were loaded into SDS-Page gels and then transferred to nitrocellulose membranes (Biorad, 
California, USA). After, the membranes were incubated with the primary antibodies: rabbit anti-p62 
(1:50, Abcam, Cambridge, UK) and rabbit anti-Beclin-1 (1:1000, Cell signaling, Beverly, MA), mouse 
anti-beta-actin (Ambion, 1:5000, Life Technologies, CA, USA), rabbit anti-LC3 (1:1000 Novus 
Biologicals, Littleton, CO) and rabbit anti-ataxin3 serum (1:5000; kindly provided by Dr. Henry Paulson). 
The secondary antibodies were incubated at the following dilutions: anti-rabbit (1:10.000, Biorad, 
California, USA) and anti-mouse (1:10.000, Biorad, California, USA). Antibody affinity was detected by 
chemiluminescence (Clarity ECL kit, Biorad, California, USA). Western-blot quantifications were 
performed using the Chemidoc XRS Software with ImageLab Software (Biorad, USA) according to the 
manufacturer’s instructions and using beta-actin as the loading control. 
 
Statistical analysis 
The experimental unit used in this study was a single animal. Power analysis was used to 
determine the sample size as previously described (36). The estimates of required number of animals 
for specific behavioral tests and time-points of analysis are described in (30). Continuous variables with 
normal distributions (K-S test p>0.05) were analyzed with the Student t-test or two-way ANOVA (Factors: 
genotype and treatment). Behavioral data were subjected to the non-parametric Mann-Whitney U-test 
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when variables were non-continuous or when a continuous variable did not present a normal 
distribution (Kolmogorov-Smirnov test p<0.05). Categorical variables in the SHIRPA protocol were 
analyzed by contingency tables (Fisher’s exact test). All statistical analyses were performed using SPSS 
22.0 (SPSS Inc., Chicago, IL). A critical value for significance of p< 0.05 was used throughout the 
study. 
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Results 
LiCl+CCI779 treatment improved locomotion deficits in a transgenic C.elegans 
model of MJD 
We evaluated compound efficacy to rescue neuronal dysfunction in a C. elegans model of MJD 
pathogenesis, in which expression of mutant ATXN3 (AT3q130) in all neuronal cells results in 
locomotion defects (37). AT3q130 animals grown in liquid medium with or without drug for four days 
were tested for defects in locomotion, by employing a motility assay. Treatment with LiCl and CCI779 
resulted in a partial rescue of locomotion impairment (Fig. 1). Taking these results in consideration, we 
pursued with this potential combinatory treatment by performing a pre-clinical trial in an MJD mouse 
model.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. AT3q130 animals treatment with the small molecules targeting autophagy. (A) AT3q130 animals 
treated with 7.5mM of LiCl plus CCI-779 at 1 μM showed a significant reduction in locomotion defects given by the motility 
assay. (B) Schematic representation of the motility assay for C.elegans. Data are the mean ± SD, at least 150 animals per 
data point. Student’s t-test, ∗p< 0.05. 
 
The CMVMJD135 transgenic mice, expressing full-length human ataxin-3 with an expanded 
polyQ repeat of 135 glutamines ubiquitously and at near endogenous levels, have previously been 
shown to develop a slowly progressive motor and neuropathological phenotype resembling MJD (36). 
We treated these mice with LiCl+CCI-779 at dosages previously described, for each compound 
individually, to activate autophagy and not to be toxic (10.4 and 20 mg/Kg respectively) (27, 28, 30). 
We started the treatment regimen at 5 weeks of age (one week before the onset of the symptoms) and 
followed the animals until they reached 24 weeks, performing a monthly extensive characterization of 
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the animals using the SHIRPA protocol and the Beam walk test. The study design is summarized in Fig. 
2A. Before the beginning of injections, at 4 weeks of age, mice were evaluated using the SHIRPA 
protocol, and no differences were observed between wild-type and transgenic animals. 
 
Survival and general health  
Survival is not a useful readout in pre-clinical trials using the CMVMJD135 model, because 
animals, although very sick, survive until quite late ages; however, during this pre-clinical trial three 
transgenic animals treated with LiCl+CCI-779 died (while none of the untreated animals died, p=0.006), 
which we attribute to the toxicity of the compounds when administered together. At the end of the 
experiment, both CMVMJD135 and wt mice treated with LiCl+CCI-779 presented an unhealthy 
appearance, but were still able to move and feed. 
Administration of LiCl+CCI-779 to wt mice caused a significant decrease in the body weight in 
comparison to the vehicle group (p=0.002). This drug combination treatment also diminished 
significantly the already reduced body weight of CMVMJD135 mice when compared to the vehicle-
treated transgenic group (p=0.001) (Fig. 2B). 
 
156 
 
Combined therapy with LiCl and CCI779 causes neurotoxicity 
 
Figure 2. Effect of LiCl+CCI779 treatment on body weight of CMVMJD135 and wild-type mice.  (A) 
Schematic timeline for the behavioral analysis of Lithium+CCI779 pre-clinical trial. (B) The body weight in grams between 8 
to 24 weeks of age is depicted for wt and CMVMJD135 mice treated with LiCl+CCI779 or vehicle (n=10-12 for each group). 
Symbols represent mean ± SEM of the different groups. * represent the p< 0.05, for genotype factor (two-way ANOVA). 
Vertical arrow represents the onset of the phenotype. 
 
SHIRPA protocol 
At 8, 16, 20 and 24 weeks of age, we observed a decreased exploratory activity in vehicle-
treated CMVMJD135 mice, while transgenic animals treated with LiCl+CCI-779 showed an increased 
exploratory activity at 8, 16 and 24 weeks of age, given by the significant increase in the number of 
rears in the viewing jar (p=0.001, p=0.04 and p=0.003 respectively), reaching a comparable 
performance to the wt vehicle-treated group (Fig. 3A). However, at eight weeks of age, there was an 
increase in exploratory behavior in wild-type mice treated with LiCl+CCI-779, suggesting a non-specific 
effect (Fig. 3A). 
157 
 
Combined therapy with LiCl and CCI779 causes neurotoxicity 
 
Figure 3. LiCl+CCI779 treatment effect on spontaneous exploratory activity and hindlimb strength. (A) 
Transgenic animals displayed decreased vertical locomotor activity at 8 weeks of age and subsequent ages, while 
CMVMJD135-treated mice showed an increased activity at 8, 16 and 24 weeks of age (n=10-12 for each group). (B) 
Transgenic animals traveled less in the arena than wild-type animals at 20 and 24 weeks of age; lithium+CCI779 treatment 
increased locomotor activity at 8 and 12 weeks of age (n=10-12 for each group). (C) On the hanging wire test all transgenic 
animals displayed a worse performance in holding the grid with age (from 8 to 24 weeks of age). A maximum time of 2 
minutes was given to each animal and the time that they took to fall was registered (n=10-12 for each group). Symbols 
represent mean ± SEM of the different groups. *, **, *** represent the p< 0.05, 0.01 or 0.001, respectively, for genotype 
factor (two-way ANOVA). Red asterisks represent factor treatment in the analysis (CMVMJD135 mice vs CMVMJD135-treated 
mice). Vertical arrow represents the onset of the phenotype. 
 
CMVMJD135 mice treated with LiCl+CCI-779 also demonstrated a significant increase in the 
locomotor activity when compared to vehicle-treated CMVMJD135 animals at 8 and 12 weeks of age 
(p=0.022 and p=0.016, respectively) (Fig. 3B). Of notice, at the age of 12 weeks we could not observe 
statistically significant differences between wt and CMVMJD135 vehicle-treated groups, meaning that 
the phenotype was not yet installed for these parameters (exploratory behavior and locomotor activity). 
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No effect of the LiCl+CCI-779 treatment was observed in the hanging wire test in CMVMJD135 mice 
(Fig. 3C). The grip strength (hanging wire test) of LiCl+CCI-779-treated wt animals was always worse 
than that of vehicle-treated wt animals. Regarding tremors, we observed a slight improvement in 
CMVMJD135 mice at 24 weeks of age (p=0.038) (Fig. 4A), as seen previously with lithium chloride 
treatment (30). We observed no therapeutic effect of LiCl+CCI-779 treatment on gait quality and limb 
clasping (Fig. 4B, C). The limb clasping reflex increased with disease progression, being statistically 
different only at 24 weeks of age. Importantly, at 16 and 20 weeks of age, the LiCl+CCI-779 treatment 
actually worsened  limb clasping in the transgenic animals when compared to CMVMJD135-vehicle 
animals (Fig. 4C, labeled with #) (p=0.05 and 0.008 respectively).  
 
Foot printing test 
Footprint patterns of wt and CMVMJD135 transgenic mice treated with vehicle or LiCl+CCI-779 
were analyzed for the presence of foot dragging. In agreement with previous observations (30, 36), at 
12 weeks of age this phenotype was established in the CMVMJD135-vehicle animals (p=2x10-5), while 
the wt-vehicle animals never presented foot dragging. LiCl+CCI-779 treatment was not able to improve 
foot dragging, and actually showed a trend to worsen the phenotype, given by the presence of foot 
dragging in the wt-treated animals and a higher percentage of LiCl+CCI-779-treated CMVMJD135 mice 
with this phenotype at 12 weeks of age (90% of CMVMJD135-vehicle animals vs. 100% of CMVMJD135-
treated animals showed foot dragging) (Fig. 4D). At 20 weeks of age all the transgenic animals analyzed 
presented this phenotype (p=2x10-5). 
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Figure 4. Effect of LiCl+CCI779 treatment on limb clasping, tremors and gait quality. (A) CMVMJD135 mice 
presented tremors from 16 weeks of age on. In the last time-point analyzed (24 weeks) LiCl+CCI779 treatment slightly 
improved this phenotype (n=10-12 for each group). (B) CMVMJD135 animals had abnormal gait at 20 and 24 weeks of age 
(qualitative assessment) which was not reverted by LiCl+CCI779 (n=10-12 for each group). (C) Limb clasping was observed 
in CMVMJD135 mice at 24 weeks of age; LiCl+CCI779 treatment anticipated the onset of this symptom, starting in the 
CMVMJD135-treated group at 16 weeks of age. Red # represents a worse phenotype observed in the treated group. (D) 
CMVMJD135 mice drag their feet since 12 weeks of age, which was not improved by LiCl+CCI779 treatment (n=10-12 for 
each group). Symbols represent mean ± SEM of the different groups. *, **, *** represent the p< 0.05; 0.01 or 0.001, 
respectively (Fisher’s exact test).  
 
Beam walk test 
The beam walk test was performed at 20 and 24 weeks of age, when the phenotype of 
CMVMJD135 mice in this motor test is well established (36). In this particular pre-clinical trial, most of 
the transgenic animals treated with LiCl+CCI-779 were unable to perform the task, as shown in Fig. 5. 
At 20 weeks of age in the 11 mm circle beam, only three (in a total of ten animals) were able to cross 
the beam (Fig. 5A); these animals performed well in terms of latency to cross the square beam (12 
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mm), where seven animals concluded the task, but at this time-point we did not observe statistically 
significant differences among wt and CMVMJD135-vehicle animals, and no differences for treated 
animals (Fig. 5B). Later on, at 24 weeks of age, none of the CMVMJD135-treated mice were able to 
perform the beam walk test, either in the square or the round beams. Taking this into consideration, it 
is reasonable to consider that LiCl+CCI-779 treatment had detrimental effects on the transgenic 
animals, reflected in this balance-dependent task. 
 
 
Autophagy induction after LiCl+CCI-779 chronic treatment 
In order to verify autophagy induction after LiCl+CCI-779 combination treatment, we measured 
in the brainstem of transgenic animals the levels of the autophagy markers LC3 (the classical marker of 
the autophagosomes; by analyzing the conversion of LC3I to LC3II (46), Beclin-1 (a protein involved in 
the nucleation step of the autophagosome formation) (47) and p62 (a scavenger protein that signals 
ubiquitylated proteins towards the autophagic machinery that directly interacts with LC3, being itself 
 
Figure 5. Effect of LiCl+CCI779 
treatment on balance and motor 
coordination. Each bar corresponds to the 
mean of two consecutive trials in (A) circle 
and (B) square beams. The time to traverse 
the beam was videotaped and then measured 
by the same experimenter. 10-12 animals 
were used for each condition. CMVMJD135-
treated mice showed severe difficulties in 
performing this task. * represents the p<0.05 
for genotype factor (two-way ANOVA). Black 
arrows highlight the low or null number of 
CMVMJD135-treated mice able to perform 
the task. 
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degraded by autophagy) (48) (Fig. 6A, B and C, respectively). Similarly to what we observed for LiCl 
treatment alone (30), this combined treatment was able to increase the expression of Beclin-1 
(p=0.006), which is associated with autophagy initiation, to increase the LC3II/LC3I ratio, and to 
decrease the protein levels of the autophagy substrate p62 (p=0.02), confirming increased autophagic 
flux. The degree of autophagy induction was, however, not significantly different between LiCl and 
LiCl+CCI-779 treatments when considering Beclin-1 and p62 autophagy markers (Fig. 6). Due to 
technical issues, we were not able to perform the western-blotting analysis for LC3 using the combined 
and single treatment samples in the same blot membrane. Nevertheless, the assessment using the 
LC3-II/LC3I ratio actually suggests the opposite, as we saw an increase of 136% in this ratio, whereas 
in our previous study with LiCl only (30) we had seen a 31% increase. So the results with different 
autophagy markers are not fully concordant regarding the relative extent of activation of autophagy of 
the combined versus single treatment.  
Figure 6. Autophagy induction by the chronic treatment with LiCl+CCI-779. (A) Anti-LC3 western-blot of 
brainstem lysates of transgenic animals injected with vehicle (n=3) or LiCl+CCI-779, at 10.4 and 20 mg/Kg respectively 
(n=3); (B) Anti-Beclin-1 western-blot of brainstem lysates of transgenic animals injected with vehicle (n=3), LiCl at 10.4 
mg/Kg (n=3) or LiCl+CCI-779, at 10.4 and 20 mg/Kg respectively (n=3); (C) Anti-p62 western-blot of brainstem lysates of 
transgenic animals injected with vehicle (n=3), LiCl at 10.4 mg/Kg (n=3) or LiCl+CCI-779 at 10.4 and 20 mg/Kg 
respectively (n=3); beta-actin was used as loading control. At least 3 technical replicates were performed. *, **, represents 
the p< 0.05 or 0.01 respectively (Student t-test). 
 
To test the effect of the combinatory drug treatment on steady-state ataxin-3 levels we 
performed western-blot analysis. The levels of mutant ataxin-3 in the brainstem of CMVMJD135 showed 
to be reduced upon LiCl+CCI779 chronic treatment (Fig. 7) (p=0.04).  
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Figure 7. LiCl+CCI-779 treatment effect on ataxin-3 protein levels. Anti-ataxin-3 western-blot of brainstem lysates 
of transgenic animals injected with vehicle (n=4) or LiCl+CCI-779, at 10.4 and 20 mg/Kg respectively (n=4); beta-actin was 
used as loading control. * represents the p< 0.05 (t-test student). 
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Discussion 
Based on the concept of autophagy induction as a potential therapeutic strategy for 
neurodegenerative diseases, here we have tested the effect of treatment with a combination of lithium 
and CCI-779 in a mouse model of MJD. It has been demonstrated in another mouse model of this 
disease that CCI-779 treatment, at the same dosage as used in this work (20mg/Kg), resulted in an 
improvement of motor coordination (19). However, the mouse model used had a very mild phenotype, 
observable only in the Rotarod and non-significantly different from the controls. The CMVMJD135 
mouse model allowed us to further test this type of therapeutic strategy, due to its more severe 
phenotype and broad range of disease features. Furthermore, the combination of an autophagy-
inducing compound with an mTOR-dependent and another with an mTOR-independent mode of action 
was used to test the therapeutic value of simultaneously modifying these complementary pathways. 
Our first significant observation was that both wt and transgenic animals treated with LiCl+CCI-
779 had a significant decrease in body weight during the treatment period. The body weight loss in both 
groups could be due to an exacerbated activation of autophagy in some tissues by the combination of 
these two drugs (although, unexpectedly, this enhanced induction was not observed with all autophagy 
markers in the brain), and/or it could reflect some systemic toxicity of this drug combination, also 
patent in the death of 30% of the treated animals, even though the doses used in this work for 
autophagy activation had already been tested in mice and shown not to be toxic, when administered 
separately (27, 28, 30). In fact, the lithium chloride dosage used here can be considered low (LiCl 
plasma levels of 0.3±0.09 mmol/L, as estimated previously by us (30)), being below the therapeutic 
range used in humans with bipolar disorder (30, 49).  
Concerning the neurological phenotype, the effects of the combination therapy were generally 
not positive. The first manifestation of the disease in the CMVMJD135 model is loss of limb strength, 
which severely progresses with age (36). Chronic LiCl+CCI-779 treatment did not improve this 
muscular strength deficit, in accordance to other treatments previously performed in same model (30, 
36). Since this phenotype starts early in life and progresses dramatically fast, the treatment regimen 
that we performed (starting one week before the appearance of the loss of muscular strength) may have 
been insufficient in terms of duration to rescue this deficit. Furthermore, the combined treatment herein 
tested appeared to have detrimental effects even in the wt animals, which performed worse in this task 
than vehicle-treated wt mice (although the difference did not reach statistical significance).  
Results concerning other neurological parameters also point to very limited therapeutic effects 
and even some neurotoxicity of the drug combination, namely concerning limb clasping and gait quality, 
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for which the treated transgenic mice presented a more severe phenotype than the vehicle-treated 
CMVMJD135 animals. Furthermore, the combination of LiCl+CCI-779 had a negative impact on the foot 
printing pattern of wt animals, since it was possible to detect dragging of the paws in these animals, 
which did not occur in vehicle-treated wt animals. LiCl+CCI-779-treated CMVMJD135 animals also 
showed severe difficulties in the beam walk test; at 24 weeks of age these animals were not able to 
perform the task in the easier beam (square), while vehicle-treated CMVMJD135 animals at the same 
age were able to cross this beam (albeit taking longer than wt animals, due to motor deficits associated 
with the disease). In addition, when difficulty was enhanced by using the round narrower beam, this 
worsening of the phenotype became detectable at 20 weeks of age. In fact, the neurotoxic effect of the 
LiCl+CCI-779 combination treatment is strongly visible in this behavioral test, not allowing the 
comparative analysis between CMVMJD135 mice (treated vs vehicle).  
Intriguingly, chronic treatment with LiCl+CCI-779 increased the vertical exploratory behavior in 
both wt and CMVMJD135 mice. Similar effects, also occurring in wt and CMVMJD135-treated animals, 
were detected in the spontaneous activity, given by the number of squares travelled in the arena. We 
had previously shown that LiCl treatment resulted in increased exploratory behavior in these mice (30), 
suggesting that the increase observed in the current study may be due to non-specific effects of this 
drug, most likely not disease-related.  
We also observed a slight improvement of the tremors, which is in agreement with our previous 
result using LiCl alone in these mice (30), suggesting that this improvement might be due to that 
component of the treatment regimen. The presence of tremors in human patients is a rare event and 
can be treated with levodopa (5, 50-52), so this improvement may not be very relevant in the disease 
context.  
In summary, these results demonstrate the negative impact of the combination of these two 
autophagy-inducing compounds when administered simultaneously, even in dosages that, upon single 
compound administration, were safe for mice (27, 28, 30). Thus, if any future LiCl+CCI-779 
combination therapy is to be considered for MJD or other polyglutamine disorders, it would be 
necessary to adjust the doses of both compounds to avoid neurotoxicity.   
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TUDCA improves MJD mouse phenotype and neuropathology 
 
Abstract  
Machado-Joseph disease (MJD) is an autosomal dominant neurodegenerative disorder for 
which no effective treatment is currently available. We have generated a new transgenic mouse model 
expressing human ataxin-3 with an expanded CAG tract ubiquitously and at near-endogenous levels. 
CMVMJD135 mice develop a severe and progressive neurologic phenotype, with intranuclear inclusions 
in neurons and brain pathology consistent with the human disease. Tauroursodeoxycholic acid (TUDCA) 
is a bile acid (BA) with neuroprotective action, through its anti-amyloidogenic and chemical chaperone 
activities and its ability to modulate apoptotic pathways. This BA is orally bioavailable, BBB permeable, 
and has a very low toxicity profile. In addition, TUDCA has been approved by FDA for chronic use in 
humans to treat liver disorders. TUDCA has been shown to be beneficial in several models of different 
neurodegenerative diseases. The objective of this work was to test the therapeutic efficacy of TUDCA on 
the motor phenotype and neuropathology of CMVMJD135 mice, and to understand the mechanism of 
action of this compound in the brain. Four groups of animals were used: CMVMJD135 and wt 
littermates (C57Bl6) under normal or supplemented diet with 0.4% of TUDCA; treatment lasted from 5 
to 34 weeks of age. A battery of motor and non-motor behavior tests was applied every two weeks.  
Our results show that food supplementation with TUDCA delayed the onset of disease and 
improved the motor phenotype of CMVMJD135 mice, including balance, motor coordination and gait 
parameters. Furthermore, TUDCA administration ameliorated neurological reflexes, exploratory 
movement deficits and partially rescued muscular strength problems.  
We also observed that TUDCA treatment was not able to reduce the ataxin-3 aggregate load in 
the pontine nuclei and LRT. Nevertheless, TUDCA normalized the mRNA levels of TNF-α, Il1β and Il10 
in the brainstem and reduced the astrogliosis in the substantia nigra and brainstem. Furthermore, 
TUDCA treatment had neuroprotective effects, by restoring the calbindin positive phenotype of Purkinje 
cells in the cerebellum. 
These results demonstrate the therapeutic efficacy of TUDCA supplementation in a mammalian 
model of MJD, and show a strong contribution of the anti-inflammatory properties of TUDCA. For this 
effect TUDCA could have important applications for therapy of neurodegenerative diseases, including 
MJD. 
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Introduction 
Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia type 3 (SCA3), is the 
most common autosomal dominant ataxia worldwide and is caused by ataxin-3 with an expanded 
polyglutamine (polyQ) stretch (1). Clinically, MJD is characterized by gait ataxia, diplopia, dysarthria and 
spastic gait (2), without cognitive decline. In vivo brain imaging and post-mortem analysis show a 
widespread neuropathology in the brain of MJD patients, with atrophy of several brain regions, including 
cerebellum, medulla oblongata, pons, cranial nerves III to XII as well as substantia nigra. Other affected 
areas include the thalamus, basal ganglia and cerebral cortex. The atrophy of these brain regions 
associate both with neuronal and myelin losses and reactive astrogliosis is also a common finding (3, 
4). Nuclear and cytoplasmic protein aggregates are found in affected and unaffected brain regions (3, 5-
7). Interestingly, ataxin-3 (ATXN-3) inclusions were also found in axons, specifically in affected tracts (8). 
Despite the knowledge of clinical and pathologic features of MJD, the mechanisms that lead to disease 
are poorly understood and constitute a topic of investigation towards the identification of new therapy 
targets. Currently, clinicians address the therapy of MJD patients by attempting to improve symptoms 
such as the restless legs syndrome, cramps and fatigue (9). No current therapy exists that slows 
disease progression or prevents disease onset.  
Potential therapeutic targets for MJD and other polyQ disorders can be divided into (i) those 
that are directed at the polyQ proteins themselves, namely gene silencing, attempts to enhance mutant 
protein degradation or inhibition/prevention of aggregation; or (ii) those that intercept the toxic 
downstream effects of the polyQ protein, such as mitochondrial dysfunction and oxidative stress, 
transcriptional abnormalities, UPS impairment, excitotoxicity, or activation of apoptotic pathways. In 
fact, some of these potential targets have already been tested in animal models of the disease and in 
some cases, a beneficial effect was found (10-21). For example, we have shown that treatment with 17-
DMAG, described as an Hsp90 inhibitor able to increase chaperone expression, had positive, but 
transient effects in CMVMJD135 mouse model, and failed to increase chaperone load in the brain but 
rather increased autophagy (15). Yet, the translation of these pre-clinical trials to human patients is still 
very limited, mainly due to safety reasons. Testing FDA-approved compounds in MJD models allows the 
avoidance of these issues and could be a good strategy for faster translation results in patients. 
Considering the multisystemic pathologic and clinical features of this disease, another interesting 
approach would be the use of combinatory treatments of compounds with multiple cellular targets.  
Ursodeoxycholic acid (UDCA) and its taurine conjugate Tauroursodeoxycholic acid (TUDCA) are 
endogenous bile acids known to cross the blood-brain barrier and to exert neuroprotection (22). They 
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are synthesized from cholesterol in the liver and are the major constituents of the bile, being 
responsible for the solubilization of dietary fats and some vitamins (23). In addition to being used in the 
clinic to treat primary biliary cirrhosis, TUDCA was recently tested as a therapeutic agent in 
Amyotrophic Lateral Sclerosis (ALS) patients, showing to be well tolerated and to slow disease 
progression (24). TUDCA acts upon multiple cellular targets and was also shown to reduce toxic 
aggregates and improve disease symptoms in different models of neurodegenerative disorders, 
including Familial Amyloidotic Polyneuropathy (FAP) (25), Alzheimer’s disease (AD) (26-28), Huntington 
disease (HD) (29) and Parkinson’s disease (PD) (30). The cytoprotective effects of TUDCA have been 
attributed to its anti-apoptotic and anti-oxidant properties (25, 29, 30), to prevention of mitochondrial 
toxicity (31) and to anti-inflammatory effects (26, 28, 32).  
In this study, we used the CMVMJD135 mouse model of MJD (15) which presents several 
quantifiable traits reflecting aspects of the human condition at the behavioral and neuropathological 
levels, thus constituting an excellent model for pre-clinical interventions. Chronic treatment with TUDCA 
significantly improved motor dysfunction of the CMVMJD135 mice, and had an anti-inflammatory effect, 
counteracting astrocytic overactivation in the brain of these mice.  
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Methods  
Ethics statement. All procedures were conducted in accordance with European regulations 
(European Union Directive 2010/63/EU). Animal facilities and the people directly involved in animal 
experiments (S.D.S, A.N.C) were certified by the Portuguese regulatory entity — Direcção Geral de 
Alimentação e Veterinária.  
All of the protocols performed were approved by the Animal Ethics Committee of the Life and 
Health Sciences Research Institute, University of Minho. 
Animals 
Female CMVMJD135 (background C57BL/6) mice were used in the study. Transgenic and non-
transgenic drug- and placebo- treated animals were alternately assigned and housed at weaning in 
groups of 5 animals in filter-topped polysulfone cages 267 × 207 × 140 mm (370 cm2 floor area) 
(Tecniplast, Buguggiate, Italy), with corncob bedding (Scobis Due, Mucedola SRL, Settimo Milanese, 
Italy) in a conventional animal facility. The progeny produced by mating MJD transgenic with wild-type 
animals were genotyped at weaning by PCR, as we previously described (33). The experiment started at 
4 weeks and ended at 34 weeks of age. All animals were maintained under standard laboratory 
conditions: an artificial 12 h light/dark cycle (lights on from 8:00 to 20:00 h), with an ambient 
temperature of 21±1°C and a relative humidity of 50–60%; the mice were given a standard diet (4RF25 
during the gestation and postnatal periods, and 4RF21 after weaning, Mucedola SRL, Settimo Milanese, 
Italy) and water ad libitum. Health monitoring was performed according to FELASA guidelines (34), 
confirming the Specified Pathogens status of sentinel animals maintained in the same animal room. 
Humane endpoints for the experiment were defined (20% reduction of the body weight, inability to reach 
food and water, presence of wounds in the body, dehydration), but not needed in practice as the study 
period was conceived to include ages at which animals do not reach these endpoints. The animals were 
sacrificed by different methods according to the final purpose: either by decapitation or exsanguination 
perfusion with saline or PFA 4%; in this case, the animals were deeply anesthetized with a mixture of 
ketamine hydrochloride (150 mg/kg) plus medetomidine (0.3 mg/kg). The timeline of this study is 
shown in Fig. 1A. 
Mouse genotyping.  
The progeny produced by mating hemizygous MJD transgenics with wild-type animals were 
genotyped at weaning by PCR, as previously described (33). The mean CAG repeat size (±SD) for all 
mice used was 139 ± 3. 
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TUDCA treatment  
CMVMJD135 and wt female mice were distributed and housed in groups of 5 animals per cage. 
TUDCA was supplemented in the standard diet at 0.4% (4RF21, Mucedola SRL, purchased at 
Ultragene, Portugal) as previously described (28). At 5 weeks of age the animals were sequentially 
assigned by cage into four groups of 15 animals each: CMVMJD135 and wt under normal diet and 
CMVMJD135 and wt under diet supplemented with TUDCA 0.4%. The treatment had the duration of 29 
weeks, until the animals reached 34 weeks of age. This endpoint was chosen based on the fact that 
CMVMJD135 mice under standard diet were still able to reach the food in the cage and perform most of 
the behavioral tests used in the study; from our knowledge of the model, after this period of time these 
animals may no longer be able to reach the food alone and/or to perform some of the behavioral tests. 
TUDCA treatment was started at 5 weeks of age due to the previous knowledge that the phenotype 
onset in this model starts at 6 weeks of age (35). An extra group of animals (wt, CMVMJD135, 
CMVMJD135-TUDCA, n=5 per group) was generated to study the molecular effects of a less prolonged 
treatment in the brain of these animals.   
Body weight. All mice were weighted from 4 to 34 weeks of age every two weeks.  
 
Behavioral analysis 
Beam walk balance test.  This test assesses balance but is also sensitive to fine motor 
coordination. The test was performed as previously described (36). The animals were trained during 3 
days in the square beam (12 mm). In the fourth day, they were tested in the training beam and also in 
one round beam (17 mm). If the animal fell or turned around in the beam, this was considered one 
failed trial. Each animal had the opportunity to fail 2 times in each beam. The time the animal took to 
cross the beam was counted, and time was discounted if the animal stopped in the beam. 
Motor swimming test. To analyse voluntary locomotion, the mice were trained for 2 
consecutive days (3 trials each animal) to traverse a clear perspex water tank to a safe platform at the 
end. The perspex tank was 100 cm long and the platform at the end was made from black perspex. 
The latency to cross the water tank was measured from a distance of 60 cm (the tank was labeled with 
a blue line to mark the initiation). The water temperature was monitored to 23 ºC using a thermostat 
(36). The mice were tested for 3 consecutive days (2 trials per animal) and the latency to traverse the 
tank registered by the experimenter.  
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Vertical movement assessment (Rears). Each mouse was placed in a viewing jar (15 cm 
diameter) for 5 minutes, and the number of vertical movements (including movements on and off-the 
wall) was registered.  
Spontaneous activity. The mice were transferred to a 15-labeled-squares arena (55×33×18 
cm), and then a series of anatomical and behavioral features were registered. The number of squares 
travelled in the arena for 1 minute was counted. The gait quality was assessed by the same 
experimenter.   
Footprint analysis. The footprint pattern was performed to assess gait as described in (36). 
To obtain footprints, the hind- and forepaws of the mice were coated with black and red non-toxic 
paints, respectively. A clean rectangular paper sheet was placed on the floor of the runway for each run. 
The animals were then allowed to walk along a 100-cm-long×4.2 cm width×10 cm height corridor in the 
direction of an enclosed black box. An inclined corridor was used instead of a horizontal one, since mice 
have the tendency to run upwards to escape. Each animal was allowed to achieve one valid trial per 
age. To evaluate the severity of foot dragging through age the foot printing pattern of CMVMJD135 and 
wt controls was classified at each time point considering six consecutive steps (0=absent/mild, up to 
three steps; 1=mild, more than three steps out of six; 2=severe, all steps out of six). The stride length 
was measured manually as the distance between two pawprints. Three values were measured for three 
consecutive steps. 
Hanging wire grip test. The mice were placed on the top of a metallic grid and inverted 
180º towards the surface of the bench. The latency to fall from the grid was registered by the 
experimenter. The maximum time of the test was 120 seconds.   
 
Western-blot. Brain tissue was homogenized in cold 0.1 M Tris-HCl, pH 7.5, 0.1 M EDTA, 
and a mixture of protease inhibitors (Complete; Roche, Swiss) and was sonicated for 10 seconds. 
Protein concentration was determined using the Bradford assay (Biorad, California, USA). Samples were 
heated for 5 minutes at 100°C, and microfuged for 10 seconds before loading. For each sample, 15 
micrograms of total protein were loaded into SDS-Page gels and then transferred to nitrocellulose 
membranes (Biorad, California, USA). After incubation with the primary antibodies: rabbit anti-ataxin-3 
(1:10.000), rabbit anti-GFAP (1:500, Dako, Denmark), mouse anti-alpha-tubulin (1:200, DSHB, 
University of Iowa, Iowa) and mouse anti-beta-actin (1:100, DSHB, University of Iowa, Iowa); the 
secondary antibodies were incubated at the following dilutions: anti-rabbit (1:10.000, Biorad, California, 
USA) and anti-mouse (1:10.000, Biorad, California, USA). Antibody affinity was detected by 
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chemiluminescence (Clarity Western ECL, Biorad, California, USA). Band quantification was performed 
using the Image Lab software according to the manufacturer’s instructions. 
qRT-PCR. Total RNA was isolated from mouse tissues using TRIZOL (Invitrogen, Calrsbad, CA, 
USA) according to the manufacturer’s protocol. First-strand cDNA, synthesized using oligo-dT (Biorad), 
was amplified by quantitative reverse-transcriptase PCR (qRT-PCR) according to the guidelines (Biorad). 
Human and mouse ataxin-3 primers were used for transgene expression quantification (37). The 
primers used were based on literature (15) or designed using PRIMER-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
 
Neuropathology and immunohistochemistry. Transgenic and wt littermate mice were 
deeply anesthetized and transcardially perfused with PBS followed by 4% paraformaldehyde (PFA) in 
PBS. Brains were post fixed overnight in fixative solution and embedded in paraffin. Slides with 4-µm-
thick paraffin sections were stained with cresyl violet or processed for immunohistochemistry with rabbit 
GFAP (1:500, DAKO Corporation), rabbit anti-ataxin-3 (1:1000) and rabbit anti-calbindin D-28K 
(1:1000, Millipore). 
Ataxin-3 positive inclusions in the pontine nuclei (PN) and Lateral reticular nucleus of the 
medulla (LRt), and calbindin positive cells in the cerebellum of 34 weeks old animals either under 
standard or TUDCA supplemented diets were quantified and normalized for total area using the Fiji 
software (Image J).  
 
Statistical analysis. The experimental unit used in this study was a single animal. Power 
analysis was used to determine the sample size as previously described (35). The estimates of required 
number of animals for specific behavioral tests and time-points of analysis are described in (16). 
Continuous variables with normal distributions (K-S test p>0.05) were analyzed with the Student t-test 
or two-way ANOVA (Factors: genotype and treatment). Behavioral data were subjected to the non-
parametric Mann-Whitney U-test when variables were non-continuous or when a continuous variable did 
not present a normal distribution (Kolmogorov-Smirnov test p<0.05). Categorical variables in the 
SHIRPA protocol were analyzed by contingency tables (Fisher’s exact test). All statistical analyses were 
performed using SPSS 22.0 (SPSS Inc., Chicago, IL). A critical value for significance of p< 0.05 was 
used throughout the study. 
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Results 
At 4 weeks of age, a pre-symptomatic age, all the animals used in this pre-clinical trial were 
tested for motor function and limb strength parameters and no differences were observed between 
groups. At 5 weeks of age, TUDCA supplemented diet was given to wild-type (wt) and CMVMJD135 
animals, while the vehicle groups (wt and CMVMJD135) remained under standard diet. TUDCA chronic 
treatment was kept until the animals reached 34 weeks of age. TUDCA had no impact on body and 
total brain weight of CMVMJD135 treated-mice (Fig. S1 A, B respectively), and had no effect on wt 
animals (Table S1). Importantly, the mean food consumption per cage was not different between 
standard and TUDCA diets (Fig. S1 C). 
 
TUDCA enhances motor function and gait in CMVMJD135 mice 
Chronic treatment with TUDCA for 29 weeks improved motor function and gait quality in 
CMVMJD135 mice. In the beam balance test, the motor deficits started manifesting at 14 weeks of age 
in untreated mice, both in the square and round beams. TUDCA had significant impact on this behavior 
since 24 weeks until 30 weeks of age on the square beam (Fig. 1B). Interestingly, in the narrowest 
beam, where difficulty is higher, CMVMJD135 animals under TUDCA treatment were able to perform 
the task at a later age (26 weeks), while transgenic animals on standard diet were not (Fig. 1C). 
Another way to test motor function is to assess the ability of mice to swim. Remarkably, TUDCA 
treatment had a strong effect on this task, and the motor improvement was observed since the onset of 
this symptom until the end of the trial, with a 76% reduction of the impairment at the age of 34 weeks 
(Fig. 1D). Gait analysis demonstrated a significant improvement of the footdragging phenotype since 12 
weeks of age (at the onset of the symptom), which lasted for 10 weeks. After this period of treatment, 
CMVMJD135 mice under TUDCA diet had the same performance as CMVMJD135 animals under a 
standard diet (Fig 2A). Additionally, qualitative analysis of the gait quality showed a transient beneficial 
effect of TUDCA (Fig. 2B). In contrast, TUDCA had no effect on stride length (data not shown). 
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Figure 1. TUDCA treatment improved the coordination deficits of the CMVMJD135 mice (A) Schematic timeline for the 
behavioral analysis of TUDCA pre-clinical trial. CMVMJD135 mice have a better performance on the beam walk test both in the (B) square 
and in the (C) round beams. In the motor swimming test (D) this improvement is even more pronounced during disease progression until 
the end of the trial at 34 weeks of age. n=15-17 for each group used. Symbols represent mean ± SD of the different groups. *, **, *** 
represent the p< 0.05; 0.01 and 0.001 respectively. Repeated measures ANOVA was used considering genotype and treatment factors.  
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Figure 2. Gait is partially ameliorated by chronic TUDCA treatment. (A) Foot dragging was analyzed since 10 to 30 weeks of 
age. CMVMJD135 drag their feet since 12 weeks of age and TUDCA improved this phenotype since the onset until 22 weeks of age. Upon 
this age this improvement is no longer observed (Mann-Whitney U test). (B) Gait quality was evaluated in an open arena being the onset of 
abnormal gait observed at 18 weeks. TUDCA improved this phenotype parameter until 26 weeks of age (Fisher’s exact test). Symbols 
represent mean ± SD of the different groups. *, **, *** represent the p< 0.05; 0.01 and 0.001 respectively.  
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Muscular strength is slightly improved by TUDCA treatment 
 Loss of limb strength is the first disease symptom observed in the CMVMJD135 mice, and it 
progresses dramatically with age (15). In fact, similarly to what was observed in other pre-clinical trials 
performed in this mouse model (15, 16), TUDCA had no major effect on the hanging wire test (Fig. 3A). 
Interestingly, however, the qualitative parameters of muscular strength, such as the hindlimb tonus and 
the forelimb strength to grab a grid scores were significantly improved by TUDCA after a long period of 
treatment (Fig. 3B, C respectively).  
Figure 3. Muscular strength is slightly improved by TUDCA. (A) The hanging wire test was performed to evaluate limb strength; 
the phenotype onset occured at 6 weeks of age (black arrow). TUDCA had no significant impact on this test (Repeated measures ANOVA 
was used considering genotype and treatment factors). (B) The hindlimb tonus was evaluated and TUDCA treatment started to have a 
detectable positive effect 4 weeks after the onset of this phenotype, at 20 weeks of age, that was maintained until the end of the trial 
(Fisher’s exact test). (C) The animals’ strength to grab a grid evaluates the forelimb strength. CMVMJD135 mice started to shw reduced 
forelimb strength at 12 weeks of age and TUDCA treatment improved this loss of strength since the onset (Fisher’s exact test). n=15-17 
for each group used. Symbols represent mean ± SD of the different groups. *, **, *** represent the p< 0.05; 0.01 and 0.001 respectively. 
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TUDCA ameliorates tremors and abnormal neurological reflexes but not the spontaneous 
activity 
The reduction of vertical movements, analysed by the number of rears on the wall of a cylinder, 
are a late manifesting aspect of the phenotype of the CMVMJD135 mice. Although TUDCA had limited 
effects on this parameter (Fig. 4A), we noticed that TUDCA-treated animals were still able to hold on 
their hindlimb paws during assessment of vertical exploratory activity at 34 weeks of age while 
CMVMJD135 mice under standard diet were unable to rise at this age, being completely immobile on 
the cylinder. Moreover, the horizontal movement analysed by the number of squares travelled in the 
arena for 1 minute showed no improvement by TUDCA (Fig 4B). Regarding other neurologic 
parameters, TUDCA treatment significantly improved the tremors and limb clasping displayed by 
CMVMJD135 mice (Fig. 4C, D respectively) comcumitantly with the appearance of these symptoms in 
the CMVMJD135 mice. 
 
 
 
 
Figure 4. Continues next page. 
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Figure 4. Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. TUDCA had no major impact on exploratory activity but strongly reduced tremors and limb clasping. 
Spontaneous activity measured by the number of vertical movements (REARS) (Mann-Whitney U test) (A) and by the number of squares 
travelled in an open arena for 1 minute (Repeated measures ANOVA) (B) was not improved by TUDCA treatment. The tremors (C) and 
limb clasping (D) observed in the CMVMJD135 mice were significantly improved by chronic treatment (Fisher’s exact test). n=15-17 for 
each group used. Symbols represent mean ± SD of the different groups. *, **, *** represent the p< 0.05; 0.01 and 0.001 respectively. 
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TUDCA treatment increases the Calbindin D28-K staining the Purkinje cell layer of the 
cerebellum of the CMVMJD135 mice 
A decreased calbindin staining in the Purkinje cell layer of the cerebellum was previously 
described by others in transgenic mouse models of MJD (38, 39). We have also found a mild decrease 
in calbindin D28-K staining in the Purkinje cell layer of the cerebellum in the CMVMJD135 mice (40). 
TUDCA treatment increased the Calbindin D28-K staining in the Purkinje cell layer of the cerebellum 
(p=0.005) (Fig. 5A and B). 
 
Figure 5. TUDCA treatment increases the Calbindin D28-K staining the Purkinje cell layer of the cerebellum of the 
CMVMJD135 mice. (A) representative images of Calbindin D28-K staining in wild-type (a-b), CMVMJD135 (c-d) and CMVMJD135-
treated animals (e-f) (n=4 per group, 4 slides per animals were analyzed) and (B) quantitative analysis of Calbindin D28-K staining  * 
represent the p< 0.05. The Calbindin D28-K positive cells were counted using the Fiji software (Image J). Scale bar 200µm. 
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Effects of TUDCA treatment on mutant ataxin-3  
The presence of nuclear aggregates is a pathological hallmark of the disease in patients as well 
as in mouse models is (5, 15, 38, 41). Next, we quantified the number of ATXN3 positive nuclear 
inclusions in the brainstem of CMVMJD135 animals under standard and TUDCA diets. We found no 
effects of the treatment on ATXN3 aggregate load both on the pontine nuclei and lateral reticular 
nucleus (LRt) sub-regions of the brainstem (Fig.6 A, B respectively). 
 
 
 
 
 
 
 
 
 
 
Figure 6. TUDCA treatment did not reduce the aggregate load in the brain of CMVMJD135 mice. Neuronal inclusions were 
counted in the LRt (A) and (B) pontine nuclei of 34-week-old animals under normal diet or TUDCA supplementation (n=3 for each 
condition). Four slides of each animal were used for the analysis (Student’s t test). Values are presented as mean ± SEM; *p<0.05. 
 
Molecular mechanism (s) of TUDCA action on the brain of CMVMJD135 mice 
To dissect the mechanism(s) underlying the positive effects of TUDCA on CMVMJD135 mice 
neurological function, we performed an exploratory study addressing known modes of action of TUDCA 
in cells. This screen was first performed in the brainstem of animals that were subjected to 29 weeks of 
TUDCA treatment (i.e. 34 weeks old). Expression levels of molecules involved in the heat-shock 
response, autophagy, anti-oxidative response, ER stress and other neuroprotection pathways were 
measured and no differences were found between groups (Fig. 7A-E). Interestingly, molecules involved 
in inflammation were significantly influenced by TUDCA treatment. An up-regulation of TNF-a, Il-1b and 
Il10 (pro and anti-inflammatory cytokines) was found in CMVMJD135 mice, and the levels of these 
molecules were normalized by TUDCA treatment (Fig. 7F). No differences were found in other 
inflammation-related molecules such as Il-6, iNOS and lipocalin-2. Intriguingly, a similar analysis was 
performed in mice after a shorter time of TUDCA supplementation (18 weeks) and no statistically 
significant differences in expression were found for any the molecular pathways evaluated (Fig. S2 A-D), 
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neither between wt and CMVMJD135 mice nor between vehicle and TUDCA-treated transgenic mice. 
This suggests that neuroinflammation may be a late component rather than a primary determinant of 
the disease process in CMVMJD135 mice. We also measured the levels of some of the proteostasis-
related genes in the spinal cord of 34 weeks old mice. We found no statistically differences in Hsp60, 
GRP75, BDNF, LC3 and GFAP. Consistently to the previous results, we found increased mRNA levels of 
TNF-α and Il1-β that were circumvented by TUDCA treatment (Fig. 8). Further studies should be 
conducted in younger animals to better understand the role of inflammation in the spinal cord and other 
brain regions besides the brainstem. 
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Figure 7. Effect of TUDCA treatment on mRNA expression of different proteostasis and inflammation-related genes. The 
expression levels of genes related to proteostasis such as (A) molecular chaperones, (B) autophagy, (C) anti-oxidative response, (D) ER 
stress, (E) neuroprotection and (F) inflammation were analyzed in the brainstem of 34 weeks-old wt and CMVMJD135 mice under normal 
and TUDCA diets. n=5-6 per group and two technical replicates were performed. Fold change (∆∆CT method) is represented using B2m 
and HPRT as housekeepings genes (Student’s t test). TUDCA was able to normalize the exacerbated inflammatory response of the 
CMVMJD135 mice. *, **, represent the p< 0.05; 0.01, respectively. 
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Figure 8. Effect of TUDCA treatment on mRNA expression of inflammation-related genes. The expression levels of TNF-α and 
Il1-β were analyzed in the spinal cord of 34 weeks-old wt and CMVMJD135 mice under normal and TUDCA diets. n=5-6 per group and two 
technical replicates were performed. Fold change (∆∆CT method) is represented using B2m and HPRT as housekeeping genes (Student’s 
t test). TUDCA was able to normalize the exacerbated inflammatory response of the CMVMJD135 mice in the spinal cord. *, **, represent 
the p< 0.05; 0.01, respectively. 
 
 
Although, when we evaluated the mRNA levels of GFAP and Iba-1 (astrocytes and microglia 
markers respectively) we found no change in the mRNA expression levels of these markers (Fig. 7F), to 
further explore glial cell activation we measured the protein levels of GFAP in the total brainstem and 
found that GFAP was increased in CMVMJD135 mice and that the levels of this astrocytic marker were 
restored by TUDCA supplementation (Fig. 9A). Consistently, immunohistochemistry analysis of 
astrocytes in the substantia nigra showed a decreased GFAP staining intensity by TUDCA treatment 
(Fig. 9B). GFAP staining intensity was also quantified in the hilus of the hippocampus (unaffected 
region) and white matter of the cerebellum (potentially affected region), but no differences were found 
between groups (Fig. S3 A and B, respectively). 
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Figure 9. TUDCA decreases astrogliosis in the brainstem of the CMVMJD135 mice. TUDCA was able to (A) reduce the total 
protein levels of GFAP (astrocyte marker) in the brainstem of 34 weeks-old CMVMJD135 animals (n=4 per group, at least 3 technical 
replicates were performed) and (B) reduce the GFAP staining in the substantia nigra of the CMVMJD135 mice (n=4 per group, 4 slides 
per animals were analyzed). Representative images of the substantia nigra at 34 weeks of age of: (a-b) wild-type, (c-d) CMVMJD135 and 
(e-f) CMVMJD135 treated mice *, *** represent the p< 0.05 and 0.001 respectively. α-tubulin was used as loading control (Student’s t 
test). The staining intensity was measured using the Fiji software (Image J).  
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Discussion 
The neuroprotective effects of TUDCA, a nontoxic, endogenously produced bile acid, have been 
described in several models of neurodegenerative diseases (25, 27-30, 32) and this compound was 
already shown to have promising effects in ALS patients (24) without major adverse events. These 
findings make TUDCA and eventually other bile acids attractive candidate drugs for neurodegenerative 
diseases that require new and effective therapeutic approaches. Here we used a dosage of 0.4% (which 
corresponds to 100mg/Kg) of TUDCA, supplemented in the food. Based on the body surface area 
normalization method for interspecies drug translation (42), the human equivalent dosage is 8 mg/Kg, 
corresponding to approximately 600 mg/day for a standard body weight of 70 Kg. Considering that the 
recommended dosage of TUDCA in humans (for liver diseases) is 250-750 mg/Kg, the dosage herein 
used would be considered safe and within the therapeutic range. In this study we have shown that 
chronic administration of TUDCA, to the CMVMJD135 transgenic mouse model of MJD significantly 
improved motor function and reduced the glial overactivation, without affecting ataxin-3 aggregation 
load in the brain of the CMVMJD135 mice. In fact, perturbations of the brain inflammatory response are 
a crucial component of neurodegenerative diseases (reviewed in (43)). Microgliosis and astrogliosis are 
present in mouse models of several diseases, such as AD (44), PD (45), ALS (46) and HD (47) and in 
some cases are a triggering event of the disease (48). Likewise, we and others have shown the 
presence of gliosis in mouse models of MJD (15, 38, 49), in accordance to observations in post-
mortem brains of MJD patients, which also showed an increase in pro and anti-inflammatory cytokines 
(50). Here we performed a detailed cytokine profile analysis in early and late-stages of the disease, and 
found a late up-regulation of both anti and pro-inflammatory molecules, as has been observed in HD 
(48, 51) and MJD patients (50). These findings were distinct from those observed for other 
neurodegenerative diseases, where inflammation takes place early in the disease course, since this 
inflammatory profile was only detected at an age when the phenotype of the CMVMJD135 mice was 
completely installed. Yet, the astrocytic marker GFAP was slightly increased (but not statistically 
different) at earlier disease stages, suggesting that the inflammatory process is likely initiated before the 
complete phenotype manifestation. Microglia might have an important role in MJD pathogenesis, a 
hypothesis which is currently being explored by us in CMVMJD135 mice brain. Interestingly, TUDCA 
treatment reverted the inflammatory process to basal levels in the brain of CMVMJD135 mice. The 
effects of TUDCA on glial cells have already been described in AD (26), but its anti-inflammatory 
properties are still poorly described in neurodegeneration. Recently, a study in a model of acute 
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neuroinflammation showed the effects of TUDCA on glial cell activation and migration, as well as on the 
expression of key inflammatory molecules. In that study, acute treatment with TUDCA was able to 
reduce the reactive gliosis as well as the levels of iNOS, by suppressing the NFkB pro- inflammatory 
pathway (32). Accordingly, studies by Joo and colleagues have previously shown that a similar bile acid, 
UDCA, was able to reduce nitrite production induced by β-amyloid deposition and that this effect was 
dependent on NFkB blockage (52). We have shown that chronic TUDCA was able to normalize the 
levels of Il1β, Il10 and TNFα in the brain, and to reduce astrogliosis in the substantia nigra at later 
stages of the disease.  
In conclusion, we have shown the efficacy and safety of chronic TUDCA treatment and 
established that the inflammation modulatory properties of this compound might be beneficial for MJD. 
The fact that this bile acid is a FDA-approved compound and that was already tested in ALS patients 
without adverse events makes us suggest that TUDCA is a good candidate to test in MJD patients.  
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Supplementary figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S1. TUDCA had no effect on body and brain weight of CMVMJD135 mice. (A) The body weight gain loss started at 10 weeks of 
age (black arrow) and (B) a 10% reduction of the total brain weight was observed for the CMVMJD135 mice at 34 weeks of age. TUDCA 
had no impact on both body and brain weight throughout the study. (C) The mean food consumption per day/per mouse was around 3 
grams and no differences were obtained between diets. *** represent the p<0.001. 
 
 
S2. Effect of a shorter TUDCA treatment on mRNA expression of different proteostasis and inflammation-related genes. 
The expression levels of genes related to proteostasis such as (A) molecular chaperones, (B) autophagy, (C) anti-oxidative response and 
(D) inflammation were analyzed in the brainstem of 23 weeks-old wt and CMVMJD135 mice under normal and TUDCA diets. n=5-6 per 
group and two technical replicates were performed. Fold change (∆∆CT method) is represented using B2m and HPRT as housekeepings 
genes (Student’s t test). *, **, represent the p< 0.05; 0.01, respectively. 
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S3. Astrogliosis assessment in the hippocampus and in the cerebellum of the CMVMJD135 mice. No differences between 
groups were observed in the (A) hippocampus and in the (B) cerebellum of 34 weeks of age animals when the GFAP astrocyte marker 
was measured by immunohistochemical procedures. (n=4 per group, 4 slides per animals were analyzed). The staining intensity was 
measured using the Fiji software (Image J).  
 
 
 
Table S1. Summary of comparisons between wt under standard diet and TUDCA supplemented food in the different phenotypic analyses. 
The values correspond to the p value for each time-point analyzed in the different behavioral tests. No differences were found between 
treated and untreated wt animals, except at one single time-point (26 weeks of age) for the number of squares travelled in the arena 
(labeled in yellow), which was 10% higher in treated animals. 
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Abstract 
Machado-Joseph disease (MJD) is an autosomal dominant neurodegenerative disorder caused 
by the expansion of a polyglutamine tract (polyQ) in the C-terminus of the ATXN3 gene product, ataxin-
3. Mitochondrial dysfunction and consequent ATP depletion has been implicated in several 
neurodegenerative diseases. Thus, buffering intracellular energy levels could be neuroprotective. 
Creatine kinase and its substrates (creatine and phosphocreatine) are known as cellular energy buffers. 
Creatine administration increases brain concentrations of phosphocreatine and an inactivation of the 
mitochondrial permeability pore, which exerts protective effects in the brain. In this study we performed 
two pre-clinical trials – PCT1 and PCT2 - using the CMVMJD135 mouse model of MJD (groups of 
animals with a 133 and 139 CAG repeat mean respectively), to which creatine 2% supplemented food 
was provided either for 19 (PCT1) or 29 (PCT2) weeks. Control animals were given the standard diet. 
The treatment started at the age of 5 weeks, one week before the previously observed onset of 
symptoms and a battery of motor and neurological behavioral tests was applied bi-weekly.  
Oral administration of creatine in the diet led to an overall improvement in the motor phenotype 
of CMVMJD135 mice on both trials. Interestingly, in PCT1, with shorter creatine treatment duration but 
with less disease severity, the muscular strength deficits of the CMVMJD135 were improved, while in 
PCT2, corresponding to a longer treatment but a high severity disease condition those improvements 
were not so evident. Creatine-treated animals did, however, show improvement in both trials in motor 
coordination, limb strength and gait quality, as well as in other neurological parameters such as tremors 
and clasping. Creatine chronic treatment delayed the onset of several symptoms and, in some cases, 
completely abolished the appearance of the phenotype until the end of the trial.   
The present findings support creatine supplementation as a useful strategy to slow the 
progression of MJD. 
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Introduction 
Machado-Joseph disease (MJD) is the most common autosomal dominant ataxia worldwide, 
being caused by a mutation leading to the production of the protein ataxin-3 (ATXN3) with an expanded 
polyglutamine (polyQ) stretch (1). The symptoms of MJD are extensively heterogeneous varying from 
ataxia, ophthalmoplegia, diplopia, and dysarthria to peripheral neuropathy, dystonia and/or spasticity 
(2, 3). Apart from its specificities, MJD shares pathogenesis mechanisms with other PolyQ diseases, 
Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease (AD), ultimately 
culminating in neuronal death. 
One such mechanism is impaired energy metabolism associated with mitochondrial 
dysfunction. In polyQ diseases, particularly in Huntington’s disease (HD), mitochondrial and energetic 
deficits are well described. Reduced concentrations of creatine and phosphocreatine have been 
observed in the basal ganglia of HD patients (4); there are also descriptions of a decrease in 
mitochondrial electron transport enzymes, such as cytochrome C oxydase I, in HD postmortem tissue 
(5, 6). Recently, a study using a transgenic mouse model of MJD revealed a decreased mtDNA copy 
number in affected brain regions that was aggravated with age and also the accumulation of mtDNA 
3867bp deletions, particularly in the initial stages of the disease (7). This is agreement with findings in 
MJD patients’ samples and in cells expressing mutant ataxin-3, which also showed decreased mtDNA 
copy number and an accumulation of mtDNA deletions (8). Considering these facts, therapeutic 
strategies that buffer cellular energy levels emerge as a possibility to prevent or improve the 
neurodegenerative process. 
Creatine is a natural substance, exogenously consumed in the diet and endogenously 
synthesized by humans (and rodents) mainly in the kidney, pancreas and liver, using the amino acids 
arginine, glycine and methionine, before entering the bloodstream (9, 10). L-arginine:glycine 
amidinotransferase (transamidinase) catalyzes the production of guanidinoacetate, that in turn is 
methylated by S-adenosyl-methionine (catalyzed by GAMT) to produce creatine (11). Nearly 95% of the 
creatine pool is found in the skeletal muscle and the remaining 5% is found in the brain, liver, testes 
and kidneys (12). Within the cell, this molecule exists both as free creatine and phosphocreatine (PCr). 
In tissues such as brain and muscle, PCr functions as an energy buffer during periods of high energy 
demand (13). The first indication of the importance of creatine in neuronal functioning arose from the 
knowledge that patients with deficiency in creatine biosynthesis (e.g. GAMT deficiency) develop 
extrapyramidal movement disorders, seizures and developmental delay (14, 15). Importantly, in two 
cases, creatine supplementation was able to reverse the neurological impairments (16, 17).   
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Creatine is considered a key component in maintaining cellular energy homeostasis, and its 
administration has been reported in a wide number of experimental models of neurodegenerative 
diseases (18-23). An early study using the MPTP-induced neurodegeneration model of PD showed 
significant neuroprotection when the mouse food was supplemented with creatine 1% (18). After this 
initial work using mice, several clinical trials were performed in PD patients, although with very limited 
results (24, 25). In ALS models, creatine was shown to protect neurons against oxidative damage and 
improve motor impairments (19). Clinical trials in ALS patients, however, also revealed little 
improvements (26, 27). Despite these disappointing results, a long-term creatine supplementation was 
completed in ALS patients (phase II), but without known results so far (ClinicalTrials.gov Identifier: 
NCT00005766). Creatine supplementation showed to be protective to rat hippocampal neurons in the 
presence of Aβ toxic species but no clinical trials were conducted to date using creatine in AD patients. 
Mitochondria dysfunction and bioenergetic deficits are well documented for HD (reviewed in (28-30) 
and creatine exogenous supplementation was shown to improve motor function, to reduce protein 
aggregates and increase survival rate or life-span of transgenic mouse models (20, 21, 31). Creatine 
supplementation to HD patients was shown to be safe and to reduce the levels of 8OH2’dG (DNA 
damage marker) (32). Accordingly, another phase II clinical trial in HD showed that a high dose (uo to 
30 mg per day) of creatine was safe and well tolerated. A phase III clinical trial of creatine usage in HD 
has terminated this year (with 650 subjects enrolled) but the results are not yet known 
(ClinicalTrials.gov Identifier: NCT00712426). Since creatine is an endogenous compound and is 
present in the daily diet, it is not surprising that the side effects caused by creatine supplementation are 
very few, both for healthy persons and patients (33-35).  
All these studies prompted us to test the efficacy of creatine in a transgenic mouse model of 
Machado-Joseph disease – CMVMJD135 - previously described by us (36), and shown to be a valuable 
model to perform pre-clinical trials (36, 37). We carried out a chronic treatment of 19 weeks using 
creatine 2% supplementation in the food of the animals. Creatine supplementation improved and 
delayed the motor symptoms and the overall phenotype of the CMVMJD135 mice. These results 
encouraged us to perform a second preclinical trial using creatine 2% supplementation for 29 weeks in 
a more severe disease condition. In this case, creatine treatment was also able to improve the overall 
phenotype of the CMVMJD135 animals, albeit to a lesser extent on what concerns muscular deficits. 
Nevertheless, both trials showed creatine to be efficacious in improving CMVMJD135 mice phenotype, 
making creatine an appealing compound for MJD treatment. 
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Material and methods 
Ethics statement. All procedures were conducted in accordance with European regulations 
(European Union Directive 2010/63/EU). Animal facilities and the people directly involved in animal 
experiments (S.D.S, A.N.C) were certified by the Portuguese regulatory entity — Direcção Geral de 
Alimentação e Veterinária.  
All of the protocols performed were approved by the Animal Ethics Committee of the Life and 
Health Sciences Research Institute, University of Minho. 
 
Animals. Female CMVMJD135 (background C57BL/6) mice were used in the study. 
Transgenic and non-transgenic drug- and placebo- treated animals were alternately assigned and 
housed at weaning in groups of 5 animals in filter-topped polysulfone cages 267 × 207 × 140 mm (370 
cm2 floor area) (Tecniplast, Buguggiate, Italy), with corncob bedding (Scobis Due, Mucedola SRL, 
Settimo Milanese, Italy) in a conventional animal facility. The progeny produced by mating MJD 
transgenic with wild-type animals was genotyped at weaning by PCR, as previously described (38). All 
animals were maintained under standard laboratory conditions: an artificial 12 h light/dark cycle (lights 
on from 8:00 to 20:00 h), with an ambient temperature of 21±1°C and a relative humidity of 50–60%; 
the mice were given a standard diet (4RF25 during the gestation and postnatal periods, and 4RF21 
after weaning, Mucedola SRL, Settimo Milanese, Italy) and water ad libitum. Health monitoring was 
performed according to FELASA guidelines (39), confirming the Specified Pathogens status of sentinel 
animals maintained in the same animal room. Humane endpoints for experiment were defined (20% 
reduction of the body weight, inability to reach food and water, presence of wounds in the body, 
dehydration), but not needed in practice as the study period was conceived to include ages at which 
animals do not reach these endpoints. The animals were sacrificed by different methods according to 
the final purpose: either by decapitation or exsanguination perfusion with saline or PFA 4%; in this case, 
the animals were deeply anesthetized with a mixture of ketamine hydrochloride (150 mg/kg) plus 
medetomidine (0.3 mg/kg).  
 
Mouse genotyping. The progeny produced by mating hemizygous MJD transgenics with wild-
type animals was genotyped at weaning by PCR, as previously described (38).  
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Creatine treatment  
 
PCT1 – Preclinical Tr ial 1. CMVMJD135 and wt female mice were distributed and housed 
in groups of 5 animals per cage. Creatine was supplemented in the standard diet at 2% (4RF21, 
Mucedola SRL, purchased at Ultragene, Portugal), as previously described to be the more efficacious 
dose in a preclinical trial with HD mice (31). At 5 weeks of age the animals were sequentially assigned 
by cage into four groups of 10-12 animals each: CMVMJD135 and wt under normal diet and 
CMVMJD135 and wt under diet supplemented with creatine 2%. The treatment had the duration of 19 
weeks, until the animals reached 24 weeks of age. Creatine 2% treatment was started at 5 weeks of age 
due to the previous knowledge that the phenotype in this model starts at 6 weeks of age (36). The 
mean CAG repeat size (±SD) for all mice used was 133 ± 1 repeat units. The timeline of experiments 
performed in this trial is represented in Supplementary Fig1A. 
PCT2 – Preclinical Tr ial 2. CMVMJD135 and wt female mice were distributed and housed 
in groups of 5 animals per cage. Creatine was supplemented in the standard diet at 2% (4RF21, 
Mucedola SRL, purchased at Ultragene, Portugal) as previously described to be the more efficacious 
dose (31). At 5 weeks of age the animals were sequentially assigned by cage into four groups of 15 
animals each: CMVMJD135 and wt under normal diet and CMVMJD135 and wt under diet 
supplemented with creatine 2%. The treatment had the duration of 29 weeks, until the animals reached 
34 weeks of age. This was chosen based on the fact that CMVMJD135 mice under standard diet were 
still able to reach the food in the cage and perform most of the behavioral tests used in the study; from 
our knowledge of the model, after this period of time these animals may no longer be able to reach the 
food alone and perform some of the behavioral tests. The mean CAG repeat size (±SD) for all mice used 
was 139 ± 4 repeat units. The timeline of experiments performed in this trial is represented in Fig 2A. 
Body weight. All mice were weighted from 4 weeks of age until the end of each trial (PCT1: 
24 and PCT2: 34 weeks of age) every two weeks.  
 
Phenotypic analysis 
 
Beam walk balance test.  This test assesses balance but is also sensitive to fine motor 
coordination. The test was performed as previously described (40). The animals were trained during 3 
days in the square beam (12 mm). In the fourth day, they were tested in the training beam and also in 
one round beam (17 mm). If the animal fell or turned around in the beam, this was considered one 
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failed trial. Each animal had the opportunity to fail 2 times in each beam. The time the animal took to 
cross the beam was counted, and time was discounted if the animal stopped in the beam. 
Motor swimming test. To analyse voluntary locomotion, the mice were trained for 2 
consecutive days (3 trials each animal) to traverse a clear perspex water tank to a safe platform at the 
end. The perspex tank was 100 cm long and the platform at the end was made from black perspex. 
The latency to cross the water tank was measured from a distance of 60 cm (the tank was labeled with 
a blue line to mark the initiation). The water temperature was monitored and set at 23 ºC using a 
thermostat (40). The mice were tested for 3 consecutive days (2 trials per animal) and the latency to 
traverse the tank registered by the experimenter.  
SHIRPA protocol. We established a protocol for phenotypic assessment based on the primary 
screen of the SHIRPA protocol, which mimics the diagnostic process of general neurological and 
psychiatric examination in humans (41). Each mouse was placed in a viewing jar (15 cm diameter) for 
5 minutes, transferred to a 15-labeled-squares arena (55×33×18 cm), and then a series of anatomical 
and behavioral features were registered. The full details of the SHIRPA protocol are available at the site: 
http://empress.har.mrc.ac.uk/browser/?sop_id=10_002_0. In addition, we included the footprint 
pattern test (see below) to assess gait as described in (40). The protocol was adjusted in order to 
minimize animal handling and to generate uniformity in waiting times between the tests (42). 
Footprint pattern. The footprint test was used to evaluate the gait of the animals. To obtain 
footprints, the hind- and forepaws of the mice were coated with black and red non-toxic paints, 
respectively. A clean rectangular paper sheet was placed on the floor of the runway for each run. The 
animals were then allowed to walk along a 100-cm-long×4.2 cm width×10 cm height corridor in the 
direction of an enclosed black box. An inclined corridor was used instead of a horizontal, since mice 
have the tendency to run upwards to escape. Each animal was allowed to achieve one valid trial per 
age. To evaluate the severity of foot dragging through age the foot printing pattern of CMVMJD135 and 
wt controls was classified at each time point considering six consecutive steps (0=absent/mild, up to 
three steps; 1=mild, more than three steps out of six; 2=severe, all steps out of six). The stride length 
was measured manually as the distance between two pawprints. Three values were measured, for six 
consecutive steps, and the mean of the three values was used. 
Hanging wire grip test. The mice were placed on the top of a metallic grid and inverted 
180º towards the surface of the bench. The latency to fall from the grid was registered by the 
experimenter. The maximum time of the test was 120 seconds.   
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Molecular analysis 
 
Western-blot. Brain tissue was homogenized in cold 0.1 M Tris-HCl, pH 7.5, 0.1 M EDTA, 
and a mixture of protease inhibitors (Complete; Roche, Swiss) and was sonicated for 10 seconds. 
Protein concentration was determined using the Bradford assay (Biorad). Samples were heated for 5 
minutes at 100°C, and microfuged for 10 seconds before loading. For each sample, 15 micrograms of 
total protein were loaded into SDS-Page gels and then transferred to nitrocellulose membranes (Biorad). 
After incubation with the primary antibodies: rabbit anti-ataxin-3 (1:10.000), mouse p62 (1:1000, 
Abnova), rabbit LC3 (1:1000, Novus Biologicals), rabbit anti-GFAP (1:500, Dako), mouse anti-α-tubulin 
(1:200, DSHB) and mouse anti-β-actin (1:200, DSHB), the secondary antibodies were incubated at the 
following dilutions: anti-rabbit (1:10.000, Biorad) and anti-mouse (1:10.000, Biorad) . Antibody affinity 
was detected by chemiluminescence (Clarity Western ECL, Biorad). Band quantification was performed 
using the Image Lab software according to the manufacturer’s instructions. 
qRTPCR. Total RNA was isolated from CMVMJD135 mouse tissues using TRIZOL (Invitrogen, 
Calrsbad, CA, USA) according to the manufacturer’s protocol. First-strand cDNA, synthesized using 
oligo-dT (Biorad), was amplified by quantitative reverse-transcriptase PCR (qRT-PCR) according to the 
guidelines (Biorad). Human and mouse ataxin-3 primers were used for transgene expression 
quantification (43). The primers used were based on literature (36) or designed using PRIMER-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), on the basis of the respective GenBank sequences. 
All accession numbers and primer sequences are available on request. The reference gene for 
hypoxanthine guanine phosphoribosyl transferase (Hprt) (accession number from GenBank: 
NM_013556) was used as an internal standard for the normalization of the expression of selected 
transcripts. qRT-PCR was performed on a CFX 96TM real time system instrument (Bio-Rad 
Laboratories, Hercules, CA, USA), with the SoFast Eva Green RT-PCR reagent kit (Bio-Rad Laboratories, 
Hercules, CA, USA) according to the manufacturer's instructions, using equal amounts of RNA from 
each sample. Product fluorescence was detected at the end of the elongation cycle. All melting curves 
exhibited a single sharp peak at the expected temperature. 
Neuropathology and immunohistochemistry. Transgenic and wt littermate mice were 
deeply anesthetized and transcardially perfused with PBS followed by 4% paraformaldehyde (PFA) in 
PBS. Brains were post fixed overnight in fixative solution and embedded in paraffin. Slides with 4-µm-
thick paraffin sections were stained with cresyl violet or processed for immunohistochemistry with rabbit 
anti-ataxin-3 (1:1000, Millipore), rabbit GFAP (1:500, DAKO Corporation) and rabbit anti-calbindin D-
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28K (1:1000, Millipore). Ataxin-3 positive inclusions in the pontine nuclei of 24 or 34 weeks old animals 
(PCT1 and PCT2, respectively) and calbindin positive cells in the Purkinje cell layer of the cerebellum of 
34 weeks old animals (PCT2) either under standard or creatine supplemented diets were quantified and 
normalized for total area using the Fiji software (Image J).  
 
Statistical analysis. The experimental unit used in this study was a single animal. Power 
analysis was used to determine the sample size as previously described (44). The estimates of required 
number of CMVMJD135 animals for specific behavioral tests and time-points of analysis are described 
in (37). Continuous variables with normal distributions (K-S test p>0.05) were analyzed with the Student 
t-test or two-way ANOVA (Factors: genotype and treatment). Behavioral data were subjected to the non-
parametric Mann-Whitney U-test when variables were non-continuous or when a continuous variable did 
not present a normal distribution (Kolmogorov-Smirnov test p<0.05). Categorical variables in the 
SHIRPA protocol were analyzed by contingency tables (Fisher’s exact test). All statistical analyses were 
performed using SPSS 22.0 (SPSS Inc., Chicago, IL). A critical value for significance of p< 0.05 was 
used throughout the study. 
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Results 
PCT1 
Treatment with creatine for 19 weeks improves body weight and muscular 
strength deficits of the CMVMJD135 mice 
The amount of food intake per mouse was found to be around 3 g per day, with no significant 
difference between treated and untreated mice (Suppl. Fig 1B). Creatine treatment for 19 weeks 
rescued the decreased body weight of CMVMJD135 mice in the last time point of analysis (at 24 weeks 
of age) (Fig 1A). Loss of muscular strength is the first disease symptom observed in these mice 
(Chapter 2), which showed to be very difficult to improve with all the compounds tested in this model so 
far (Chapters 2 to 5). Yet, in this pre-clinical trial creatine 2% avoided the loss of muscular strength 
during disease progression until the end of the trial, at 24 weeks of age (Fig 1B).  
 
Chronic treatment with creatine improved motor and gait deficits of the 
CMVMJD135 mice 
The beam walk test was performed at two time-points (18 and 24 weeks of age). In this test we 
evaluate balance and fine coordination of the animals. In the square beam (Fig 1C), the phenotype is 
generally detectable at 18 weeks of age and progresses during age. Creatine 2% treated mice clearly 
showed an improvement of the coordination deficits. Also, in the circle beam the phenotype was 
observed at 24 weeks of age and creatine 2% treatment significantly improved the phenotype to wild-
type animals’ performance (Fig 1D). Motor coordination was also evaluated in the motor swimming test, 
this phenotype of the CMVMJD135 mice being evident at 22 weeks of age. In accordance with the 
previous results observed in the beam walk test, creatine 2% treatment significantly improved this motor 
deficit in both time points analyzed (Fig 1E). Also, the foot dragging phenotype was improved by 
creatine 2% treatment since 18 to 24 weeks of age (Fig 1F).  
 
Creatine 2% reduces the ataxin-3 positive nuclear aggregates in key-disease brain 
regions 
We quantified the number of ATXN3 positive nuclear inclusions in the brainstem of 
CMVMJD135 animals under standard and creatine diets. Creatine 2% treatment was able to 
significantly decrease the aggregate load in the pontine nuclei and LRt of CMVMJD135 animals (Fig 1G 
and H respectively). 
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Figure 1. Effect of creatine treatment during 19 weeks on CMVMJD135 mice – PCT1 (A) The body weight gain loss of the 
CMVMJD135 mice started at 10 weeks of age (arrow) and Creatine 2% improved body weight gain loss at 24 weeks of age (Repeated 
measures ANOVA) (B) The hanging wire test was performed to evaluate limb strength, and the phenotype onset occurred at 6 weeks of 
age. Creatine 2% improved this phenotype since the onset of the phenotype until the end of this study (Repeated measures ANOVA was 
used considering genotype and treatment factors).  CMVMJD135-treated mice have a better performance on the beam walk test both in 
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the (C) square and in the (D) round beams. In the motor swimming test (E) this improvement is also observed in both time-points tested 
(F) the foot dragging phenotype starts being detectable at 16 weeks of age and progresses as animal’s age; creatine supplementation 
improved this phenotype since 18 weeks of age until the end of this pre-clinical study. n=10 for each group used. Symbols represent 
mean ± SD of the different groups.*, **, *** represent the p< 0.05, 0.01 and 0.001 respectively. The nuclear inclusions positive for 
ATXN3 are reduced in the CMVMJD135 treated with Creatine 2% in the (G) pontine nuclei and (H) in the LRt. n=4 for each group (4 
slides per animal). Symbols represent mean ± SD of the different groups.*, **, represent the p< 0.05 and 0.01 respectively. 
 
PCT2 
Effect of creatine supplementation on body and brain weight of the CMVMJD135 
animals 
All the animals were tested before any treatments were initiated, at 4 weeks of age. The body 
weight (Fig 2C), motor coordination (Fig 4A) and muscular strength (Fig 5A) were not different between 
groups at this age. At 5 weeks of age, creatine 2% supplemented diet started being given to wild-type 
(wt) and CMVMJD135 animals, while the vehicle groups (wt and CMVMJD135) remained under 
standard diet. Creatine chronic treatment was kept until the animals reached 34 weeks of age. The 
amount of food intake per mouse was found to be around 3 g per day, with no significant difference 
between treated and untreated mice (Fig 2B). Creatine treatment had no impact on body weight gain 
(Fig 2C). Interestingly, creatine was able to slightly ameliorate the loss in total brain weight of the 
transgenic animals at 34 weeks of age (Fig 2D). 
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Figure 2. Creatine treatment effects on body and brain weight of CMVMJD135 mice (A) Schematic timeline for the 
behavioral analysis of creatine 2% pre-clinical trial (B) The mean food consumption per day/per mouse was around 3 grams and no 
differences were obtained between diets (Student’s t test). (C) The body weight gain loss started at 10 weeks of age and creatine 2% had 
no impact (Repeated measures ANOVA)(D) A 10% reduction of the total brain weight was observed for the CMVMJD135 mice at 34 weeks 
of age. In creatine-treated animals the brain weight loss was only 6% (Student’s t test). *, *** represent the p<0.05 and 0.001 respectively. 
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Creatine supplementation treatment delayed onset and improved symptoms 
related to muscular strength 
The CMVMJD135 mice treated with creatine showed improved forelimb strength and hindlimb 
muscular tonus (Fig 3A and B, respectively) until the end of the pre-clinical trial, at 34 weeks of age. 
Furthermore, the onset of these deficits was delayed by 8 weeks (labeled with green #). Yet, the overall 
muscular strength measured by the hanging wire test showed only a transient amelioration of the 
phenotype at 12 weeks of age, which was no longer observed as disease progressed (Fig 3C). The 
muscular strength deficits seem to correlate directly with the CAG repeat length, since in the PCT1 that 
we performed, this symptom was significantly ameliorated for a longer period of time, and the effect of 
creatine was sustained until the end of the trial (Fig 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 continues next page. 
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Figure 3 (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Muscular strength deficits improved by creatine. (A) The animal’s strength to grab a grid evaluates the forelimb 
strength. CMVMJD135 mice started to lose forelimb strength at 12 weeks of age and creatine 2% treatment delayed disease onset by 8 
weeks and improved this loss of strength until the end of the study (Fisher’s exact test). (B) The hindlimb tonus was evaluated and 
creatine 2% treatment delayed the onset of the phenotype 4 weeks; this improvement was maintained until the end of the trial (Fisher’s 
exact test) (C) The hanging wire test was performed to evaluate limb strength and the phenotype onset occurs at 6 weeks of age. Creatine 
2% started at 5 weeks had no major impact on this test, except for very transient improvements (Repeated measures ANOVA was used 
considering genotype and treatment factors). n=15-17 for each group used. Symbols represent mean ± SD of the different groups. **, *** 
represent the p< 0.01 and 0.001 respectively. 
 
Motor coordination was ameliorated by creatine supplementation 
To assess motor coordination the beam walk and the motor swimming tests were performed. 
The onset of the phenotype was observed at 14 and 10 weeks of age, respectively, in this group of 
CMVMJD135 mice. In the training square beam (12mm), it was possible to observe an improvement by 
creatine 2% after a long period of treatment, at 26 and 30 weeks of age (Fig 4A). Nevertheless, creatine-
treated animals seemed to be improving in this test as animals’ age. We were not able to pursue this 
test to prove this amelioration given that the untreated CMVMJD135 mice were no longer able to 
traverse the beam. When difficulty was added by using a smaller and round beam (11mm), 
CMVMJD135 mice under a standard diet were only able to perform the task until 20 weeks of age (Fig 
4B). In agreement with the previous result, creatine-treated animals showed an improved phenotype 
late in life, at 20 weeks of age (Fig 4B). Regarding the motor swimming test, the phenotype onset was 
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observed at 10 weeks of age (Fig 4C). Creatine treatment improved the coordination deficits since the 
onset of the phenotype until the end of this pre-clinical trial (34 weeks of age), this improvement being 
highly significant. Not unexpectedly, wt animals under Creatine 2% diet also performed better at some 
time-points (14, 16, 18, 20 and 34 weeks of age) when compared with wt animals under standard diet 
(Fig 4C, green *). The same result was obtained in the PCT1 for the time-points analyzed (22 and 24 
weeks of age) (Fig 1E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Creatine treatment improved motor uncoordination observed in the CMVMJD135 animals. CMVMJD135-treated 
mice show a better performance on the beam walk test both in the (A) square and in the (B) round beams. In the motor swimming test 
(C) this improvement is even more pronounced during disease progression until the end of the trial at 34 weeks of age. Wild-type mice 
under creatine 2% diet also improved their performance in this test when comparing to wild-type mice under standard diet (green 
asterisks). n=15-17 for each group used. Symbols represent mean ± SD of the different groups. *, **, *** represent the p< 0.05; 0.01 and 
0.001 respectively. Repeated measures ANOVA was used considering genotype and treatment factors.  
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Creatine chronic treatment improved the quality of movement of the CMVMJD135 
mice 
Gait quality was qualitatively assessed by observing the animals freely moving in an open arena. 
The quality of the movement of this group of CMVMJD135 animals became abnormal at 18 weeks of 
age. Creatine treatment was able to improve and delay this symptom until 34 weeks of age (Fig 5A). 
Unexpectedly, other parameters used to measure the gait quality of the animals, such as foot dragging 
and stride length, were not improved by creatine treatment (Fig 5B and C respectively) in this group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 continues next page. 
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Figure 5 (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Creatine food supplementation had mild effects on gait quality. (A) Gait quality was evaluated in an open arena being 
the onset of abnormal gait observed at 18 weeks. Creatine 2% improved this phenotype parameter until 34 weeks of age (Fisher’s exact 
test). (B) Foot dragging was analyzed since 10 to 30 weeks of age. CMVMJD135 drag their feet since 12 weeks of age and creatine 2% 
had no major impact on this parameter (Mann-Whitney U test). (C) The stride length was measured and creatine 2% showed no impact on 
the decreased step length observed in the CMVMJD135 animals (Repeated measures ANOVA was used considering genotype and 
treatment factors.). n=15-17 for each group used. Symbols represent mean ± SD of the different groups. *, **, *** represent the p< 0.05; 
0.01 and 0.001 respectively. 
 
222 
 
Creatine supplementation improves MJD mouse model phenotype 
Creatine had mild effects on spontaneous exploratory activity but significant 
impact on tremors and limb clasping 
Spontaneous exploratory activity was measured by counting the number of squares that 
animals travelled in an arena when there were freely moving. Also, the number of vertical movements 
(rears) was counted while animals explored a cylinder viewing jar. This group of CMVMJD135 mice 
travelled significantly less in the arena at 18 weeks of age (Fig 6A) and later. Creatine improved this 
phenotype very limitedly and only after a long period of treatment, by the age of 34 weeks. In the case 
of vertical movements, this group of CMVMJD135 mice started to explore significantly less at the age of 
22 weeks, and after 29 weeks of creatine 2% treatment transgenic mice performed better and the 
phenotype is no longer observed (green # at 34 weeks of age) (Fig 6B). Of notice, at the last time-point 
of analysis (34 weeks of age) untreated CMVMJD135 mice did not perform any vertical movement 
during the 5 minutes of the test, whereas treated animals showed some (albeit low) exploratory 
behavior.  
Limb clasping is another phenotypic characteristic of the CMVMJD135 mouse model, with 
onset at 18 weeks of age in this group. Remarkably, creatine treatment delayed the appearance of this 
symptom by 8 weeks and was able to improve it until the end of the pre-clinical trial (Fig 6C). The effect 
of creatine treatment was even more pronounced concerning tremors. Creatine completely abolished 
the onset of this symptom, treated CMVMJD135 animals being comparable to wt mice (Fig 6D).  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 continues next page 
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Figure 6 (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Creatine slightly improves exploratory activity very limitedly and late in life but strongly impacts on tremors 
and abnormal neurological reflexes. Spontaneous activity was measured by the number of (A) squares travelled in an open arena 
for 1 minute (Repeated measures ANOVA) and (B) by the number of vertical movements (rears) (Mann-Whitney U test); these parameters 
were improved by creatine 2% after a long period of treatment. The limb clasping (C) and tremors (D) observed in the CMVMJD135 mice 
were significantly improved by chronic treatment; the phenotype onset was delayed by 8 weeks on the limb clasping and completely 
abolished in the tremors (Fisher’s exact test),  n=15-17 for each group used. Symbols represent mean ± SD of the different groups. *, **, 
*** represent the p< 0.05; 0.01 and 0.001 respectively. 
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Effect of creatine supplementation on mutant ataxin-3 aggregation 
We quantified the number of ATXN3 positive nuclear inclusions in the brainstem of 
CMVMJD135 animals under standard and creatine diets. As seen in PCT1, creatine 2% treatment was 
able to significantly decrease the aggregate load in the pontine nuclei of CMVMJD135 animals (Fig 7A). 
Additionally, we found no differences in the levels of mutant ataxin-3 mRNA or total protein levels upon 
treatment (Fig 7B and C, respectively). Creatine does not seem to be inducing the degradation of 
mutant ATXN3, namely through autophagy, since LC3 and p62 (autophagy markers) were not altered 
upon treatment (Fig 7D and E, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Ataxin-3 positive nuclear inclusions in CMVMJD135 mice brainstem are reduced upon creatine treatment. (A) 
Neuronal inclusions were counted in the pontine nuclei of 34-week-old animals under normal diet or TUDCA supplementation (n=3 for 
each condition). Four slides of each animal were used for the analysis (student’s t test) (B) qRT-PCR analysis of human ATXN3 mRNA 
expression levels (n=5 and two technical replicates were performed) showed no differences by creatine 2% treatment. Fold change (∆∆CT 
method) is represented using B2m as housekeeping gene (student’s t test) (C) Anti-ataxin-3 western-blot of 34-week-old CMVMJD135 
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mice (n=4 for each condition; at least 3 technical replicates were performed) in the whole brainstem showed that creatine 2% had no 
effect on the protein levels of total mutant ataxin-3 (hATXN3). Endogenous ataxin-3 protein (mATXN3) was used as loading control 
(student’s t test). hATXN3 has a molecular weight of approximately 90 kDa and mATXN3 42 kDa. (D) Anti-LC3 western-blot of 34-week-old 
CMVMJD135 mice (n=4 for each condition; at least 3 technical replicates were performed) in the whole brainstem. LC3II was normalized 
to LC3I. (E) Anti-p62 western-blot of 34-week-old CMVMJD135 mice (n=4 for each condition; at least 3 technical replicates were 
performed) in the whole brainstem. p62 was normalized to β-actin. Values are presented as mean ± SEM; *p<0.05. 
 
 
Creatine treatment increases the Calbindin D28-K staining the Purkinje cell layer 
of the cerebellum and decreases astroglisosis in the brainstem of the CMVMJD135 mice 
Previously we have shown a mild decrease in calbindin D28-K staining in the Purkinje cell layer of the 
cerebellum in the CMVMJD135 mice (45) and (Chapter 5). In this study we found that creatine 
treatment increased the calbindin D28-K staining in the Purkinje cell layer of the cerebellum (p=0.009) 
(Fig. 8A and B) at 34 weeks of age (PCT2), suggesting preservation of these neurons, as shown 
previously for a SCA1 mouse model (46). Also, we have previously shown that astrogliosis occurs in the 
brain of CMVMJD135 mice (45) (Chapters 2 and 5) which was normalized by creatine chronic 
treatment in the brainstem of the CMVMJD135 mice (Fig 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Creatine treatment increases the calbindin D28-K staining the Purkinje cell layer of the cerebellum of the 
CMVMJD135 mice. (A) representative images of calbindin D28-K staining in wild-type (a-b), CMVMJD135 (c-d) and CMVMJD135-
226 
 
Creatine supplementation improves MJD mouse model phenotype 
treated animals (e-f) (n=4 per group, 4 slides per animals were analyzed) and (B) quantitative analysis of calbindin D28-K staining. 
**p<0.01. The calbindin D28-K positive cells were counted using the Fiji software (Image J). Scale bar 200µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Creatine decreases astrogliosis in the brainstem of the CMVMJD135 mice. Creatine was able to reduce the GFAP 
staining in the substantia nigra of the CMVMJD135 mice (n=4 per group, 4 slides per animals were analyzed). (A) Representative images 
of GFAP immunohistochemistry analysis in the substantia nigra at 34 weeks of age of: (a-b) wild-type, (c-d) CMVMJD135 and (e-f) 
CMVMJD135 treated mice. (B) The GFAP staining intensity was measured using the Fiji software (Image J). (C) qRT-PCR analysis of Gfap 
mRNA expression levels (n=5 and two technical replicates were performed) showed to be reduced by creatine 2% treatment in the 
brainstem of CMVMJD135 animals. Fold change (∆∆CT method) is represented using B2m as housekeeping gene (Student’s t test). (D) 
Anti-GFAP western-blot of 34-week-old CMVMJD135 mice (n=4 for each condition; at least 3 technical replicates were performed) in the 
whole brainstem showed that creatine 2% normalized the GFAP protein levels. α-tubulin was used as loading control (Student’s t test). 
Values are presented as mean ± SEM; *p<0.05. 
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Discussion 
Bioenergetic dysfunction and mitochondrial deficits contribute to the pathogenesis of several 
neurodegenerative diseases either directly and/or indirectly (47-49). Considering this, treatments aimed 
at improving this cellular energy deficits or improving mitochondrial function may prove to be useful in 
MJD patients. The neuroprotective role of Creatine in other neuromuscular and neurodegenerative 
diseases is well documented (18, 19, 23, 46, 50-55).  
Here we have shown that creatine 2% food supplementation (500 mg/Kg) during a shorter (19 
weeks) or longer period of time (29 weeks) was safe, well tolerated and had a significant impact on 
CMVMJD135 behavior. The dosage herein used was previously describe to be the most effective in 
mice (31), corresponding to a consumption of 3 g per day in humans, which is below the dosages 
tested so far in human neurodegenerative diseases (27, 32). Creatine treatment was able to delay 
symptom onset as assessed by several behavior parameters such as muscular strength, gait, limb 
clasping and tremors, the latter symptom being completely abolished. Furthermore, in the first 
preclinical trial, in which the mean CAG repeat length was lower (133 ± 1 vs 139 ± 4, p=0.007) and 
disease severity less, other phenotypic aspects of the CMVMJD135 mice were also ameliorated, such 
as gait and body weight.  
Creatine supplementation effects on muscle strength and growth are largely documented in a 
larger number of sports (56, 57). Muscular strength loss is the first disease sign in the CMVMJD135 
animals (by 6 weeks of age), and it progresses very fast and severely. In the first preclinical trial 
performed, creatine supplementation had a significant impact on muscular strength deficits, the 
treated-CMVMJD135 mice always being better when compared to untreated animals. Yet, creatine 
treatment in the PCT2 showed a very limited effect on this test, seen only at 12 weeks of age. Previous 
pre-clinical trials performed in the CMVMJD135 model, such as 17-DMAG (36) or lithium chloride (37), 
showed no effect at all on this test, which is very difficult to revert due to the early onset and severity of 
the phenotype. An earlier treatment would probably be needed to rescue this aspect of the phenotype. 
Nevertheless, creatine treatment in this study showed a strong impact on other muscular strength 
parameters, such as hindlimb tonus and forelimb strength even in PCT2. The motor performance of 
CMVMJD135 animals was significantly improved by creatine treatment in both the beam walk and 
motor swimming tests. Accordingly, in HD mouse models the motor performance on the rotarod was 
ameliorated by creatine 2% treatment (21, 31). Nevertheless, studies showed no effect of Creatine 2% 
on motor performance in SCA1 and ALS mouse models (46, 58). Not unexpectedly, our results showed 
that creatine 2% supplementation also had an impact on the motor performance of wt mice, namely in 
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the motor swimming test, showing that the effects of creatine are not limited to the disease state. 
Creatine supplementation was shown to have beneficial effects on healthy people (59), and in 
conjugation with exercise was shown to improve muscle performance in elderly men and women (60, 
61). Accordingly, 1% creatine supplementation increased the lifespan of aged wild-type C57Bl/6J mice 
and improved the performance in several neurobehavioral tests. This suggests that creatine has a 
positive impact on health and longevity of wt mice and may justify our results (62).  
Furthermore, creatine-fed CMVMJD135 mice showed a mild improvement on gait quality. Yet, it 
was not possible to observe an improvement in the length of the mouse stride length, a parameter 
which is consistently diminished in CMVMJD135 mice after a certain age. The lack of efficacy of 
creatine treatment on gait was also shown in a SCA1 mouse model, where creatine-fed mice did not 
show improve gait width despite the preservation of Purkinje cells in the cerebellum (46). Nevertheless, 
in the case of our study the CAG repeat tract length seems to impact the likelihood of improvement of 
gait abnormalities, since in the first preclinical that we have performed, the foot dragging phenotype of 
the CMVMJD135 animals was significantly improved throughout the trial, while in PCT2 a very limited 
improvement was only observed at 14 weeks of age. Consistently, the appearance of this symptom in 
the PCT1 was observed at 16 weeks of age, while in PCT2 it appeared earlier (12 weeks of age), which 
may explain our results.  
Interestingly, in both trials creatine-treated animals did show a significant improvement in limb 
clasping, an abnormal reflex that is observed in several brain and spinal cord pathologies, when lesions 
are present in the cerebellum, basal ganglia and neocortex (63) and which appears later that strength 
and gait alterations in CMVMJD135 mice.  
Although tremors are a rare event in MJD (64), they are quite evident in the CMVMJD135 mice; 
interestingly, they were completely abolished by creatine 2% treatment, as this symptom remains 
absent in treated animals until the end of this pre-clinical trial.  
In accordance to previous reports in an HD mouse model (21, 31), creatine 2% treatment 
showed to have a protective effect on gross brain atrophy, given by the total brain weight measured in 
the endpoint of this pre-clinical trial at 34 weeks of age. CMVMJD135 animals under standard diet at 
this time-point showed 10% reduction on brain weight, while creatine-treated mice showed 6% of 
reduction when compared to wt mice at the same age. Nevertheless, a more detailed stereological 
analysis of the brain addressing neuronal loss in specific brain and spinal cord regions needs to be 
performed to complement this result.  
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Creatine 2% treatment has previously been shown to be able to reduce both striatal and 
pancreatic huntingtin-positive nuclear aggregates (31). Accordingly, we found a reduction on aggregate 
load in the pontine nuclei of creatine-fed mice at 34 (PCRT2) and at 24 weeks of age (PCRT1), although 
no differences were found on total mutant ataxin-3 protein and mRNA levels. Recently, it was 
demonstrated that β-GPA, a creatine analogue, was able to extend the lifespan of Drosophila 
melanogaster and to increase Atg8 levels suggesting that this lifespan extension might take place via 
the activation of AMPK-Atg1-autophagy signaling pathway (65). It is possible that, similar to its 
analogue, creatine might be able to induce autophagy and therefore reduce the levels of ataxin-3-
positive aggregates, a hypothesis that requires further testing. Although the mechanism by which 
creatine decreases the aggregate load was not addressed in the present study and is also not described 
in other studies (20, 31), our results suggest that it does not act by increasing mutant ATXN3 
degradation, namely through autophagy (data not shown). Alternatively, the energy-dependent protein 
folding/refolding systems challenged by mutant ATXN3 may become more effective in the presence of 
creatine supplementation, thus leading to increased solubility of the mutant protein.  
An interesting study by Yang and collaborators demonstrated the neuroprotective effects of 
creatine 2% and Coenzyme 10 (CoQ10) 1% in animals models of PD and HD, and showed the additive 
effects of both compounds when administered together (66). It would be interesting to test the 
combination of creatine 2%/CoQ10 1% in CMVMJD135 animals, as this combination might potentiate 
the effects observed for creatine alone and could eventually further improve the motor benefits that 
were so evident in this pre-clinical trial.  
In summary, the present findings support creatine treatment as a novel therapeutic strategy to 
delay disease progression and improve symptoms in MJD. 
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Supplementary figure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. Fig 1. (A) Schematic timeline for the behavioral analysis of creatine 2% pre-clinical trial (B) The mean food consumption per 
day/per mouse was around 3 grams and no differences were obtained between diets (Student’s t test). 
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7. General Discussion and Future Perspectives 
7.1 MJD mouse models for pre-clinical trials: the CMVMJD135 mouse line 
Machado-Joseph disease is a severe and clinically heterogeneous disease for which there is no 
effective therapy.  
Mouse models of human diseases are created both to understand the pathogenesis of the 
disorders and to find successful therapies for them. The MJD mouse models generated so far are of 
extreme importance because they allow an increase in the knowledge of MJD pathogenesis and 
potential therapeutic targets. Ideally, mouse models should recapitulate the human phenotype and 
neuropathology to a full extent. However, this rarely occurs and scientists try their best to generate the 
closest model to the human condition. Almost all MJD transgenic models follow the construct validity 
criterium to validate an animal model as they are based on expression of a mutant version of the 
ATXN3 gene bearing an expanded polyQ tract (1). Yet, not all recapitulate the face validity criterium. 
Face validity comprises the disease phenotype, including physical symptoms, neuropathologic and 
neurochemical aspects, and also accounts for the temporal progression of the disease. The 
CMVMJD135 mouse model (Chapter 2, 3, 4, 5, and 6) used in this thesis work mimics the human 
disorder quite closely at the phenotypic level (Table 1). The disease symptoms of this model appear 
gradually in life and progress as the mice age. Motor and gait deficits, loss of muscular strength and 
other neurological symptoms such as abnormal reflexes and tremors are present (Fig 1).  
This model also present intranuclear inclusions, as well as neuropathologic affection in key 
disease regions resembling the human disease such as (i) cellular loss in the pontine and dentate 
nuclei, in substantia nigra and spinal cord (ii) a reduction of calbindin positive Purkinje cells (Chapter 5) 
as well as a reduced thickness of the molecular layer of the cerebellum, (iii) reduced cholinergic 
neurons in the facial nuclei and spinal cord, (iv) a reduction of TH positive neurons and astrogliosis in 
the substantia nigra (Chapter 2, 5 and 6), (v) gross brain atrophy (late in life) and (vi) and alterations in 
the brain cytokine profile (Chapter 5), as was described for MJD patients (2-5) (Fig 1). Although the 
onset of the symptoms occurs very early in this model (at 6 weeks of age), the disease progresses 
slowly over time and the animals do not die prematurely, living as long as the wild type mice under the 
standard conditions of care in our animal facility (including making food and water available to animals 
that are unable to reach them).  
 
 
 
241 
 
General Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Summary of the progression of behavioral and pathological findings in the CMVMJD135 mice. Ages at onset of symptoms are 
an estimate from the earlier studies of this model, described in Chapters 2-6. The dashed lines indicate unknown age of onset of the 
pathologic findings, as further mapping of the appearance of pathological features is ongoing. Ages presented are an estimate from the 
studies of this model in chapters 2-6 and (6). 
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Body weight loss
Loss of limb tonus
Dysfagy
Gait ataxia
Decreased exploratory activity
Tremors
Human MJD patients
Symptoms
Muscular strength deficits Muscle atrophy
Balance and motor problems
Diplopia
Restless legs syndrome
Bradykinesia
Hyporeflexia
Hyperreflexia
Bulging eyes
CMVMJD135 mouse model Human MJD patients
Pathologic aspects
Face validity
Dysarthria
Weight loss
Dystonia
Motor uncoordination
Intention and resting tremor
Cramps
Peripheral neuropathy
Gait abnormalities
Ophthalmoplegia
Spasticity
CMVMJD135 mouse model
Muscle atrophy
Ataxin-3 inclusions in the CNS
Loss of brain weight
Altered cytokine profile
Loss of Chat+ neurons in the 7N
Loss of Calbindin+ neurons in the Cerebellum
Loss of brain weight
Muscle atrophy
Ataxin-3 inclusions in the CNS
Atrophic hypercromatic neurons in the PN
Astrogliosis in the SN
Loss of TH+ neurons in the SN
Atrophy in total brainstem, including midbrain, pons and 
medulla, total cerebellum, cerebellar hemispheres and 
cerebellar vermis, putamen and caudate nucleus
Neuronal loss and gliosis in the SN, PN and VN, as well 
as in cranial nerves, Clarke’s columns and anterior 
horns of the spinal cord
Decresead thickness of the molecular layer of the 
Cerebellum
Microgliosis in the PN
Altered cytokine profile
Table 1. Phenotypic and pathologic aspects of the CMVMJD135 mouse model and MJD patients. List of symptoms and pathologic aspects of MJD found in the CMVMJD135 mice and human 
patients. CNS – central nervous system; PN – pontine nuclei; SN – substantia nigra; 7N – facial nuclei; TH – tyrosin hydroxilase; VN – vestibular nuclei. 
 
 
243 
 
General discussion 
During disease progression, MJD patients have concomitant complications such as respiratory 
infections or bronchopneunomia, mostly due to the bed ridden status and/or dysphagia problems, that 
ultimately constitutes one of the most frequent causes of death in MJD (7, 8). In mice respiratory 
problems were not observed, most likely due to the horizontal and downward aspect of mice’s upper 
respiratory and gastrointestinal tract, which becomes less favorable to the occurrence of aspirations 
pneumonia or other respiratory pathology. Together, all the phenotypic and neuropathologic readouts, 
makes the CMVMJD135 an excellent model to perform pre-clinical trials and to study the mechanism(s) 
underlying MJD pathogenesis, which are comprised in the two main goals of animal models 
development according to Chadman and collaborators: (i) testing hypotheses about the mechanisms 
underlying the disease, and (ii) translational evaluation of pharmacological, behavioral, and other 
treatments for the disease (1). Regarding the last criterium for validating animal models, Predictive 
validity exists when the response of the model to known treatments is similar to that in the human 
disease; i.e., if a treatment is known to be effective in humans it should also be in the animal models 
for that specific disease. In the particular case of MJD, no standard treatment exists for comparison. 
Importantly, no pre-clinical trials were used to test the potential efficacy of the few specific drugs that 
have been taken to the actual clinical trials performed so far in humans (Chapter 1, table 6). Some 
studies performed in animal models have shown some promising results, as is the case for autophagy 
inducers or HDCA inhibitors (9, 10), among others. Yet, none of these approaches have been tested in 
MJD patients to date. Nevertheless, we have performed one pre-clinical trial using lithium chloride 
(Chapter 3) that showed to have no overall impact in the CMVMJD135 phenotype, a result that was in 
accordance with the clinical trial performed simultaneously in MJD patients (11) that also showed no 
efficacy concerning its defined primary outcome. 
7.2 Are we performing good pre-clinical trials? Problems and recommendations 
The spreading of knowledge in Science is of extreme importance since it drives scientific 
progress. A major problem regarding pre-clinical trials, and knowing that new discoveries hinge on 
previous observations, consists on the lack of or insufficient reporting of the study design, experiment 
conduction and analysis. This issues leads to the inability to replicate the majority of findings between 
different labs or even by the original authors of the work (12, 13), the estimates for irreproducible 
studies being 70-90% (13). Reproducibility does not mean that the studies should be replicated in 
perfect detail, but should corroborate the major findings of the original study. A major issue contributing 
to irreproducibility is that the majority of experiments are performed in a non-blinded fashion, driving to 
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observer bias (14, 15). Rigorous methodologies (blinding, repeating experiments, use of validated 
reagents, use of the correct controls) should be performed since the initial step of the experiment, and 
pilot studies should be performed as rigorously as the study itself, since this will avoid unnecessary 
costs for the investigators and also for pharmaceutical companies that might be interested in testing the 
investigators findings (16). In order to improve animal studies and consequently the translation with 
success to the clinics, researchers have argued for a focus on hypothesis-based research, a rigorous 
study plan, training and more adequate statistics (17, 18). Also, pharmacokinetic studies are of extreme 
importance before any evaluation of potential effect (19). Besides the most common recommendations, 
including blinding, randomization and power analysis, other issues should be taken in consideration 
such the correct use of controls, dose-response determination, replication in different models and 
independent replication. Considering this, the US National Institute of Neurological Disorders and Stroke 
(NINDS) developed several recommendations for improving the reporting and design of the pre-clinical 
trials. In this meeting, the committee board found several issues regarding transparency of reporting: 
(1) poor experimental design, (2) lack of information on research parameters when reporting the results 
using animal model and suggested that a effort should be done by the funding agencies and journal 
editorial boards to allow and demand more detailed methodologies in the manuscripts and research 
grant applications (20). Animal experiments often fail to be reproduced when tested in humans (21, 
22). Landis et al listed some parameters that should be followed to obtain a rigorous study design (20) 
(Box 1). 
BOX 1 -  Standards for rigorous study design 
 
(i) Randomization 
Animals should be randomly assigned to the experimental groups and the collected data should be processed randomly or blocked in a 
proper manner. 
(ii) Blinding 
The experimenters should consider three different situations. Allocation concealment, where the researcher should be blind of the group 
to which a given animal will be allocated; Blinded conduct, states that investigators and animal caretakers involved in the study should be 
blinded to de allocation sequence and finally Blinded assessment of the outcome, where the researcher performing the experiments and 
analyzing the data should be blinded to the treatments. 
(iii) Sample-size estimation 
Statistical method used to determine sample size should be reported; statistic methods should be reported. 
(iv) Data handling 
The endpoint of the pre-clinical trial should be defined in advance according to the study purpose. Any data removed before analysis 
should be reported. The readouts should be defined and potential replicate issues need to be considered during study design.  
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After the publication of these suggestions to improve reporting transparency and study design in 
2012, the National Institute of Health (NIH) proposed additional recommendations based on the 
previous study described above (20). The later recommendations are more directed to the journals 
boards where the Information for Authors should be reformulated, including a statistical analysis 
checklist and no limit space or generous limits for the methods section (including online versions). 
Furthermore, (and some journals already adopted this), community-based standards should be used, 
such as nomenclature standards and reporting standards for animal studies (e.g. ARRIVE guidelines 
(23)). NIH also strongly encourages the scientific community to share information as much as possible. 
This might be achieved by deposition of the data in public repositories, sharing software’s and describe 
as much as possible the biological material (animal model, cell lines) and the reagents (antibodies 
characteristics, primers, among others).  
Chance and bias are two aspects that should be taken in consideration when performing pre-
clinical trials. Several studies in neurodegenerative diseases have demonstrated the lack of efficacy of 
the compounds tested in mouse models when translated to humans. On these reviews, 
recommendations are suggested for each specific disease (24-27). In the case of MJD, the pre-clinical 
and clinical trials are not as explored as for other polyglutamine diseases. As discussed in Chapter 1, 
very few clinical trials were conducted for MJD, most of them being case reports (Chapter 1, table 6). 
Double-blinded clinical trials were performed, but the sample size of those trials was very small and the 
duration often short (Table 5, Chapter 1). Also for pre-clinical trials, very few compounds were tested to 
date in MJD mouse models (Table 4, Chapter 1) and most often the same compound was not tested in 
different mouse models of the disorder.  
In the present work, five hypothesis-based compounds were tested in the CMVMJD135 mouse 
model, one of which was tested in two independent replicates (Chapter 6). The pre-clinical trials 
performed here were initiated before publication of the recommendations mentioned previously in this 
section (Box 1), however they were conducted having in consideration the points (iii) and (iv). Also, the 
statistical analysis was carried out rigorously and considering all the multiple evaluations performed in 
the tests. Regarding points (i) and (ii), logistic issues did not allow us to perform the studies using 
randomization or blinding (the experimenter was only blind to the genotype of the animals). At this 
moment and for the future, with the gathering of more human resources, pre-clinical trials in the 
CMVMJD135 mice will be performed randomly and in a blinded manner to avoid bias. Although, during 
the CMVMJD135 mice phenotype characterization, we had performed the behavior tests both in male 
and females and the symptoms progression is similar between genders (Chapter 2) , the compounds 
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presented in this work, should also be tested in both genders; we have used males in Chapters 2, 3 
and 4, and females in Chapters 5 and 6. These compounds were tested in an early symptomatic stage 
(one week before the disease onset) in order to study if the disease progression could be delayed. This 
approach could be beneficial to those patients who are diagnosed molecularly before the symptoms’ 
appearance due to the availability of a genetic test specific for MJD. Nevertheless, some MJD patients 
are only diagnosed after disease onset, and in that way, it would be important to test these compounds 
post-symptomatically, to validate them further before human trials.  
In all pre-clinical studies presented here, four groups of animals were used. Wild-type 
littermates were in all cases also assigned to treatment groups, which allowed us to study possible 
effects of the compounds in wild-type animals. Indeed, confirming the relevance of including such 
control groups, the combination of lithium chloride and CCI-779 showed to be detrimental to wild-type 
mice (Chapter 3), while Creatine improved the performance of wild-type animals suggesting some lack 
of specificity of its action, which does not diminish the relevance of the findings (Chapter 6).  
Furthermore, the study design was slightly different between the different studies. In each pre-
clinical trial we learned more about the CMVMJD135 mouse model (both at phenotypic and 
neuropathologic levels), which allowed us to improve and re-design the study in the following trials. The 
first trials (Chapter 2, 3 and 4) allowed us to understand that the duration of the trial should be 
increased, and that was applied in the following studies (chapter 5 and 6). Nevertheless, we could only 
increase the treatment duration until after a certain age, after which CMVMJD135 mice are not able to 
adequately reach food and water by themselves and/or to perform many of the tasks.  
Also, it was possible to verify a direct and positive correlation between genotype/phenotype, 
meaning that higher CAG repeat length leads to a more severe phenotype; this correlation forced us to 
control the CAG repeat length of each individual in each trial in order to obtain homogeneous groups in 
the preclinical studies. We also shortened the interval of the phenotype evaluation, testing the animals 
every two weeks; this allowed a better phenotype discrimination of the possible effects of the compound 
under test, however it also resulted in a training effect that modified the phenotype.  
Five of the compounds (except TUDCA) were tested previously in our lab in another animal 
model, a C. elegans model of MJD (28) as recommended by FELASA (to test first in alternative models) 
(29), showing beneficial effects. Yet, it is of great importance to test those that had positive effects in 
mice (17-DMAG – Chapter 2; TUDCA – Chapter 5 and Creatine – Chapter 6) in other mouse models of 
MJD, to further demonstrate their efficacy. In addition, it is also important to replicate these pre-clinical 
trials in the CMVMJD135 model itself and in different genders. We have replicated the Creatine study, 
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mainly because the results obtained in the first trial (PCT1 – Chapter 6) prompted us to perform an 
improved trial using a more extensive and optimized study design (PCT2 - Chapter 6), and even though 
the second group of transgenic animals had a higher mean repeat length, the results between both 
independent studies were consistent, further strengthening the findings. 
 
What have we learned about MJD pathogenesis and therapeutic targets with pre-
clinical trials? 
 
7.3 Hsp90 inhibitors and autophagy inducers in MJD 
Hsp90 inhibitors are known to possess the unique pharmacological effect of inducing a stress 
response, and, in addition to their use as anticancer agents, have also been developed as 
pharmacological HSP inducers for application in protein folding disorders (30, 31). We tested the 
efficacy of 17-DMAG, an Hsp90 inhibitor, in improving the behavioral deficits of the CMVMJD135 mice. 
Several studies demonstrated the positive effects of 17-AAG and its analogues (including 17-DMAG, 
which is less toxic) in models of polyQ diseases (32-35). Accordingly, in our study (Chapter 2) 
behavioral deficits were transiently improved by 17-DMAG administration and neuropathologic findings 
were ameliorated. Surprisingly, 17-DMAG did not induce the HSR in the brain of CMVMJD135 animals 
as we were expecting. However, the protein levels of mutant ataxin-3 as well as the aggregate load were 
diminished after 17-DMAG treatment, suggesting that other mechanism (s) would be occurring in the 
cells. Indeed, we found that 17-DMAG was inducing autophagy and therefore probably the degradation 
of mutant ataxin-3 through this mechanism (not excluding others, as the UPS). Other studies have also 
shown that 17-DMAG is able to induce autophagy (36, 37), and other mechanism(s) of action of 17-
DMAG rather than inducing the HSR were proposed for SBMA (35). We evaluated the autophagy 
process in the brain of the CMVMJD135 animals by using autophagy markers according to the 
guidelines for autophagy evaluation (38) and found no significant differences in several autophagy 
markers (Chapter 3 and Chapter 5), suggesting that autophagy is not overactived or blocked in this 
model. Nevertheless, autophagy induction seems to be a promising target to modulate in polyQ 
diseases and there is an extensive body of literature demonstrating its beneficial effects (9, 39-50). 
Thus, and considering the benefic effects of 17-DMAG, we tested other autophagy inducers: lithium 
chloride and CCI-779. The potential beneficial effects of pharmacological autophagy induction was 
previously suggested in studies using CCI-779 or beclin-1 overexpression in rodent models of MJD (9, 
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51). Unexpectedly, the use of lithium chloride (Chapter 3) had no overall effect on the behavioral 
deficits of CMVMJD135 mice, in spite of activating autophagy as expected. Accordingly, a human 
clinical trial using lithium carbonate was performed in the same year demonstrating that albeit well 
tolerated, lithium had no major impact on disease progression in MJD patients (11). In another attempt 
to increase autophagy, we also tested a combination of two autophagy inducers that act independent or 
dependently of mTOR, lithium and CCI-779, respectively (Chapter 4). This combinatory approach was 
previously tested in a HD fly model with promising results (43). Also, this combination was tested in our 
C.elegans MJD model and shown to be non-toxic and to improve the locomotor deficit observed in the 
AT3q130 worms. In the CMVMJD135 mice, however, this combinatory therapy showed no beneficial 
effects and even demonstrated to be deleterious to both transgenic and wild-type mice perturbating 
neurological function and general health, at doses that shown to be safe in mice when administered 
alone (Chapter 3 and (9)). These discrepant results suggest that the same compounds can have 
different outcomes in different animal models, which reinforces the importance of testing the same 
compound in different models. Pre-clinical trials with compounds that revealed to be ineffective in the 
disease models are often more difficult to publish and, therefore, often remain not known by the 
scientific community. This may lead to a bias and to the continuously re-testing of these compounds 
that might not offer success in humans. The editorial decisions might, thus have implications in the 
decision of performing (or not) clinical trials in humans. Here, and for this reason, we made a point of 
reporting negative results with lithium chloride and lithium chloride in combination with temsirolimus.  
  
7.4 Supplementation with endogenously produced neuroprotective compounds in MJD 
TUDCA and creatine are two compounds produced endogenously by the human body (52-54) 
and commonly used as diet supplements. These two diet supplements are considered safe, even at 
high concentrations and used in a chronic basis (55-57). Furthermore, they are able to cross the blood 
brain barrier and exert neuroprotection (58-61). In our study, both TUDCA and creatine showed an 
overall improving of the CMVMJD135 mice phenotype (Chapter 5 and 6).  
TUDCA was extensively studied in models of different neurodegenerative diseases and in all 
cases the results have been very promising (62-67); furthermore, this compound was already shown to 
have promising effects in ALS patients (56) without major adverse events. 
TUDCA is considered a pleiotropic signaling molecule, which might be of extreme relevance in 
disorders that are complex and multi-factorial. Classically, TUDCA act as an anti-apoptotic agent at the 
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mitochondrial level, physically binding to the Bax protein, inhibiting its translocation from the cytosol do 
the mitochondria (68, 69). However, TUDCA targets several other cellular pathways, having anti-oxidant 
(65-67), mitochondria-protective (68) and anti-inflammatory properties (62, 63, 70). In chapter 5, we 
show that TUDCA acted in CMVMJD135 mice most likely through its anti-inflammatory properties by 
reducing astrogliosis and normalizing the cytokine profile in the brain. However, we also tested other 
target cellular pathways, such as the HSR, (which we have shown not to be altered in the basal 
situation in CMVMJD135 mice - chapter 2). Indeed, we found no differences in the HSR in the 
CMVMJD135 model at late stages (34 weeks of age), but we cannot exclude that this is not happening 
earlier in life, as was shown for HD (71) or in specific cellular subtypes. Furthermore, we have shown 
that mutant ataxin-3 and aggregate load in the brain of the CMVMJD135 mice were reduced upon 
autophagy induction by 17-DMAG (Chapter 2), reinforcing the importance of autophagy in this type of 
disease, as suggested by others (9, 44, 49). TUDCA is also known as an autophagy inducer (72), but in 
our study we did not observe autophagy induction upon treatment with this compound, nor a reduction 
in the aggregate load in the brain of CMVMJD135 mice. Nevertheless, TUDCA showed to be 
neuroprotective in CMVMJD135 mice. As previously shown by us (6), a loss of Calbindin staining of the 
Purkinje cell layer of the cerebellum occurs in CMVMJD135 animals, which was significantly improved 
by TUDCA chronic treatment. 
Creatine, an important molecule in the body and especially in the skeletal muscle (54), 
improved both coordination deficits but only partially rescued the muscular strength deficits of the 
CMVMJD135 mice, suggesting an effect at the level of neurons. Furthermore, and in agreement with 
what was observed in Chapter 2 for 17-DMAG, creatine diminished the ataxin-3 positive aggregates in 
the brainstem. So far, we do not known the molecular mechanism (s) underlying these effects of 
creatine in CMVMJD135 mice. In further studies we plan to address the metabolic profile in the muscle 
and brain of these mice, as well as other possible neuroprotective mechanism of creatine, which may 
be of relevance to different diseases for which this compound exerted neuroprotection (73-75).  
7.5 Relevance of the novel findings and main conclusions of the work 
In this work we have characterized and validated a new MJD mouse model that constitutes a 
powerful framework for pre-clinical studies. The CMVMJD135 mice carry several measurable readouts 
at the phenotypic and neuropathologic levels, recapitulating several key pathological hallmarks of MJD 
and displaying an early-onset, and readily quantifiable motor phenotype. Because the CMVMJD135 
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mirrors several aspects of the human disorder, it may represent the best available mouse model for 
future preclinical trials. 
We also conducted five hypothesis-based preclinical trials with candidate therapeutic 
compounds for MJD (Fig 2). The main advantage of hypothesis-based pre-clinical trials relies on the 
previous known target of each compound, making it a more goal-directed study, together with the 
possibility of understanding the drug effect at the behavior and molecular levels and therefore 
contributing to the continuous exploration of pathogenic mechanism(s). 
 
 
Figure 2. Summary of the beneficial effect of the different compounds tested on CMVMJD135 phenotype and neuropathology. The color 
lines represent the duration of the improvement for each preclinical trial.  
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Although the major goal of this thesis was to test proteostasis network-related targets and 
compounds, the experiments may conduct us to other possibilities, as for instance neuroinflammation 
(the effect of the compounds tested in this work, in several proteostasis-related branches and 
inflammation, are summarized in Fig 3). From the five compounds tested here, TUDCA and creatine 
showed the most significant impact at the behavioral level. The percentage of effect on the motor 
swimming test for TUDCA was 57.25%, for creatine 85.39% and for 17-DMAG 45.26%. We were not 
able to calculate the percentage of effect of lithium since in this trial we did not perform motor 
swimming test. Interestingly, the effect of Citalopram (a molecule found by unbiased screening in C. 
elegans and shown to be highly effective in the CMVMJD135 mouse (6) was similar to that observed for 
creatine, i.e., 82.51%. Indeed, when we compare the performance of the CMVMJD135 mice on the 
motor swimming test in all ages tested (10 to 34 weeks of age, tested every two weeks) we do not 
observe differences between the treatments (TUDCA versus creatine, p=0.557, repeated measures). 
Nevertheless, taking into account a more refined analysis, using the first five points of analysis (10 to 
20 weeks of age) we can conclude that CMVMJD135 mice under creatine supplementation performed 
better in the motor swimming test when compared to the CMVMJD135 mice under TUDCA 
supplementation (TUDCA versus creatine, p=0.010, repeated measures), suggesting that creatine had 
a greater positive effect during the first 10 weeks and after this time-point (20 weeks of age), TUDCA 
and creatine have the same effect on this test. These results reinforce the value of these compounds as 
promising ones to be further tested in human clinical trials, particularly given their safety profile. 
Furthermore, these compounds are FDA-approved and were already tested for toxicity in several 
diseases as well as in healthy persons. Both compounds are considered to be pleiotropic molecules 
acting at several cellular targets which might explain, to some extent, their positive impact at the 
behavior level. Another interesting approach may comprise the combination one of these compounds 
with others tested in our lab, or with each other, possibly leading to synergistic effects, an approach that 
needs to be adequately tested at the pre-clinical and clinical levels.  Furthermore, the non-positive 
results obtained in pre-clinical trials are equally important for the MJD therapy field, since they bring 
significant improvements in the knowledge of the molecular mechanism (s) that are (or not) underlying 
neuropathology in CMVMJD135 mice, and help to guide the future preclinical and clinical trials, in MJD 
and also in other polyQ diseases towards more relevant targets. 
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Figure 3. Schematic representation of proteostasis-related signaling pathways and inflammation, and the impact of each compound 
tested in this work on those branches. 
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Appendix 1 
List of primers used in this thesis work. 
Primer ID Forward Reverse 
Hsp105 TCTATTCTGACCCTCAAGGAGTTCC TGTTCCAGCTTCACTGTTGTCTTGC 
Hsp90 CACCCTGCTCTGTACTACTACTCGG GCCAATGCCTGTGTCCACCAAAGTC 
Hsp70 ATCAGTGGGCTGTACCAGGG TTGACAGTAATCGGTGCCCAA 
Hsp60 CTCGGGCCTATGCCAAAGAT TTCTTCCCTTTGGCCCCATT 
Hsp40 CGCTACCACCCGGACAAG GGTACCATTAGCACCACCACT 
Hsp27 TCACGGCTACTATGTTCGGC CAGAAACGCCTGGAACTTGC 
GRP75 AAGAGAGAGACAGGGGTTGATT CCAGAAGCATCCATGGTAAGG 
HO-1 CAGAAGAGGCTAAGACCGCC GCAGTATCTTGCACCAGGCTA 
NQO1 ACGGTCCTTTCCAGAATAAGAAGA ACCTGGAAGCCACAGAAACG 
BDNF GACAAGGCAACTTGGCCTAC TTCGATGACGTGCTCAAAAG 
LC3 TTCTTCCTCCTGGTGAATGG GTGGGTGCCTACGTTCTCAT 
Beclin-1 CTTACCACAGCCCAGGCGAAA GCCAGAGCATGGAGCAGCAA 
TNFa GCCACCACGCTCTTCTGTCT TGAGGGTCTGGGCCATAGAAC 
Il1b ACCTTCCAGGATGAGGACATGA AACGTCACACACCAGCAGGTTA 
Il6 ACACATGTTCTCTGG GAAATCGT AAGTGCATCATCGTTGTTCATACA 
Il10 AGGACTTTAAGGGTTACTTGGGTT GCTCCACTGCCTTGCTCTTATT 
iNOS CTCGGAGGTTCACCTCACTGT GCTGGAAGCCACTGACACTT 
Iba-1 GAAGCGAATGCTGGAGAAAC CTCATACATCAGAATCATTCTC 
GFAP GGCGAAGAAAACCGCATCAC CCCGCATCTCCACAGTCTTT 
LCN2 CCAGTTCGCCATGGTATTTT GGTGGGGACAGAGAAGATGA 
XBP7 CAGCACTCAGACTATGTGCA  
XBP10  GTCCATGGGAAGATGTTCTGG 
XBP11 CTGAGTCCGAATCAGGTGCAG  
IMPA-1 CAGGGACAGCAAGGATGAACAT TTGGGATTGTGTACAGCTGTGTGG 
B2m CCTTCAGCAAGGACTGGTCT TCTCGATCCCAGTAGACGGT 
HPRT GCTGGTGAAAAGGACCTCT CACAGGACTAGAACACCTGC 
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